0001079973-17-000662.txt : 20171113 0001079973-17-000662.hdr.sgml : 20171113 20171113141007 ACCESSION NUMBER: 0001079973-17-000662 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 57 CONFORMED PERIOD OF REPORT: 20170930 FILED AS OF DATE: 20171113 DATE AS OF CHANGE: 20171113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProtoKinetix, Inc. CENTRAL INDEX KEY: 0001128189 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943355026 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-32917 FILM NUMBER: 171195171 BUSINESS ADDRESS: STREET 1: 705 DUGAN ROAD CITY: BELPRE STATE: OH ZIP: 45714 BUSINESS PHONE: 304-299-5070 MAIL ADDRESS: STREET 1: 705 DUGAN ROAD CITY: BELPRE STATE: OH ZIP: 45714 FORMER COMPANY: FORMER CONFORMED NAME: RJV NETWORK INC DATE OF NAME CHANGE: 20010130 10-Q 1 pktx_10q-093017.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

FORM 10-Q

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2017

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to ___________________.

Commission file number:

	PROTOKINETIX, INCORPORATED
	(Exact name of registrant as specified in its charter)

Nevada		94-3355026
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

412 Mulberry St.

Marietta, Ohio 45750

(Address of principal executive offices)

304-299-5070

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐		Accelerated filer ☐
Non-accelerated filer ☐	(Do not check if a smaller reporting company)	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 13, 2017, there were 250,352,433 shares of ProtoKinetix, Incorporated that were issued and outstanding.

PROTOKINETIX, INCORPORATED

TABLE OF CONTENTS

PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Unaudited Condensed Balance Sheets	3

Unaudited Condensed Statements of Operations	4

Unaudited Condensed Statement of Stockholders’ Equity	5

Unaudited Condensed Statements of Cash Flows	6

Notes to Unaudited Condensed Financial Statements	7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	21

Item 3. Quantitative and Qualitative Disclosures About Market Risk	25

Item 4. Controls and Procedures	25

PART II

OTHER INFORMATION

Item 1. Legal Proceedings	26

Item 1A. Risk Factors	26

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	26

Item 3. Defaults Upon Senior Securities	26

Item 4. Mine Safety Disclosure	26

Item 5. Other Information	26

Item 6. Exhibits	27

Signatures	28

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

BALANCE SHEETS

(Unaudited)


	September 30, 2017			December 31, 2016
ASSETS
Current Assets
Cash	$	386,142		$	371,029
Prepaid expenses and deposits (Notes 3 and 11)		97,723			70,384
Total current assets		483,865			441,413

Intangible assets (Note 4)		153,778			100,681

Total assets	$	637,643		$	542,094
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued liabilities (Note 10)	$	19,818		$	45,295
Total current liabilities		19,818			45,295
Stockholders' Equity
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 250,352,433 and 237,952,433 shares issued and outstanding as at September 30, 2017 and December 31, 2016 respectively (Note 9)		1,339			1,273
Additional paid-in capital		30,242,806			29,115,795
Accumulated deficit		(29,626,320	)		(28,620,269	)
Total stockholders’ equity		617,825			496,799
Total liabilities and stockholders’ equity	$	637,643		$	542,094

Basis of Presentation – Going Concern Uncertainties (Note 1)

Commitments and Contingency (Note 11)

Subsequent Events (Note 12)

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

STATEMENTS OF OPERATIONS

(Unaudited)

For the Three and Nine Months Ended September 30, 2017 and 2016

	Three months ended September 30, 2017			Three months ended September 30, 2016			Nine months ended September 30, 2017			Nine months ended September 30, 2016

EXPENSES
Amortization – intangible assets (Note 4)	$	750		$	750		$	2,250		$	2,250
General and administrative		12,500			17,341			74,437			70,441
Professional fees (Note 10)		42,549			39,664			109,823			147,977
Research and development		72,857			174,957			228,130			355,089
Share-based compensation (Note 10)		170,536			199,365			587,077			574,128

		(299,192	)		(432,077	)		(1,001,717	)		(1,149,885	)


OTHER ITEM
Foreign exchange loss		(100	)		-			(4,334	)		-
Net loss for the period	$	(299,292	)	$	(432,077	)	$	(1,006,051	)	$	(1,149,885	)

Net loss per common share (basic and diluted)	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.01	)

Weighted average number of common shares outstanding (basic and diluted)		247,148,085			222,088,754			245,315,070			219,242,214

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

STATEMENT OF STOCKHOLDERS’ EQUITY

(Unaudited)

For the Period from December 31, 2016 to September 30, 2017

	Common Stock				Additional Paid-in		Accumulated
	Shares		Amount		capital		deficit			Total
Balance, December 31, 2016		237,952,433	$	1,273	$	29,115,795	$	(28,620,269	)	$	496,799

Issuance of common stock pursuant to private placement offering		8,000,000		43		319,957		-			320,000

Fair value of compensatory options issued		-		-		587,077		-			587,077

Issuance of common stock pursuant to private placement offering		4,400,000		23		219,977		-			220,000

Net loss for the period		-		-		-		(1,006,051	)		(1,006,051	)

Balance, September 30, 2017		250,352,433	$	1,339	$	30,242,806	$	(29,626,320	)	$	617,825

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

STATEMENTS OF CASH FLOWS

(Unaudited)

For the Nine Months Ended September 30, 2017 and 2016

	Nine Months ended September 30, 2017			Nine Months ended September 30, 2016

CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the period	$	(1,006,051	)	$	(1,149,885	)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization – intangible assets		2,250			2,250
Issuance and amortization of common stock for services		-			7,000
Fair value of compensatory options granted		587,077			574,128

Changes in operating assets and liabilities:
Accounts receivable		-			8,023
Prepaid expenses and deposits		(42,953	)		(91,032	)
Accounts payable and accrued liabilities		(25,034	)		(5,002	)

Net cash used in operating activities		(484,711	)		(654,518	)

CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of intangible assets		(40,176	)		(7,589	)

Net cash used in investing activities		(40,176	)		(7,589	)


CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash		540,000			380,000

Net cash from financing activities		540,000			380,000

Net change in cash		15,113			(282,107	)

Cash, beginning of period		371,029			371,072

Cash, end of period	$	386,142		$	88,965

Cash paid for interest	$	-		$	-

Cash paid for income taxes	$	-		$	-
Supplementary information – non-cash transactions:
Common stock issued for consulting services	$	-		$	7,000
Intangible asset costs previously included in accounts payable and accrued liabilities		3,631			-
Intangible asset costs previously included in prepaid expenses and deposits		15,614			-
Intangible asset costs included in accounts payable and accrued liabilities		3,188			-

See Notes to Financial Statements

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 1. Basis of Presentation – Going Concern Uncertainties

ProtoKinetix, Incorporated (the “Company”), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999. The Company is a medical research company whose mission is the advancement of human health care.

The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (“AFGP”) or anti-aging glycoproteins, trademarked AAGP™. During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).

During the year ended December 31, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission.

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2017. These factors raise substantial doubt about the Company's ability to continue as a going concern.

The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective. Management is presently engaged in seeking additional working capital through equity financing or related party loans.

The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 2. Summary of Significant Accounting Policies (cont’d)

Use of Estimates

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.

Cash

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

Fair Value of Financial Instruments

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.

The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Level 1 inputs are used to measure cash. At September 30, 2017 there were no other assets or liabilities subject to additional disclosure.

Income Taxes

The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 2. Summary of Significant Accounting Policies (cont’d)

Intangible Assets – Patent and Patent Application Costs

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.

As at September 30, 2017, the Company does not hold any intangible assets with indefinite lives.

Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.

Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2017.

Research and Development Costs

Research and development costs are expensed as incurred.

Loss per Share and Potentially Dilutive Securities

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 55,100,000 stock options (September 30, 2016 – 28,600,000) and 6,500,000 warrants (September 30, 2016 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

Share-Based Compensation

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 2. Summary of Significant Accounting Policies (cont’d)

Share-Based Compensation (cont’d)

The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Common Stock

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete.

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

Related Party Transactions

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

Recent Accounting Pronouncements

In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements.

Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 2. Summary of Significant Accounting Policies (cont’d)

Recent Accounting Pronouncements (cont’d)

Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Company’s financial statements.

Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.

Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

Note 3. Prepaid Expenses and Deposits

The following summarizes the Company’s prepaid expenses and deposits outstanding as at September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016

Deposit on research agreement (Note 11(c))	$	97,723	$	54,770
Other prepaid expenses		-		15,614

	$	97,723	$	70,384

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 4. Intangible Assets

Intangible asset transactions are summarized as follows:

	Patent Rights		Patent Application Rights		Total
Cost
Balance, December 31, 2015	$	30,000	$	41,760	$	71,760
Additions		-		33,421		33,421
Balance, December 31, 2016	$	30,000	$	75,181	$	105,181
Additions		-		55,347		55,347
Balance, September 30, 2017	$	30,000	$	130,528	$	160,528

Accumulated amortization
Balance, December 31, 2015	$	1,500	$	-	$	1,500
Amortization		3,000		-		3,000
Balance, December 31, 2016	$	4,500	$	-	$	4,500
Amortization		2,250		-		2,250
Balance, September 30, 2017	$	6,750	$	-	$	6,750

Net carrying amounts
December 31, 2016	$	25,500	$	75,181	$	100,681
September 30, 2017	$	23,250	$	130,528	$	153,778

During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the “Patent Assignment”) with the Institut National des Sciences Appliquees de Rouen (“INSA”) for the assignment of certain patents and all rights associated therewith (the “Patents”). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the nine month period ended September 30, 2017, the Company recorded $2,250 (September 30, 2016 - $2,250) in amortization expense associated with the Patents.

During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the “Patent Application Rights”). In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company has incurred $82,047 in direct costs relating to the Patent Application Rights, $44,277 of which were incurred during the nine month period ended September 30, 2017.

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 4. Intangible Assets (cont’d)

During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells” (the “New Patent Application Rights”). In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid). The Company has incurred $13,481 in direct costs relating to the New Patent Application Rights, $11,065 of which were incurred during the nine month period ended September 30, 2017.

No amortization was recorded on the Patent Application Rights to September 30, 2017.

Note 5. Credit Facility

On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia. Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly. The Company’s President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells”. As at December 31, 2016, the balance outstanding was $nil. As of September 30, 2017, the line of credit was canceled and the pledged assets were released.

Note 6. Common Shares Issued for Services

During the nine month periods ended September 30, 2017 and 2016, the Company issued shares of common stock for services and other value rendered as follows:

2017	Number of Shares		Value per Share			Total

January - September 2017		-		$	-		$	-
		-					$	-

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

Note 7. Stock Options

On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”). The Board of Directors adopted the 2017 Plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.

The aggregate number of shares that may be issued under the 2017 Plan is 30,000,000 shares subject to adjustment as provided therein. The 2017 Plan includes two types of options. Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options. Options which are not intended to qualify as incentive options are referred to as non-qualified options.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 7. Stock Options (cont’d)

As of September 30, 2017, 27,200,000 options and no shares of common stock have been granted under the 2017 Plan.

The 2017 Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors. In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted. The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the 2017 Plan. The committee may determine the purchase price of the shares of common stock covered by each option. The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the 2017 Plan. The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the 2017 Plan.

In the event that a change, such as a stock split, is made in the Company’s capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option. The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock. Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the 2017 Plan shall terminate as of a date fixed by the committee.

The exercise price of any option granted under the 2017 Plan must be no less than 100% of the “fair market value” of the Company’s common stock on the date of grant. The exercise period of any option shall not exceed ten years from the date of grant of the option. Any incentive stock option granted under the 2017 Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant and the term shall be for no more than five years.

Stock option transactions are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2016		28,900,000			0.06		0.04
Options granted		27,200,000			0.05		0.03
Options expired		(1,000,000	)		0.10		0.03
Outstanding, September 30, 2017		55,100,000			0.06		0.04		2.77

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 7. Stock Options (cont’d)

The fair values of the stock options granted during the nine month periods ended June 30, 2017 and 2016 were estimated using the Black-Scholes Option Pricing Model. The weighted average assumptions used in the pricing model for these options are as follows:

	September 30, 2017	September 30, 2016
Risk-free interest rate	1.05%	0.56%
Dividend yield	0.00%	0.00%
Expected stock price volatility	125.00%	125.00%
Expected forfeiture rate	0.00%	0.00%
Expected life	3.46 years	3.94 years

The following non-qualified stock options were outstanding and exercisable at September 30, 2017:

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
	$
February 25, 2020		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		15,000,000
October 05, 2018		0.08		300,000		300,000
December 31, 2020		0.05		16,200,000		12,150,000
August 31, 2021		0.06		11,000,000		-
				55,100,000		38,050,000

As at September 30, 2017, the aggregate intrinsic value of the Company’s stock options is $392,000 (December 31, 2016 – $110,000). The weighted average fair value of stock options granted during the nine month period ended September 30, 2017 is $0.03 (2016 - $0.05).

Note 8. Warrants

Warrant transactions for the nine month period ended September 30, 2017 are summarized as follows:

		Number of Warrants				Weighted Average Exercise Price
Balance, December 31, 2016 and September 30, 2017			6,500,000			$	0.11

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 8. Warrants (cont’d)

The following warrants were outstanding and exercisable as at September 30, 2017:

Number of Warrants		Exercise Price ($)		Expiry Date
	500,000		0.25	November 8, 2018
	6,000,000		0.10	April 22, 2020
	6,500,000

Note 9. Stockholders’ Equity

The Company is authorized to issue 400,000,000 (December 31, 2016 – 400,000,000) shares of $0.0000053 par value common stock. Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2017 (December 31, 2016 - $nil).

During the nine month period ended September 30, 2017, the Company:

a)	Issued 8,000,000 shares of common stock to investors (which included both the President and CEO as well as the CFO of the Company) at $0.04 for gross proceeds of $320,000.

b)	Issued 4,400,000 shares of common stock to investors at $0.05 for gross proceeds of $220,000.

Note 10. Related Party Transactions and Balances

During the nine month period ended September 30, 2016, the Company:

Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at September 30, 2017.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 10. Related Party Transactions and Balances (cont’d)

Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event. Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at September 30, 2017. A total of $54,000 was paid to the Company’s CFO during the nine month period ended September 30, 2016 and is included in professional fees.

Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at September 30, 2017.

Recognized $407,780 in share-based compensation associated with stock options granted to key management personnel.

During the nine months ended September, 30, 2017, the Company:

Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control. In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of a sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement. Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.

Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Company’s CFO $72,000 per year of service (including the pro-rata amount for partial years of service) if terminated without cause or upon termination due to a change of control event. Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. A total of $54,000 was paid to the Company’s CFO during the period ended September 30, 2017 and is included in professional fees.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 10. Related Party Transactions and Balances (cont’d)

Entered into a directorship agreement with an effective date of January 1, 2017 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 1,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.

d)	Recognized $297,412 in share-based compensation associated with stock options granted to key management personnel.

As at September 30, 2017 and December 31, 2016, the following amounts are due to related parties:

			September 30, 2017				December 31, 2016
Clarence Smith (CEO)	Accounts payable and accrued liabilities		$	-			$	81

Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

Note 11. Commitments and Contingency

As at September 30, 2017, the Company has the following commitments:

Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services. Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew. The consulting agreement was also amended to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7). The options vest quarterly in equal installments beginning December 31, 2017.

Entered into a consulting agreement for business development services effective January 1, 2017. The consultant was granted 1,200,000 stock options exercisable into common shares of the Company at a price of $0.05 per share until December 31, 2020 (Note 7). The options vest in equal installments on a quarterly basis beginning March 31, 2017.

Entered into a Collaborative Research Agreement (the “CREA”) effective May 31, 2016 with The University of British Columbia (“UBC”) for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, and paid an additional CAD $201,500 ($146,585) during the nine month period ended September 30, 2017, in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days’ written notice. As at September 30, 2017, a total of $97,723 is included in prepaid expenses and deposits (December 31, 2016 - $54,770).

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 11. Commitments and Contingency (cont’d)

Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice, for providing public relations services. The consultant is also entitled to 400,000 shares of common stock, which will be issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (100,000 shares issued during the nine month period ended September 30, 2016 (Note 6)). The consultant was also issued 1,000,000 stock options on signing during the year ended December 31, 2015, with each stock option exercisable into a common share at a price of $0.10. The stock options expired March 12, 2016.

Entered into a royalty agreement with the Governors of the University of Alberta (the “University”) whereby the University had developed certain intellectual property (the “Additional Patent Rights”) in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the “Royalty”) derived from products arising from the Patent Rights.

Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice for providing research and development services. During the nine month period ended September 30, 2017 the contract was revised whereby the Company would pay the consultant CAD $4,000 per month retroactively beginning January 1, 2017.

g)	Entered into a Material Transfer Agreement effective March 31, 2017 with Proactive Immune Sciences Corporation (“Proactive”) for a term of 1 year. The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.

The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, “Report of Foreign Bank and Financial Accounts” (“FBARs”). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs. Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities. The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements. No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.

PROTOKINETIX, INCORPORATED

(A Development Stage Company)

NOTES TO FINANCIAL STATEMENTS

September 30, 2017

(Unaudited)

Note 12. Subsequent Event

Subsequent to the nine month period ended September 30, 2017, the Company:

Entered into two Promissory Notes (the “Notes”) with the Company’s President and CEO whereby a total of $116,000 was loaned to the Company. The Notes bear interest at a rate of 8% per annum, are unsecured and are repayable on demand. The funds from these Notes will be used to make payment under the Settlement Agreement referred to below.

Entered into a Settlement Agreement with the Company’s CFO on November 3, 2017 whereby she will leave her position as CFO effective upon the filing of the Company’s quarterly report for the nine month period ended September 30, 2017. Pursuant to the Settlement Agreement, the Company will pay the former CFO $6,000 for December 2017 consulting services (Note 10) and $110,000 in exchange for the return of stock options to purchase up to 12,000,000 shares of the Company’s common stock currently held by the CFO, which will be subsequently cancelled.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Unless the context requires otherwise, references in this document to “ProtoKinetix”, “we”, “our”, “us” or the “Company” are to ProtoKinetix, Incorporated.

The following discussion provides information regarding the results of operations for the nine month period ended September 30, 2017 and 2016, and our financial condition, liquidity and capital resources as of September 30, 2017, and December 31, 2016. The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion.

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this Quarterly Report on Form 10-Q include “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”). All statements, other than statements of historical facts, included herein and therein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. These forward looking statements are identified by their use of terms and phrases such as “may,” “expect,” “estimate,” “project,” “plan,” “believe,” “intend,” “achievable,” “anticipate,” “will,” “continue,” “potential,” “should,” “could,” and similar terms and phrases. Although we believe that the expectations reflected in these forward looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not considered to be) guarantees of future performance. Our results could differ materially from those anticipated in these forward looking statements as a result of certain factors, including, among others:

•

Our capital requirements and the uncertainty of being able to obtain additional funding on terms acceptable to us;

•

Our plans to develop and commercialize products from the AAGP™ molecule;

•

Ongoing testing of the AAGP™ molecule;

•

Our intellectual property position;

•

Our commercialization, marketing and manufacturing capabilities and strategy;

•

Our ability to retain key members of our senior management and key scientific consultants;

•

The effects of competition;

•

Our potential tax liabilities resulting from conducting business in the United States and Canada;

•

The effect of further sales or issuances of our common stock and the price and volume volatility of our common stock; and

•

Our common stock’s limited trading history.

Finally, our future results will depend upon various other risks and uncertainties, including, but not limited to, those detailed in our filings with the SEC under the Exchange Act and the Securities Act, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2016. All forward looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph and elsewhere in this Quarterly Report. Other than as required under securities laws, we do not assume a duty to update these forward looking statements, whether as a result of new information, subsequent events or circumstances, changes in expectations or otherwise.

Business Overview

ProtoKinetix, Incorporated is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs™. The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGPs™ in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP™ to market.

Results of Operations

The following table shows selected financial data and operating results for the periods noted. Following the table, please see management’s discussion of significant changes.

	For the Nine Months Ended
	September 30,
	2017			2016
Revenues	$	-		$	-
Cost of Sales		-			-
Gross (Loss) Profit		-			-
Operating Expenses
Amortization-Intangible Assets	$	2,250		$	2,250
General and Administrative		74,437			70,441
Professional Fees		109,823			147,977
Research and Development		228,130			355,089
Share-Based Compensation		587,077			574,128
Total Operating Expenses		1,001,717			1,149,885
Loss from Operations		(1,001,717	)		(1,149,885	)

Other Item
Foreign Exchange Loss		(4,334	)		-
Total Other Item		(4,334	)		-
Net Loss	$	(1,006,051	)		(1,149,885	)

Revenues

We had no revenues for the nine month periods ended September 30, 2017 and 2016.

Gross Profit and Expenses

The Company’s net loss was $1,006,051 for the nine month period ended September 30, 2017 compared to $1,149,885 for the nine month period ended September 30, 2016. These expenses were primarily incurred for professional fees, consulting services related to the operations of the Company’s business, research and development and other general and administrative expenses. Significant changes from the prior nine month period ended September 30, 2016 include:

Professional fees decreased by $38,154 from $147,977 to $109,823 primarily as a result of a decrease in legal fees associated with Company operations and the Company no longer being subject to Canadian reporting requirements.

Research and development decreased by $126,959 from $355,089 to $228,130 primarily as a result of completion of needed testing for inclusion in the Investigational Testing Authorization Application to Health Canada by the Governors of the University of Alberta.

Share-based compensation increased by $12,949 from $574,128 to $587,077 primarily as a result of an increase in stock option valuation for the current year.

Liquidity and Capital Resources

The following summarizes our statements of cash flows at September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016

Cash	$	386,142	$	371,029

Working Capital	$	464,047	$	396,118

At September 30, 2017, we had $386,142 in cash and $483,865 in total current assets. As of September 30, 2017 we had a working capital position of $464,047. Based upon our working capital equity as of September 30, 2017, we require additional equity and/or debt financing in order to meet cash flow projections and carry forward our business objectives. There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our new business.

The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity.

Sources and Uses of Cash

Net Cash Used in Operating Activities

Net cash used in operating activities decreased by $169,807 from $654,518 to $484,711 for the nine months ended September 30, 2016 and 2017, respectively. This decrease was predominantly due to a decrease in payments made to the Company’s vendors along with a decrease in prepaid expenses and deposits.

Net Cash Used in Investing Activities

Net cash used in investing activities was $40,176 for the nine month period ended September 30, 2017 while the Company had net cash used in investing activities of $7,589 for the comparative period. The difference is attributable to an increase in the purchase of intangible assets.

Net Cash Provided by Financing Activities

Net cash provided by financing activities increased by $160,000 from $380,000 to $540,000 for the nine months ended September 30, 2016 and 2017, respectively due to an increase in private placements.

Going Concern

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which contemplate continuation of the Company as a going concern. The history of losses and the inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock. However, the Company’s common stock is at a low price and is not actively traded.

Off-Balance Sheet Arrangements

None.

Contractual Obligations

As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item.

Critical Accounting Policies

The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements.

Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-Q.

While all of the significant accounting policies are important to the Company’s financial statements, the following accounting policies and the estimates derived there from have been identified as being critical.

Share-Based Compensation

On July 1, 2015, the Board of Directors of the Company adopted the 2015 Stock Option and Stock Bonus Plan (the “Plan”). The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services outside of the Plan, and beginning July 1, 2015 and ending December 31, 2016 pursuant to the Plan. On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”). During the nine month period ended June 30, 2017, the Company granted options pursuant to the 2017 Plan. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.

Sales and Marketing

The Company is currently not selling or marketing any products.

Inflation

Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the nine months ended September 30, 2017.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item.

Item 4: Controls and Procedures

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (the “1934 Act”) is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the 1934 Act is accumulated and communicated to management, including our principal executive officer and our principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, under the direction of our Chief Executive Officer (who is our principal executive officer), and Chief Financial Officer (who is our principal accounting officer) has evaluated the effectiveness of our disclosure controls and procedures as required by 1934 Act Rule 13a-15(b) as of September 30, 2017 (the end of the period covered by this report). Based on that evaluation, our principal executive officer and our principal accounting officer concluded that these disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the 1934 Act is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosure and are effective to provide reasonable assurance that such information is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

The Company, including its Chief Executive Officer and Chief Financial Officer, does not expect that its internal controls and procedures will prevent or detect all error and all fraud. A control system, no matter how well conceived or operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated by the SEC under the 1934 Act) during the nine months ended September 30, 2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

Other than reported in the Company’s Quarterly Report on Form 10-Q for the nine month period ended September 30, 2017, the Company and its management are not aware of any regulatory or legal proceedings or investigations pending involving the Company, any of its subsidiaries or affiliates, or any of their respective officers, directors or employees.

Item 1A. Risk Factors

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. However, our current risk factors are set forth in our Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the SEC on February 21, 2017, and such risk factors are incorporated herein by this reference.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Other than previously reported, there have been no unregistered sales of equity securities during the nine month period ended September 30, 2017.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information

Effective June 30, 2017, the Company entered into a Material Transfer Agreement with Proactive Immune Sciences Corporation (“Proactive”) for a term of one year. The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.

Effective upon filing of this Quarterly Report on Form 10-Q, the Company’s address has been changed to: 412 Mulberry St., Marietta, Ohio 45750.

On November 3, 2017, the Company and Susan M. Woodward agreed that Ms. Woodward will leave her position as chief financial officer (CFO), effective upon the filing of the Company’s quarterly report for the quarter ended September 30, 2017, in satisfactory form, but will remain engaged to assist the Company through December 31, 2017, and to transition books and records of the Company. The Company is working on securing a successor CFO who will take over upon Ms. Woodward’s departure from the Company. Ms. Woodward’s departure from her position as chief financial officer will be prior to the natural expiration of her consulting agreement, dated December 30, 2016 and due to expire on December 31, 2017 (the “Consulting Agreement”). Upon the filing of the Company’s quarterly report for the quarter ended September 30, 2017, and Ms. Woodward’s subsequent resignation, the Consulting Agreement will terminate.

On October 23, 2017, the Company issued an unsecured promissory note to Clarence E. Smith in the amount of $86,000. The outstanding principal balance on the promissory note is due on demand by Clarence E. Smith and shall accrue simple interest at a rate of 8% per annum from the date the principal balance was advanced.

On November 3, 2017 the Company issued a second unsecured promissory note to Clarence E. Smith in the amount of $30,000. The outstanding principal balance on the promissory note is due on demand by Clarence E. Smith and shall accrue simple interest at a rate of 8% per annum from the date the principal balance was advanced.

The above-listed promissory notes were issued by the Company in order to acquire the funds necessary to re-purchase Susan M. Woodward’s stock options to purchase up to 12 million shares of common stock of the Company pay Ms. Woodward’s compensation for December 2017 pursuant to the settlement agreement discussed above.

Item 6. Exhibits

The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

EXHIBIT INDEX

The following documents are being filed with the Commission as exhibits to this Quarterly Report on Form 10-Q.

Exhibit		Description
3.1		Certificate of Incorporation¹
3.2		Bylaws¹
4.1		2015 Stock Option and Stock Bonus Plan²
4.2		2017 Stock Option and Stock Bonus Plan⁷
10.1		Assignment of Patents and Patent Application between the Company and Institut National des Sciences Appliquées de Rouen dated January 5, 2015³
10.2		Settlement and Indemnity Agreement by and between the Company and Standard Bankcorp Inc. and Mark Ralston dated March 2, 2015³
10.3		Royalty Agreement between the Company and The Governors of the University of Alberta, dated April 8, 2015³
10.4		Technology Transfer Agreement between the Company and Grant Young, dated April 22, 2015⁴
10.5		ITR Master Contract between the Company and ITR Laboratories Canada Inc., dated April 19, 2016⁸
10.6		Universal Agreement between the Company and Grant Young, dated May 20, 2016⁹
10.7		Collaborative Research Agreement between the Company and the University of British Columbia, dated May 31, 2016⁹
10.8		Consulting Agreement between the Company and Clarence E. Smith, dated December 30, 2016⁷
10.9		Consulting Agreement between the Company and Susan M. Woodward, dated December 30, 2016⁷
10.10		Director Consulting Agreement between the Company and Edward P. McDonough, dated December 30, 2016⁷
10.11		First Amendment to Consulting Agreement between Clarence E. Smith and the Company dated September 1, 2017¹⁰
10.12		First Amendment to Consulting Agreement between Edward P. McDonough and the Company dated September 1, 2017¹⁰
10.13		Consulting Agreement between the Company and Grant Young, dated December 30, 2016^*
10.14		First Amendment to Consulting Agreement between Grant Young and the Company dated September 1, 2017¹⁰
10.15		Settlement Agreement and General Release between the Company and Susan M. Woodward, dated November 3, 2017.¹¹
10.16		Unsecured Promissory Note issued by the Company to Clarence E. Smith dated October 23, 2017.¹¹
10.17		Unsecured Promissory Note issued by the Company to Clarence E. Smith dated November 3, 2017.¹¹
14.1		Code of Ethics⁶
31.1		Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002^*
31.2		Certification of the Principal Financial Officer and Principal Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002^*
32.1		Certification of the Principal Executive Officer and the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002^**

101.INS		XBRL Instance Document
101.SCH		XBRL Schema Document
101.CAL		XBRL Calculation Linkbase Document
101.DEF		XBRL Definition Linkbase Document
101.LAB		XBRL Label Linkbase Document
101.PRE		XBRL Presentation Linkbase Document

	1.	Incorporated by reference from the Company’s registration statement on Form 10-SB filed on June 22, 2001 with the SEC.
	2.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 14, 2015 with the SEC.
	3.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 14, 2015 with the SEC.
	4.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on May 20, 2015 with the SEC.
	5.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on March 30, 2016 with the SEC.
	6.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on April 13, 2006 with the SEC.
	7.	Incorporated by reference from the Company’s Annual Report on Form 10-K filed on February 21, 2017 with the SEC.
	8.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on May 16, 2016 with the SEC.
	9.	Incorporated by reference from the Company’s Quarterly Report on Form 10-Q filed on August 15, 2016 with the SEC.
	10.	Incorporated by reference from the Company’s Current Report on Form 8-K filed on September 7, 2017 with the SEC.
	11.	Incorporated by reference from the Company’s Current Report on Form 8-K filed on November 9, 2017 with the SEC.
	*.	Filed herewith.
	**	Furnished, not filed herewith.

SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 13, 2017		PROTOKINETIX, INCORPORATED

		By: /s/ Clarence E. Smith
		Clarence E. Smith
		Chief Executive Officer

		By: /s/ Susan M. Woodward
		Susan M. Woodward
		Chief Financial Officer

EX-10.13 2 ex10x13.htm EXHIBIT 10.13

Exhibit 10.13

PROTOKINETIX, INCORPORATED

CONSULTING AGREEMENT

This CONSULTING AGREEMENT (the “Agreement”) is made and entered into as of December 30, 2016 and made effective as of January 1, 2017 (the “Effective Date”), by and between ProtoKinetix, Incorporated, a Nevada corporation (“Company”), and Grant Young, an individual (“Consultant”).

WHEREAS, the Company is a bio-technology company in the business of developing anti-aging glycoproteins (“AAGP”) for the purpose of enhancing cell survival and health in various applications including transplant procedures, engraftment of tissue and cell preservation (the “Objectives”);

WHEREAS, the Company and Consultant entered into an agreement to perform services for the Company effective January 1, 2016 and terminating December 31, 2016 (the “Prior Consulting Agreement”);

WHEREAS, effective January 1, 2017, the Company and Consultant desire to enter into a new agreement to perform certain services for the Company and Consultant has agreed to provide such services, on the terms and conditions set forth herein.

AGREEMENT:

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Consultant agree as follows:

1. Services.

(a) General Services. During the Term (as defined below) of this Agreement Consultant will provide the Company with such technical and management services to assist the Company to achieve its Objectives (collectively, the “Services”).

(b) Specific Services. Without limiting the generality of the Services to be provided as set forth above, it is hereby acknowledged and agreed that Consultant will provide the following specific services:

(i) Conducting or supervising (as appropriate) planning and implementing of research and development of AAGP and, where possible, employing third party resources and government grants and facilities but with a comparative plan of the efficiency of third party resources versus the cost in royalty requirements to maintain patent rights or avoid the loss of patent opportunities;

(ii) Supervising research and development and effecting best reasonable efforts to ensure that all patentable discoveries are owned by the Company or the same are assigned to the Company at the best price possible with priority given to acquisition rather than licensing;

(iii) Supervising the hiring of competent personnel and third party resources as are required for the efficient operation of research and development;

(iv) Supervising the dissemination of accurate technical information and publications by or for the Company and by third party research resources; and

(v) Such other activities as are necessary or incidental to the above from time to time and as requested by the Board of the Directors of the Company or its Chief Executive Officer to achieve the Objectives.

2. Compensation and Expenses.

(a) Compensation. Consultant shall receive compensation equal to $7,000 per month in exchange for the Services provided to the Company. Consultant hereby guarantees a commitment to the Company of providing the Services over no less than 200 days per year which shall be performed with the highest priority. The Company agrees to pay Consultant on the first day of every month during the Term of this Agreement.

(b) Expenses. Promptly upon the completion of each month of Services, but no later than the 10th day of the following month, Consultant shall provide the Company with an invoice for Permitted Expenses (defined below). Such invoice shall be accurate, complete, and include sufficient detail and receipts to substantiate amounts due hereunder. Amounts due shall be payable within 30 business days of the Company’s receipt of a correct and undisputed invoice from Consultant. “Permitted Expenses” include the following: (i) when requested by the Company, reasonable expenses for travel, and (ii) other expenses specifically approved by the Company in writing. Notwithstanding the above, the Company will not be responsible for any single expense in excess of $500 or aggregate expenses in any one month of more than $2,000 without prior written approval of the Company.

(c) Stock Option. On the Effective Date, Consultant will receive an option to purchase 5,000,000 shares of common stock of the Company pursuant to the Company’s 2017 Stock Option and Stock Bonus Plan and the Stock Option Agreement between the Company and Consultant dated January 1, 2017.

3. Ownership. (a) Ownership of Work Products. To the extent that the Services provided hereunder include original material subject to copyright (referred to as “Work Product”), Consultant agrees that the Services are done as a “work for hire” as that term is defined under U.S. copyright law, and that as a result, the Company shall own all copyrights in and to the Work Product. To the extent that the Work Product does not qualify as a work for hire under applicable law, and to the extent that the Work Product includes material subject to copyright, patent, trade secret, or other proprietary right protection, Consultant hereby assigns to the Company, its successors and assigns, all right, title and interest in and to the Work Product, including all copyrights, patents, trade secrets, and other proprietary rights therein (including renewals thereof). Consultant shall execute and deliver such instruments and take such other action as may be required and requested by the Company to carry out the assignment contemplated by this paragraph. To the extent permitted by applicable law, Consultant hereby waives all moral rights in and to the Work Product.

(b) License for Prior Works. By incorporating into any Services any original work or authorship created prior to this Agreement (“Prior Works”), Consultant thereby grants the Company a worldwide, perpetual, nonexclusive, transferable license to use, distribute, publish, or publicly display such Prior Works and modify such Prior Works as incorporated into the Services.

(c) Ownership of Equipment. Unless otherwise expressly set forth elsewhere in this Agreement, any and all tangible equipment, materials, documentation, or other items provided by the Company in connection with this Agreement shall remain the property of the Company.

(d) Ownership of Intellectual Property. The Company shall retain title to and all rights in all intellectual property provided by the Company in connection with the Services, including, but not limited to, any know-how related to the Services or products provided or developed in the course of Consultant’s Services or the creation of Work Product, such as hardware, software, data, media or other tools or technologies.

4. Confidentiality.

(a) Nature of Confidential Information. In this Agreement, “Confidential Information” includes, but is not limited to, information, whether or not in written form, which has a business purpose and is not known or generally available from sources outside the Company or typical of industry practice, including but not limited to, the Company’s internal structure, financial affairs, programs, software systems, procedures, manuals, confidential reports, marketing methods, the amount, nature and type of services and methods used and preferred by the Company’s vendors and customers and the fees paid by such persons or entities; the identity of the Company’s present and prospective customers and vendors; customer and vendor lists; any data relating to a customer or vendor of the Company; the Company’s business arrangements and costs; and information regarding earnings, forecasts, reports and technical data of the Company, provided that Confidential Information does not include:

(i) Information that is in the public domain at the date hereof or becomes part of the public domain after the date hereof through no act or omission of Consultant;

(ii) Information which Consultant can prove was in its possession prior to the date hereof and was not acquired by Consultant from the Company or any person under a confidentiality obligation to the Company;

(iii) Documents or information independently developed by or for Consultant; and

(iv) Information received by Consultant without restriction as to disclosure from a third party who has the lawful right to disclose the same.

(b) Agreement to Keep Information Confidential. Consultant acknowledges the confidential and proprietary nature of the Confidential Information, shall keep all Confidential Information in strict confidence and will not disclose or dispose of any Confidential Information to any third party. Consultant may, however, disclose the Confidential Information to its officers, employees, advisers and agents who need to know the Confidential Information for the purposes of the evaluating and assessing the Confidential Information. All individuals receiving any Confidential Information under this Agreement shall be directed by Consultant to treat the Confidential Information confidentially pursuant to the terms of this Agreement. Nothing in this Agreement prevents Consultant from disclosing any Confidential Information as may be required by applicable law, regulation, court order or securities regulatory authority.

(c) No-Trade. Consultant acknowledges that it may be in possession of material nonpublic information which is considered to be any information concerning the Company that is both (i) material (meaning the average investor would want to know such information before deciding whether to buy, sell or hold securities of the Company, or, in other words, information that could affect the market price of Company securities); and (ii) nonpublic (meaning the information has not been disclosed in the Company’s filings with the SEC or in a press release issued by the Company that has been broadly disseminated to the investing public). Information is not considered public until the second business day after such disclosure in an SEC filing or press release. If such material nonpublic information is disclosed to the public, Consultant may not trade in Company securities until the second business day after such disclosure (i.e., the second day after the applicable SEC filing or press release). The prohibition on trading while in possession of material nonpublic information continues for as long as any information Consultant has is both material and nonpublic and can continue even after Consultant’s engagement with the Company has terminated.

5. Termination.

(a) Term. This Agreement shall commence as of the Effective Date and continue until December 31, 2017 (the “Term”).

(b) Termination for Cause. The Company will have the right to terminate Consultant upon written notice for Cause. The term “Cause” means as a result of (i) any breach of any written policy of the Company; (ii) conduct involving moral turpitude, including, but not limited to, misappropriation or conversion of assets of the Company (other than immaterial assets); (iii) Consultant’s conviction of, or entry of a plea of nolo contendere to, a felony; or (iv) a material breach of this Agreement. The term “Cause” shall not mean as a result of the death or disability of Consultant.

(c) Termination Upon a Change of Control. This Agreement shall terminate automatically upon a Change of Control of the Company. For purposes of this Agreement, a “Change of Control” shall mean any of the following:

(i) Any consolidation or merger of the Company with or into any other corporation or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the shareholders of the Company immediately prior to such consolidation, merger or reorganization, continue to hold at least a majority of the voting power of the surviving entity in substantially the same proportions (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; or (B) any transaction or series of related transactions to which the Company is a party in which in excess of 50% of the Company’s voting power is transferred; or

(ii) The sale, lease, transfer, or other disposition of all or substantially all of the assets of the Company, except where such sale, lease transfer or other disposition is to a wholly owned subsidiary of the Company.

(d) Survival. In the event of termination of this Agreement for any reason, Sections 3 through 6 shall survive indefinitely.

6. Indemnification.

(a) Indemnification. Each party agrees to indemnify and save the other, its affiliates and their respective directors, officers, consultants and agents (each an “Indemnified Party”) harmless from and against any and all losses, claims, actions, suits, proceedings, damages liabilities or expenses of whatsoever nature or kind, including any investigation expenses incurred by any Indemnified Party to which an Indemnified Party may become subject by reason of breach of this Agreement or of law by the defaulting party. Notwithstanding the above, the Company shall indemnify and hold harmless Consultant from and against any claims, damages, losses or expenses incurred by Consultant which arise out of any acts or omissions taken in good faith by Consultant in connection with or related to Consultant’s performance of the Services.

7. General Terms.

(a) Return of Work Product. Consultant agrees, promptly upon completion of the Services or other termination of this Agreement, to deliver to the Company all Work Product and to return all notes, designs, code, storage devices, documents and any other Company materials, including Confidential Information. Consultant shall not retain any such materials without the Company’s written approval.

(b) No Employer-Employee Relationship. The Company and Consultant understand, acknowledge, and agree that Consultant’s relationship with the Company will be that of an “independent contractor” and not that of an employee. Contractor will be an “independent contractor” and Contractor will be entitled to work at such times and places as Contractor determines appropriate, will not be under the direction or control of the Company or the manner in which Contractor performs the Services. Consultant will not be entitled to any of the benefits which the Company may make available to its employees (which benefits may in the future include, but not be limited to, group health or life insurance, profit-sharing or retirement benefits).

(c) Taxes. Consultant is and will be solely responsible for, and will file, on a timely basis, all tax returns and payments required to be filed with, or made to, any federal, state or local tax authority (including, but not limited to Social Security, federal, state, Medicare, and all of other taxes) with respect to the performance of Services and receipt of fees under this Agreement. No part of the compensation payable to Consultant will be subject to withholding by the Company for the payment of any social security, federal, state or any other employee payroll taxes. If required by the Company, Consultant shall prepare and sign such documents affirming Consultant’s citizenship and residency for tax purposes.

(d) Client Solicitation. While providing Services to the Company, Consultant shall not solicit work, remuneration or other benefits of any kind directly from any the Company contacts or affiliates without the express, prior written consent of the Company.

(e) Notices. All notices, demands, requests, or other communications that may be or are required to be given, served, or sent by any party to any other party pursuant to this Agreement shall be in writing and shall be sent by email, next-day courier, or mailed by first-class, registered or certified mail, return receipt requested, postage prepaid, or transmitted by hand delivery, addressed as follows:

If to the Company:

ProtoKinetix, Incorporated

Attn: Clarence E. Smith, President & CEO

9176 South Pleasants Highway

St. Marys, WV 26170

If to Consultant:

Grant Young

With a copy to:

Burns Figa & Will PC

Attn: Victoria B. Bantz, Esq.

6400 S. Fiddlers Green Cir., #1000

Greenwood Village, CO 80111

(f) Assignment. This Agreement may not be assigned by either party without prior written consent of the other.

(g) Entire Agreement. This Agreement, not including any other agreement pursuant to which securities of the Company are issued to Consultant, represents the entire agreement between the parties and supersedes all prior negotiations, representations, agreements, arrangements, and understandings, if any, either written or oral, between the parties with respect to the subject matter of this Agreement, none of which shall be used to interpret or construe this Agreement. If any term, covenant, condition or provision of this Agreement or the documents and instruments executed and delivered in connection herewith is held by a court of competent jurisdiction to be invalid, void or unenforceable, the remainder of the provisions shall remain in full force and effect and shall in no way be affected, impaired or invalidated.

(h) Law Governing. This Agreement shall be construed and enforced in accordance with the laws of the State of Colorado even though Consultant may perform services or reside in other states or countries.

(i) Amendments. Neither party may amend this Agreement or rescind any of its existing provisions without the prior written consent of the other party.

(j) Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and will become effective and binding upon the parties at such time as all of the signatories hereto have signed a counterpart of this Agreement. All counterparts so executed shall constitute one Agreement binding on all of the parties hereto, notwithstanding that all of the parties are not signatory to the same counterpart. In all other respects, this Agreement shall continue to remain in full force and effect. Facsimile or .pdf transmissions containing signatures shall be considered delivery and shall be deemed binding.

(k) Remedies. As the violation by Consultant of the provisions of Sections 3 and/or 4 of this Agreement would cause irreparable injury to the Company, and there is no adequate remedy at law for such violation, the Company shall have the right to seek specific performance or injunctive relief against Consultant without the posting of a bond or other security. The remedies available with respect to the rights and obligations under this Agreement are cumulative, and this section shall not be construed to limit in any manner whatsoever any other rights or remedies that may be available for any breach of this Agreement.

8. Venue. All disputes arising out of or relating to this Agreement and all actions to enforce this Agreement shall be adjudicated in the state or federal courts sitting in Denver, Colorado. The parties hereto irrevocably submit to the jurisdiction of such courts in any suit, action or proceeding relating to any such dispute. So far as is permitted under applicable law, this consent to personal jurisdiction shall be self-operative and no further instrument or action, other than service of process or as permitted by law, shall be necessary in order to confer jurisdiction upon the undersigned in any such court.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have executed this Consulting Agreement on the date first written above.

ProtoKinetix, Incorporated

By: /s/Clarence E. Smith

Clarence E. Smith, President and CEO

Consultant

/s/Grant Young

Grant Young

EX-31.1 3 ex31x1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Clarence E. Smith, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended September 30, 2017;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 13, 2017	/s/ Clarence E. Smith
	Name:	Clarence E. Smith
	Title:	Chief Executive Officer (Principal Executive Officer)

EX-31 4 ex31x2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Susan M. Woodward, certify that:

I have reviewed this Quarterly Report on Form 10-Q of ProtoKinetix, Incorporated for the period ended September 30, 2017;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 13, 2017	/s/ Susan M. Woodward
	Name:	Susan M. Woodward
	Title:	Chief Financial Officer (Principal Financial Officer)

EX-32.1 5 ex32x1.htm EXHIBIT 32.1

EXHIBIT 32

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of ProtoKinetix, Incorporated, (the “Company”) on Form 10-Q for the period ended September 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Clarence E. Smith, Chief Executive Officer and Principal Executive Officer of the Company and Susan M. Woodward, Chief Financial Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of the undersigned’s knowledge and belief:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

November 13, 2017	/s/ Clarence E. Smith
	Name:	Clarence E. Smith
	Title:	Chairman of the Board and Chief Executive Officer (Principal Executive Officer)

November 13, 2017	/s/ Susan M. Woodward
	Name:	Susan M. Woodward
	Title:	Chief Financial Officer (Principal Financial Officer)

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-101.INS 6 pktx-20170930.xml XBRL INSTANCE DOCUMENT 0001128189 2017-01-01 2017-09-30 0001128189 2016-12-31 0001128189 2017-09-30 0001128189 pktx:ClarenceSmithCEOMember 2016-12-31 0001128189 pktx:ClarenceSmithCEOMember 2017-09-30 0001128189 us-gaap:CommonStockMember 2016-12-31 0001128189 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001128189 us-gaap:RetainedEarningsMember 2016-12-31 0001128189 us-gaap:CommonStockMember 2017-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0001128189 us-gaap:RetainedEarningsMember 2017-09-30 0001128189 2016-01-01 2016-09-30 0001128189 2016-07-01 2016-09-30 0001128189 2017-07-01 2017-09-30 0001128189 us-gaap:CommonStockMember 2017-01-01 2017-09-30 0001128189 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-09-30 0001128189 us-gaap:RetainedEarningsMember 2017-01-01 2017-09-30 0001128189 us-gaap:WarrantMember 2016-01-01 2016-03-31 0001128189 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0001128189 us-gaap:StockOptionMember 2017-01-01 2017-09-30 0001128189 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001128189 2017-06-30 0001128189 2016-01-01 2016-03-31 0001128189 us-gaap:StockOptionMember 2016-12-31 0001128189 us-gaap:StockOptionMember 2017-09-30 0001128189 pktx:Date3Member 2017-09-30 0001128189 pktx:Date2Member 2017-09-30 0001128189 pktx:Date4Member 2017-09-30 0001128189 pktx:Date12Member 2017-09-30 0001128189 pktx:Date9Member 2017-09-30 0001128189 pktx:Date11Member 2017-09-30 0001128189 pktx:Date6Member 2017-09-30 0001128189 pktx:Date1Member 2017-09-30 0001128189 us-gaap:StockOptionMember 2016-01-01 2016-09-30 0001128189 pktx:WarrantOneMember 2017-09-30 0001128189 pktx:WarrantTwoMember 2017-09-30 0001128189 pktx:WarrantTwoMember 2017-01-01 2017-09-30 0001128189 pktx:WarrantOneMember 2017-01-01 2017-09-30 0001128189 2015-12-31 0001128189 2016-09-30 0001128189 2017-11-13 0001128189 pktx:August312021Member 2017-09-30 0001128189 us-gaap:PatentsMember 2016-01-01 2016-12-31 0001128189 us-gaap:PatentsMember 2015-12-31 0001128189 us-gaap:PatentsMember 2016-12-31 0001128189 pktx:PatentApplicationRightsMember 2016-01-01 2016-12-31 0001128189 pktx:PatentApplicationRightsMember 2015-12-31 0001128189 pktx:PatentApplicationRightsMember 2016-12-31 0001128189 2016-01-01 2016-12-31 0001128189 us-gaap:PatentsMember 2017-01-01 2017-09-30 0001128189 us-gaap:PatentsMember 2017-09-30 0001128189 pktx:PatentApplicationRightsMember 2017-01-01 2017-09-30 0001128189 pktx:PatentApplicationRightsMember 2017-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure --12-31 pktx 2017-09-30 No Smaller Reporting Company No 10-Q false 2017 ProtoKinetix, Inc. 0001128189 Yes Q3

0.0000053

400000000

441413

483865

542094

637643

45295

19818

45295

19818

542094

637643

496799

617825

1273

29115795

-28620269

1339

30242806

-29626320

-28620269

-29626320

29115795

30242806

1273

1339

237952433

250352433

237952433

250352433

-1006051

-1149885

-432077

-299292

-1006051

320000

319957

587077 0 587077 0

6500000

28600000

55100000

6500000

54770

97723

15614

250000

100000

0 0.07

407780

55100000

28900000

55100000

2000000

1000000

5000000

16200000

15000000

300000

4000000

600000

11000000

0.11

0.06

0.04

0.05

0.04

0.05

0.08

0.04

0.1

0.06

0.03

0.05

0.03

0.0105

0.0056

0.0000

1.2500

0.0000 0.0000

P3Y5M16D

P3Y11M8D

38050000

1000000

5000000

12150000

15000000

300000

4000000

600000

6500000

500000

6000000

0.25 0.10 April 22, 2020 November 8, 2018

54000

110000

392000

6500000

250352433

27200000

1000000

0.05

0.1

0.04

0.03

P2Y9M7D

54770

97723

70384

97723

1001717

1149885

432077

299192

587077

574128

199365

170536

228130

355089

174957

72857

109823

147977

39664

42549

74437

70441

17341

12500

245315070

219242214

222088754

247148085

-0.00

-0.01

-0.00

-4334

-100

371029

386142

371072

88965

15113

-282107

540000

380000

-40176

-7589

40176

7589

587077 574128 0 7000

540000

380000

15614 0 3631 0 0 7000

237952433

250352433

8000000

ProtoKinetix, Incorporated (the “Company”), a development stage company, was incorporated under the laws of the State of Nevada on December 23, 1999.  The Company is a medical research company whose mission is the advancement of human health care.   The Company is currently researching the benefits and feasibility of synthesized Antifreeze Glycoproteins (“AFGP”) or anti-aging glycoproteins, trademarked AAGP™.  During the year ended December 31, 2015, the Company acquired certain patents and rights for cash consideration of $30,000 (25,000 Euros), as well as additional patent applications for cash consideration of $10,000 and 6,000,000 share purchase warrants with a fair value of $25,000 (Note 4).   During the year ended December 31, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission.   The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.   The Company has not developed a commercially viable product, has not generated any significant revenue to date, and has incurred losses since inception, resulting in a net accumulated deficit at September 30, 2017.  These factors raise substantial doubt about the Company's ability to continue as a going concern.   The Company needs additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities.  Therefore, continuation of the Company as a going concern is dependent upon obtaining the additional working capital necessary to accomplish its objective.  Management is presently engaged in seeking additional working capital through equity financing or related party loans.   The accompanying financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company fail in any of the above objectives and is unable to operate for the coming year.

Basis of Presentation   The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.   Use of Estimates   Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.   Cash   Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.   Fair Value of Financial Instruments   Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:   Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   Level 1 inputs are used to measure cash. At September 30, 2017 there were no other assets or liabilities subject to additional disclosure.   Income Taxes   The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.”  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.   Intangible Assets – Patent and Patent Application Costs   The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.   As at September 30, 2017, the Company does not hold any intangible assets with indefinite lives.   Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.   Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.   Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2017.   Research and Development Costs   Research and development costs are expensed as incurred.   Loss per Share and Potentially Dilutive Securities   Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 55,100,000 stock options (September 30, 2016 – 28,600,000) and 6,500,000 warrants (September 30, 2016 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.   Share-Based Compensation   The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.   The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.   The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.   Common Stock   Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete.   Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.   Related Party Transactions   A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.   Recent Accounting Pronouncements   In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements.   Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements.   Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Company’s financial statements.   Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.   Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

Intangible asset transactions are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">Patent Rights</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid"> Patent Application Rights</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Cost</td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 52%; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">41,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">71,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">105,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">55,347</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">55,347</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, September 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">130,528</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">160,528</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Accumulated amortization</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">2,250</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">2,250</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, September 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,750</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,750</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Net carrying amounts</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">25,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">100,681</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">September 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">23,250</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">130,528</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">153,778</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> </table>     During the year ended December 31, 2015, the Company entered into an Assignment of Patents and Patent Application (effective January 1, 2015) (the “Patent Assignment”) with the Institut National des Sciences Appliquees de Rouen (“INSA”) for the assignment of certain patents and all rights associated therewith (the “Patents”). The Company and INSA had previously entered into a licensing agreement for the Patents in August 2004. The Patent Assignment transfers all of the Patents and rights associated therewith to the Company upon payment to INSA in the sum of $30,000 (25,000 Euros) (paid). During the nine month period ended September 30, 2017, the Company recorded $2,250 (September 30, 2016 - $2,250) in amortization expense associated with the Patents.   During the year ended December 31, 2015, the Company entered into a Technology Transfer Agreement with Grant Young for the assignment of his 50% ownership of certain patents and all rights associated therewith (the “Patent Application Rights”).  In exchange for the Patent Application Rights, the Company agreed to pay $10,000 (paid) and to issue 6,000,000 warrants (issued) to purchase shares of the Company's common stock at an exercise price of $0.10 per share for a period of five years. The Patent Application Rights had a total fair value of $35,000, which was allocated as $10,000 to the cash consideration paid, with the remaining $25,000 being allocated to the warrant component of the overall consideration. The Company has incurred $82,047 in direct costs relating to the Patent Application Rights, $44,277 of which were incurred during the nine month period ended September 30, 2017.   The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.   During the year ended December 31, 2016, the Company entered into a Universal Assignment with Grant Young for the assignment of his ownership of certain new and useful improvements in an invention entitled “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells” (the “New Patent Application Rights”).  In exchange for the New Patent Application Rights, the Company agreed to pay $1 (paid).  The Company has incurred $13,481 in direct costs relating to the New Patent Application Rights, $11,065 of which were incurred during the nine month period ended September 30, 2017.   No amortization was recorded on the Patent Application Rights to September 30, 2017.

On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia.  Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly.  The Company’s President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells”. As at  December 31, 2016, the balance outstanding was $nil.  As of September 30, 2017, the line of credit was canceled and the pledged assets were released.

During the nine month periods ended September 30, 2017 and 2016, the Company issued shares of common stock for services and other value rendered as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">   2017</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 52%; text-align: justify">January - September 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">   2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 52%; text-align: justify">March 2016</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 13%; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>

The Company is authorized to issue 400,000,000 (December 31, 2016 – 400,000,000) shares of $0.0000053 par value common stock.  Each holder of common stock has the right to one vote but does not have cumulative voting rights. Shares of common stock are not subject to any redemption or sinking fund provisions, nor do they have any preemptive, subscription or conversion rights. Holders of common stock are entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid as of September 30, 2017 (December 31, 2016 - $nil).   During the nine month period ended September 30, 2017, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif">a)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Issued 8,000,000 shares of common stock to investors (which included both the President and CEO as well as the CFO of the Company) at $0.04 for gross proceeds of $320,000.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif; text-align: justify">b)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Issued 4,400,000 shares of common stock to investors at $0.05 for gross proceeds of $220,000.</td></tr> </table>

During the nine month period ended September 30, 2016, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="width: 2%"> </td> <td style="vertical-align: top; width: 3%; font: 12pt Times New Roman, Times, Serif">a)</td> <td style="vertical-align: top; width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2016. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control.  In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of an Application Sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement.  Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options are fully vested as at September 30, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="width: 2%"> </td> <td style="vertical-align: top; width: 3%; font: 12pt Times New Roman, Times, Serif">b)</td> <td style="vertical-align: top; width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2016 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2016.  The agreement also stipulates a termination fee that would pay the Company’s CFO $36,000 if terminated without cause or $72,000 upon termination due to a change of control event.  Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7).  The options are fully vested as at September 30, 2017.  A total of $54,000 was paid to the Company’s CFO during the nine month period ended September 30, 2016 and is included in professional fees.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="width: 2%"> </td> <td style="vertical-align: top; width: 3%; font: 12pt Times New Roman, Times, Serif">c)</td> <td style="vertical-align: top; width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a directorship agreement with an effective date of January 1, 2016 with a director of the Company. Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2019 at a price of $0.08 per share (Note 7). The options are fully vested as at September 30, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="width: 2%"> </td> <td style="vertical-align: top; width: 3%; font: 12pt Times New Roman, Times, Serif">d)</td> <td style="vertical-align: top; width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Recognized $407,780 in share-based compensation associated with stock options granted to key management personnel.</td></tr> </table>   During the nine months ended September, 30, 2017, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif">a)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s President and CEO whereby he will be compensated at a nominal amount of $1 for services through to December 31, 2017. The agreement also stipulates a termination fee that would pay the Company’s President and CEO $100,000 per year of service if terminated without cause or in the case of termination upon a change of control event, the termination fee would be equal to $100,000 per year of service plus 2.5% of the aggregate transaction value of the change of control.  In addition, the agreement stipulates that he would be entitled to a bonus payment equal to 2.5% of the aggregate transaction value of a sale or license of any Patent Rights, Patent Application Rights or products effected during the term of his agreement.  Pursuant to the agreement, he was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note7).  The options vest in equal installments on a quarterly basis beginning March 31, 2017. On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew.  The consulting agreement was also amended to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7).  The options vest quarterly in equal installments beginning December 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif">b)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2017 with the Company’s CFO whereby she will be compensated at a monthly fee of $6,000 for services through to December 31, 2017.  The agreement also stipulates a termination fee that would pay the Company’s CFO $72,000 per year of service (including the pro-rata amount for partial years of service) if terminated without cause or upon termination due to a change of control event.  Pursuant to the agreement, she was also granted 4,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vest in equal installments on a quarterly basis beginning March 31, 2017.  A total of $54,000 was paid to the Company’s CFO during the period ended September 30, 2017 and is included in professional fees.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 12pt Times New Roman, Times, Serif">c)</td> <td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a directorship agreement with an effective date of January 1, 2017 with a director of the Company.  Pursuant to the agreement, the director was issued 1,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vest in equal installments on a quarterly basis beginning March 31, 2017.  On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew.  The consulting agreement was also amended to grant an additional 1,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7).  The options vest quarterly in equal installments beginning December 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif">d)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Recognized $297,412 in share-based compensation associated with stock options granted to key management personnel.</td></tr> </table>   As at September 30, 2017 and December 31, 2016, the following amounts are due to related parties:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">September 30, 2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">December 31, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">Clarence Smith (CEO)</td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">Accounts payable and accrued liabilities</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif; text-align: right">81</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

As at September 30, 2017, the Company has the following commitments:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 12pt Times New Roman, Times, Serif">a)</td> <td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement with an effective date of January 1, 2017 whereby the Company would pay the consultant $7,000 per month for providing research and development services.  Pursuant to the agreement, the consultant was also granted 5,000,000 stock options exercisable into common shares of the Company until December 31, 2020 at a price of $0.05 per share (Note 7).  The options vest in equal installments on a quarterly basis beginning March 31, 2017.  On September 1, 2017 the consulting agreement was amended to continue the term of the agreement until December 31, 2018 and thereafter to automatically renew.  The consulting agreement was also amended to grant an additional 5,000,000 stock options exercisable into common shares of the Company until August 31, 2021 at a price of $0.06 per share (Note 7).  The options vest quarterly in equal installments beginning December 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 12pt Times New Roman, Times, Serif">b)</td> <td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement for business development services effective January 1, 2017.  The consultant was granted 1,200,000 stock options exercisable into common shares of the Company at a price of $0.05 per share until December 31, 2020 (Note 7).  The options vest in equal installments on a quarterly basis beginning March 31, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 5%; font: 12pt Times New Roman, Times, Serif">c)</td> <td style="width: 95%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a Collaborative Research Agreement (the “CREA”) effective May 31, 2016 with The University of British Columbia (“UBC”) for a term of 2 years. Pursuant to the CREA, the Company paid a total of CAD $169,000 ($131,448) in advance for services to be provided by UBC in the first year, and paid an additional CAD $201,500 ($146,585) during the nine month period ended September 30, 2017, in advance of services to be provided by UBC in the second year. The CREA can be terminated by either party with 30 days’ written notice.  As at September 30, 2017, a total of $97,723 is included in prepaid expenses and deposits (December 31, 2016 - $54,770).</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 12pt Times New Roman, Times, Serif">d)</td> <td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement effective March 1, 2015, whereby the Company would pay the consultant $2,700 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice, for providing public relations services. The consultant is also entitled to 400,000 shares of common stock, which will be issued at a rate of 25% (100,000 shares) every 3 months over the term of the agreement (100,000 shares issued during the nine month period ended September 30, 2016 (Note 6)). The consultant was also issued 1,000,000 stock options on signing during the year ended December 31, 2015, with each stock option exercisable into a common share at a price of $0.10. The stock options expired March 12, 2016.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 12pt Times New Roman, Times, Serif">e)</td> <td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a royalty agreement with the Governors of the University of Alberta (the “University”) whereby the University had developed certain intellectual property (the “Additional Patent Rights”) in conjunction with and by permission of the Company employing patented intellectual property of the Company. The agreement assigns the Additional Patent Rights to the Company in return for 5% of any future gross revenues (the “Royalty”) derived from products arising from the Patent Rights.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; font: 12pt Times New Roman, Times, Serif">f)</td> <td style="width: 96%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a consulting agreement effective May 1, 2015, whereby the Company would pay the consultant $4,000 per month for an initial term of 1 year, continued on a year-to-year basis thereafter unless otherwise terminated by either party with at least 30 days’ notice for providing research and development services.  During the nine month period ended September 30, 2017 the contract was revised whereby the Company would pay the consultant CAD $4,000 per month retroactively beginning January 1, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif">g)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a Material Transfer Agreement effective March 31, 2017 with Proactive Immune Sciences Corporation (“Proactive”) for a term of 1 year.  The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.</td></tr> </table>   The Company was delinquent in filing certain income tax returns with the U.S. Internal Revenue Service and reports disclosing its interest in foreign bank accounts on form TDF 90-22.1, “Report of Foreign Bank and Financial Accounts” (“FBARs”). In September 2015, the Company filed the delinquent income tax returns and has sought waivers of any penalties under the IRS Offshore Voluntary Disclosure Program for late filing of the returns and FBARs.  Under the program, the IRS has indicated that it will not impose a penalty for the failure to file delinquent income tax returns if there are no underreported tax liabilities.  The Company may be liable for civil penalties for certain tax years in an indeterminate amount for not complying with the FBAR reporting and recordkeeping requirements.  No claim has been asserted by the U.S. Internal Revenue Service; before any claim is expressly asserted the Company intends to cooperate with the Internal Revenue Service to minimize any liability. The Company is unable to determine the amount of any penalties that may be assessed at this time.

The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period.  Actual results could differ from those estimates.  The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.

Cash consists of funds held in checking accounts.  Cash balances may exceed federally insured limits from time to time.

Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.   The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value:   Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   Level 1 inputs are used to measure cash. At September 30, 2017 there were no other assets or liabilities subject to additional disclosure.

The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.”  Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases.  The Company applies the accounting guidance issued to address the accounting for uncertain tax positions.  This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition  Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.

The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred.   As at September 30, 2017, the Company does not hold any intangible assets with indefinite lives.   Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually.   Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates.   Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2017.

Research and development costs are expensed as incurred.

Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period.  Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities.  The effect of 55,100,000 stock options (September 30, 2016 – 28,600,000) and 6,500,000 warrants (September 30, 2016 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.

The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services.  The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model.   The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest.  The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance.   The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.

Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete.   Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company.  A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.

In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements.   Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements.   Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Company’s financial statements.   Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements.   Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

The following summarizes the Company’s prepaid expenses and deposits outstanding as at September 30, 2017 and December 31, 2016:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">December 31, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 68%; text-align: justify">Deposit on research agreement (Note 11(c))</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">97,723</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">54,770</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Other prepaid expenses</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">15,614</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">97,723</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">70,384</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> </table> Intangible asset transactions are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">Patent Rights</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid"> Patent Application Rights</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">Cost</td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 52%; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">41,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">71,760</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">33,421</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">105,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Additions</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">55,347</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">55,347</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, September 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">30,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">130,528</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">160,528</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Accumulated amortization</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2015</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">3,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">4,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify">Amortization</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">2,250</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">2,250</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">Balance, September 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,750</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,750</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Net carrying amounts</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">December 31, 2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">25,500</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">75,181</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">100,681</td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; border-bottom: black 2.25pt double; text-align: justify">September 30, 2017</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">23,250</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">130,528</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">153,778</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">   2017</td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td colspan="3" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td colspan="3" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 52%; text-align: justify">January - September 2017</td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%; text-align: right"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">   2016</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: center">Number of Shares</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; padding-bottom: 1.5pt; text-align: center">Value per Share</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td nowrap="nowrap" style="padding-bottom: 1.5pt"> </td></tr> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: bottom"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="vertical-align: top"> </td> <td nowrap="nowrap" style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 52%; text-align: justify">March 2016</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 13%; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">0.07</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 13%; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; padding-bottom: 3pt; text-align: right">100,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">7,000</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Stock Options</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Fair Value</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average  Remaining Life</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">(Years)</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding, December 31, 2016</td> <td> </td> <td> </td> <td style="text-align: right">28,900,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.06</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>      Options granted</td> <td> </td> <td> </td> <td style="text-align: right">27,200,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.03</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid">      Options expired</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid">)</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">0.10</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">0.03</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 36%; border-bottom: black 2.25pt double">Outstanding, September 30, 2017</td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: right">55,100,000</td> <td nowrap="nowrap" style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: center">0.06</td> <td nowrap="nowrap" style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: center">0.04</td> <td nowrap="nowrap" style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 1%; border-bottom: black 2.25pt double"> </td> <td style="width: 13%; border-bottom: black 2.25pt double; text-align: center">2.77</td> <td nowrap="nowrap" style="width: 1%; border-bottom: black 2.25pt double"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; width: 51%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; width: 24%; border-bottom: black 1.5pt solid">   September 30, 2017</td> <td style="vertical-align: bottom; width: 25%; border-bottom: black 1.5pt solid; text-align: center">September 30, 2016</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: 0.05in">Risk-free interest rate</td> <td style="text-align: right">1.05%</td> <td style="text-align: right">0.56%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Dividend yield</td> <td style="text-align: right">0.00%</td> <td style="text-align: right">0.00%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: 0.05in">Expected stock price volatility</td> <td style="text-align: right">125.00%</td> <td style="text-align: right">125.00%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Expected forfeiture rate</td> <td style="text-align: right">0.00%</td> <td style="text-align: right">0.00%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; text-indent: 0.05in">Expected life</td> <td style="border-bottom: black 1.5pt solid; text-align: right">3.46 years</td> <td style="border-bottom: black 1.5pt solid; text-align: right">3.94 years</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> Number of Warrants</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 68%; padding-bottom: 3pt; text-align: justify">Balance, December 31, 2016 and September 30, 2017</td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 2.25pt double; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; width: 13%; border-bottom: black 2.25pt double; padding-bottom: 3pt; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; width: 1%; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; width: 13%; border-bottom: black 2.25pt double; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: 21pt">Number of Warrants</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price ($)</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid">   Expiry Date</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 30%; text-align: right">500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 30%; text-align: right">0.25</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: top; width: 35%; text-align: right">November 8, 2018</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">6,000,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right">April 22, 2020</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">September 30, 2017</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center">December 31, 2016</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 34%; border-bottom: black 1.5pt solid">Clarence Smith (CEO)</td> <td style="vertical-align: top; width: 34%; border-bottom: black 1.5pt solid">Accounts payable and accrued liabilities</td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; width: 13%; border-bottom: black 1.5pt solid; text-align: right">-</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid">$</td> <td style="vertical-align: bottom; width: 13%; border-bottom: black 1.5pt solid; text-align: right">81</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%; border-bottom: black 1.5pt solid"> </td></tr> </table>

4400000 220000 23 219977 0 3188 0

8023

42953

91032

-25034

-5002

-484711

-654518

27200000

7000

105181

160528

71760

30000

41760

75181

30000

130528

55347

33421

55347

4500

6750

1500

4500

6750

2250

3000

2250

100681

153778

25500

75181

23250

130528

2250

750

On December 30, 2016, the Board of Directors of the Company adopted the 2017 Stock Option and Stock Bonus Plan (the “2017 Plan”).  The Board of Directors adopted the 2017 Plan as it anticipates utilizing equity compensation as part of its ongoing standard corporate operations and in connection with its contemplated activities going forward.   The aggregate number of shares that may be issued under the 2017 Plan is 30,000,000 shares subject to adjustment as provided therein.  The 2017 Plan includes two types of options.  Options intended to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended are referred to as incentive options.  Options which are not intended to qualify as incentive options are referred to as non-qualified options. As of September 30, 2017, 27,200,000 options and no shares of common stock have been granted under the 2017 Plan.   The 2017 Plan is administered by the Board of Directors, or a committee appointed by the Board of Directors.  In addition to determining who will be granted options or stock bonuses, the committee has the authority and discretion to determine when options and bonuses will be granted and the number of options and bonuses to be granted.  The committee also may determine a vesting and/or forfeiture schedule for bonuses and/or options granted, the time or times when each option becomes exercisable, the duration of the exercise period for options and the form or forms of the agreements, certificates or other instruments evidencing grants made under the 2017 Plan.  The committee may determine the purchase price of the shares of common stock covered by each option.  The committee also may impose additional conditions or restrictions not inconsistent with the provisions of the 2017 Plan.  The committee may adopt, amend and rescind such rules and regulations as in its opinion may be advisable for the administration of the 2017 Plan.    In the event that a change, such as a stock split, is made in the Company’s capitalization which results in an exchange or other adjustment of each share of common stock for or into a greater or lesser number of shares, appropriate adjustments will be made to unvested bonuses and in the exercise price and in the number of shares subject to each outstanding option.  The committee also may make provisions for adjusting the number of bonuses or underlying outstanding options in the event the Company effects one or more reorganizations, recapitalizations, rights offerings, or other increases or reductions of shares of its outstanding common stock.  Options and bonuses may provide that in the event of the dissolution or liquidation of the Company, a corporate separation or division or the merger or consolidation of the Company, the holder may exercise the option on such terms as it may have been exercised immediately prior to such dissolution, corporate separation or division or merger or consolidation; or in the alternative, the committee may provide that each option granted under the 2017 Plan shall terminate as of a date fixed by the committee.   The exercise price of any option granted under the 2017 Plan must be no less than 100% of the “fair market value” of the Company’s common stock on the date of grant.  The exercise period of any option shall not exceed ten years from the date of grant of the option. Any incentive stock option granted under the 2017 Plan to a person owning more than 10% of the total combined voting power of the common stock must be at a price of no less than 110% of the fair market value per share on the date of grant and the term shall be for no more than five years.    Stock option transactions are summarized as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Stock Options</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Fair Value</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average  Remaining Life</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">(Years)</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Outstanding, December 31, 2016</td> <td> </td> <td> </td> <td style="text-align: right">28,900,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.06</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>      Options granted</td> <td> </td> <td> </td> <td style="text-align: right">27,200,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: center">0.03</td> <td nowrap="nowrap"> </td> <td> </td> <td colspan="2"> </td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid">      Options expired</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid">)</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">0.10</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">0.03</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double">Outstanding, September 30, 2017</td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">55,100,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: center">0.06</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: center">0.04</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: center">2.77</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table> The fair values of the stock options granted during the nine month periods ended June 30, 2017 and 2016 were estimated using the Black-Scholes Option Pricing Model.  The weighted average assumptions used in the pricing model for these options are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; width: 51%; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; width: 24%; border-bottom: black 1.5pt solid">   September 30, 2017</td> <td style="vertical-align: bottom; width: 25%; border-bottom: black 1.5pt solid; text-align: center">September 30, 2016</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: 0.05in">Risk-free interest rate</td> <td style="text-align: right">1.05%</td> <td style="text-align: right">0.56%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Dividend yield</td> <td style="text-align: right">0.00%</td> <td style="text-align: right">0.00%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-indent: 0.05in">Expected stock price volatility</td> <td style="text-align: right">125.00%</td> <td style="text-align: right">125.00%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-indent: 0.05in">Expected forfeiture rate</td> <td style="text-align: right">0.00%</td> <td style="text-align: right">0.00%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid; text-indent: 0.05in">Expected life</td> <td style="border-bottom: black 1.5pt solid; text-align: right">3.46 years</td> <td style="border-bottom: black 1.5pt solid; text-align: right">3.94 years</td></tr> </table>   The following non-qualified stock options were outstanding and exercisable at September 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Expiry date</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Outstanding</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Exercisable</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">February 25, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">0.04</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">2,000,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 24, 2018</td> <td> </td> <td> </td> <td style="text-align: center">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 25, 2020</td> <td> </td> <td> </td> <td style="text-align: center">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 28, 2020</td> <td> </td> <td> </td> <td style="text-align: center">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>June 30, 2018</td> <td> </td> <td> </td> <td style="text-align: center">0.10</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2019</td> <td> </td> <td> </td> <td style="text-align: center">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>October 05, 2018</td> <td> </td> <td> </td> <td style="text-align: center">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: center">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">16,200,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">12,150,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid">August 31, 2021</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">0.06</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: center"> </td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">55,100,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">38,050,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td></tr> </table>   As at September 30, 2017, the aggregate intrinsic value of the Company’s stock options is $392,000 (December 31, 2016 – $110,000). The weighted average fair value of stock options granted during the nine month period ended September 30, 2017 is $0.03 (2016 - $0.05).

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid">Expiry date</td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Outstanding</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Options Exercisable</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center">$ </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 52%">February 25, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: center">0.04</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">2,000,000</td> <td nowrap="nowrap" style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 13%; text-align: right">-</td> <td nowrap="nowrap" style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 24, 2018</td> <td> </td> <td> </td> <td style="text-align: center">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>February 25, 2020</td> <td> </td> <td> </td> <td style="text-align: center">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">4,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>February 28, 2020</td> <td> </td> <td> </td> <td style="text-align: center">0.04</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">5,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>June 30, 2018</td> <td> </td> <td> </td> <td style="text-align: center">0.10</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2019</td> <td> </td> <td> </td> <td style="text-align: center">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">15,000,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>October 05, 2018</td> <td> </td> <td> </td> <td style="text-align: center">0.08</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">300,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>December 31, 2020</td> <td> </td> <td> </td> <td style="text-align: center">0.05</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">16,200,000</td> <td nowrap="nowrap"> </td> <td> </td> <td> </td> <td style="text-align: right">12,150,000</td> <td nowrap="nowrap"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid">August 31, 2021</td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">0.06</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">11,000,000</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: center"> </td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">55,100,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">38,050,000</td> <td nowrap="nowrap" style="border-bottom: black 2.25pt double"> </td></tr> </table>

Warrant transactions for the nine month period ended September 30, 2017 are summarized as follows:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid; padding-bottom: 1.5pt"> Number of Warrants</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> Weighted Average Exercise Price</td> <td nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; padding-bottom: 3pt; text-align: justify">Balance, December 31, 2016 and September 30, 2017</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 12pt Times New Roman, Times, Serif; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 12pt Times New Roman, Times, Serif; padding-bottom: 3pt; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 3pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 12pt Times New Roman, Times, Serif">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; font: 12pt Times New Roman, Times, Serif; text-align: right">0.11</td> <td nowrap="nowrap" style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 3pt"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table> The following warrants were outstanding and exercisable as at September 30, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; text-indent: 21pt">Number of Warrants</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price ($)</td> <td nowrap="nowrap" style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid">   Expiry Date</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 30%; text-align: right">500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 30%; text-align: right">0.25</td> <td nowrap="nowrap" style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: top; width: 35%; text-align: right">November 8, 2018</td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">6,000,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: right">0.10</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 1.5pt solid"> </td> <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: right">April 22, 2020</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">6,500,000</td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right"> </td> <td nowrap="nowrap" style="vertical-align: bottom; border-bottom: black 2.25pt double"> </td> <td style="vertical-align: top; border-bottom: black 2.25pt double"> </td></tr> </table>

Note 12. Subsequent Event   Subsequent to the nine month period ended September 30, 2017, the Company:   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif">a)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into two Promissory Notes (the “Notes”) with the Company’s President and CEO whereby a total of $116,000 was loaned to the Company.  The Notes bear interest at a rate of 8% per annum, are unsecured and are repayable on demand.  The funds from these Notes will be used to make payment under the Settlement Agreement referred to below.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="width: 3%; font: 12pt Times New Roman, Times, Serif">b)</td> <td style="width: 97%; font: 12pt Times New Roman, Times, Serif; text-align: justify">Entered into a Settlement Agreement with the Company’s CFO on November 3, 2017 whereby she will leave her position as CFO effective upon the filing of the Company’s quarterly report for the nine month period ended September 30, 2017.  Pursuant to the Settlement Agreement, the Company will pay the former CFO $6,000 for December 2017 consulting services (Note 10) and $110,000 in exchange for the return of stock options to purchase up to 12,000,000 shares of the Company’s common stock currently held by the CFO, which will be subsequently cancelled.</td></tr> </table>

EX-101.SCH 7 pktx-20170930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 1. Basis of Presentation - Going Concern Uncertainties link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 2. Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 3. Prepaid Expenses and Deposits link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 4. Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 5. Credit Facility link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 6. Common Shares Issued for Services link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 7. Stock Options link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 8. Warrants link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 9. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 10. Related Party Transactions and Balances link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 11. Commitments and Contingency link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 12. Subsequent Event link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 3. Prepaid Expenses and Deposits (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 4. Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 6. Common Shares Issued for Services (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 7. Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 8. Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 10. Related Party Transactions and Balances (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 3. Prepaid Expenses and Deposits (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 4. Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 4. Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 5. Credit Facility (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 6. Common Shares Issued for Services (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 7. Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 7. Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 7. Stock Options (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 7. Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 8. Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 8. Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 9. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 10. Related Party Transactions and Balances (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - 10. Related Party Transactions and Balances (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - 11. Commitments and Contingency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pktx-20170930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pktx-20170930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pktx-20170930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Related Party [Axis] Clarence Smith (CEO) Statement, Equity Components [Axis] Common Stock Additional paid-in capital Accumulated Deficit Antidilutive Securities [Axis] Warrant Award Type [Axis] Stock options Exercise Price Range [Axis] February 25, 2020 February 24, 2018 February 28, 2020 December 31, 2020 December 31, 2019 October 05, 2018 February 25, 2020 One June 30, 2018 Warrant One Warrant Two August 31, 2021 Finite-Lived Intangible Assets by Major Class [Axis] Patent Rights [Member] Patent Application Rights [Member] Document and Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Document Period End Date Trading Symbol Current Fiscal Year End Date Entity Filer Category Entity Voluntary Filers Entity Well Known Seasoned Issuer Entity Current Reporting Status Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Prepaid expenses and deposits (Notes 3 and 11) Total current assets Intangible assets (Note 4) Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued liabilities (Note 10) Total current liabilities Stockholders' Equity Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 250,352,433 and 237,952,433 shares issued and outstanding as at September 30, 2017 and December 31, 2016 respectively (Note 9) Additional paid-in capital Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Common Stock, Par Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] EXPENSES Amortization - intangible assets (Note 4) General and administrative Professional fees (Note 10) Research and development Share-based compensation (Note 10) Total OTHER ITEM Foreign exchange loss Net loss for the period Net loss per common share (basic and diluted) Weighted average number of common shares outstanding (basic and diluted) Statement [Table] Statement [Line Items] Equity Components [Axis] Beginning Balance, Shares Beginning Balance, Amount Issuance of common stock pursuant to private placement offering, shares Issuance of common stock pursuant to private placement offering, amount Fair value of compensatory options issued Issuance of common stock pursuant to private placement offering, shares Issuance of common stock pursuant to private placement offering, amount Net loss for the period Ending Balance, Shares Ending Balance, Amount Statement of Cash Flows [Abstract] CASH FLOWS USED IN OPERATING ACTIVITIES Adjustments to reconcile net loss to cash used in operating activities: Amortization - intangible assets Issuance and amortization of common stock for services Fair value of compensatory options granted Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and deposits Accounts payable and accrued liabilities Net cash used in operating activities CASH FLOWS USED IN INVESTING ACTIVITIES Purchase of Intangible assets Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Issuance of common stock for cash Net cash from financing activities Net change in cash Cash, beginning of period Cash, end of period Cash paid for interest Cash paid for income taxes Supplementary information - non-cash transactions: Common stock issued for consulting services Intangible asset costs previously included in accounts payable and accrued liabilities Intangible asset costs previously included in prepaid expenses and deposits Intangible asset costs included in accounts payable and accrued liabilities Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation - Going Concern Uncertainties Accounting Policies [Abstract] Summary of Significant Accounting Policies Prepaid Expenses And Deposits Prepaid Expenses and Deposits Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Debt Disclosure [Abstract] Credit Facility Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Common Shares Issued for Services Stock Options Stock Options Warrants Warrants Stockholders' Equity Note [Abstract] Stockholders' Equity Related Party Transactions [Abstract] Related Party Transactions and Balances Commitments and Contingencies Disclosure [Abstract] Commitments and Contingency Subsequent Events [Abstract] Subsequent Event Basis of Presentation Use of Estimates Cash Fair Value of Financial Instruments Income Taxes Intangible Assets - Patent and Patent Application Costs Research and Development Costs Loss per Share and Potentially Dilutive Securities Share-Based Compensation Common stock Related Party Transactions Recent Accounting Pronouncements Prepaid Expenses And Deposits Tables Prepaid expenses and deposits Intangible asset transactions Schedule of Stock Incentive Plan, Issuances Schedule of Share-based Compensation, Stock Options, Activity Schedule of valuation assumptions for options Schedule of options by exercise price Schedule of Warrant Activity Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of related party transactions Antidilutive Securities Excluded from Computation of Earnings Per Share Prepaid Expenses And Deposits Details Deposit on research agreement (Note 11(c)) Other prepaid expenses Prepaid expenses and deposits Range [Axis] Cost Beginning balance Additions Ending balance Accumulated amortization Beginning balance Amortization Ending balance Net carrying amounts Line of credit Number of Shares Value per Share Total Outstanding, beginning Options granted Options expired Outstanding, ending Weighted Average Exercise Price beginning Weighted Average Exercise Price, granted Weighted Average Exercise Price, expired Weighted Average Exercise Price ending Weighted Average Fair Value, beginning Weighted Average Fair Value, granted Weighted Average Fair Value, expired Weighted Average Fair Value, ending Weighted Average Remaining Life (Years) Risk-free interest rate Dividend yield Expected stock price volatility Expected forfeiture rate Expected life Exercise Price EX-101.PRE 11 pktx-20170930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2017	Nov. 13, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ProtoKinetix, Inc.
Entity Central Index Key	0001128189
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Trading Symbol	pktx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Voluntary Filers	No
Entity Well Known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		250,352,433
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Unaudited) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Current Assets
Cash	$ 386,142	$ 371,029
Prepaid expenses and deposits (Notes 3 and 11)	97,723	70,384
Total current assets	483,865	441,413
Intangible assets (Note 4)	153,778	100,681
Total assets	637,643	542,094
Current Liabilities
Accounts payable and accrued liabilities (Note 10)	19,818	45,295
Total current liabilities	19,818	45,295
Stockholders' Equity
Common stock, $0.0000053 par value; 400,000,000 common shares authorized; 250,352,433 and 237,952,433 shares issued and outstanding as at September 30, 2017 and December 31, 2016 respectively (Note 9)	1,339	1,273
Additional paid-in capital	30,242,806	29,115,795
Accumulated deficit	(29,626,320)	(28,620,269)
Total stockholders' equity	617,825	496,799
Total liabilities and stockholders' equity	$ 637,643	$ 542,094

XML 14 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Common Stock, Par Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	400,000,000	400,000,000
Common Stock, Shares, Issued	250,352,433	237,952,433
Common Stock, Shares, Outstanding	250,352,433	237,952,433

XML 15 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
EXPENSES
Amortization - intangible assets (Note 4)	$ 750	$ 750	$ 2,250	$ 2,250
General and administrative	12,500	17,341	74,437	70,441
Professional fees (Note 10)	42,549	39,664	109,823	147,977
Research and development	72,857	174,957	228,130	355,089
Share-based compensation (Note 10)	170,536	199,365	587,077	574,128
Total	(299,192)	(432,077)	(1,001,717)	(1,149,885)
OTHER ITEM
Foreign exchange loss	(100)	0	(4,334)	0
Net loss for the period	$ (299,292)	$ (432,077)	$ (1,006,051)	$ (1,149,885)
Net loss per common share (basic and diluted)	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.01)
Weighted average number of common shares outstanding (basic and diluted)	247,148,085	222,088,754	245,315,070	219,242,214

XML 16 R5.htm IDEA: XBRL DOCUMENT

STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - 9 months ended Sep. 30, 2017 - USD ($)	Common Stock	Additional paid-in capital	Accumulated Deficit	Total
Beginning Balance, Shares at Dec. 31, 2016	237,952,433
Beginning Balance, Amount at Dec. 31, 2016	$ 1,273	$ 29,115,795	$ (28,620,269)	$ 496,799
Issuance of common stock pursuant to private placement offering, shares	8,000,000
Issuance of common stock pursuant to private placement offering, amount	$ 43	319,957	0	320,000
Fair value of compensatory options issued	$ 0	587,077	0	587,077
Issuance of common stock pursuant to private placement offering, shares	4,400,000
Issuance of common stock pursuant to private placement offering, amount	$ 23	219,977	0	220,000
Net loss for the period	$ 0	0	(1,006,051)	(1,006,051)
Ending Balance, Shares at Sep. 30, 2017	250,352,433
Ending Balance, Amount at Sep. 30, 2017	$ 1,339	$ 30,242,806	$ (29,626,320)	$ 617,825

XML 17 R6.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	9 Months Ended
STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss for the period	$ (1,006,051)	$ (1,149,885)
Adjustments to reconcile net loss to cash used in operating activities:
Amortization - intangible assets	2,250	2,250
Issuance and amortization of common stock for services	0	7,000
Fair value of compensatory options granted	587,077	574,128
Changes in operating assets and liabilities:
Accounts receivable	0	8,023
Prepaid expenses and deposits	(42,953)	(91,032)
Accounts payable and accrued liabilities	(25,034)	(5,002)
Net cash used in operating activities	(484,711)	(654,518)
CASH FLOWS USED IN INVESTING ACTIVITIES
Purchase of Intangible assets	(40,176)	(7,589)
Net cash used in investing activities	(40,176)	(7,589)
CASH FLOWS FROM FINANCING ACTIVITIES
Issuance of common stock for cash	540,000	380,000
Net cash from financing activities	540,000	380,000
Net change in cash	15,113	(282,107)
Cash, beginning of period	371,029	371,072
Cash, end of period	386,142	88,965
Cash paid for interest	0	0
Cash paid for income taxes	0	0
Supplementary information - non-cash transactions:
Common stock issued for consulting services	0	7,000
Intangible asset costs previously included in accounts payable and accrued liabilities	3,631	0
Intangible asset costs previously included in prepaid expenses and deposits	15,614	0
Intangible asset costs included in accounts payable and accrued liabilities	$ 3,188	$ 0

XML 18 R7.htm IDEA: XBRL DOCUMENT

1. Basis of Presentation - Going Concern Uncertainties

9 Months Ended

Sep. 30, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation - Going Concern Uncertainties

During the year ended December 31, 2016, the Company filed Form 51-105F1 – Notice – OTC Issuer Ceases to be an OTC Reporting Issuer with the British Columbia Securities Commission.

The Company's financial statements are prepared consistent with accounting principles generally accepted in the United States applicable to a going concern.

XML 19 R8.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2017

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Cash

Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.

Fair Value of Financial Instruments

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Level 1 inputs are used to measure cash. At September 30, 2017 there were no other assets or liabilities subject to additional disclosure.

Income Taxes

Intangible Assets – Patent and Patent Application Costs

As at September 30, 2017, the Company does not hold any intangible assets with indefinite lives.

Research and Development Costs

Research and development costs are expensed as incurred.

Loss per Share and Potentially Dilutive Securities

Share-Based Compensation

Common Stock

Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.

Related Party Transactions

Recent Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

3. Prepaid Expenses and Deposits

9 Months Ended

Sep. 30, 2017

Prepaid Expenses And Deposits

Prepaid Expenses and Deposits

The following summarizes the Company’s prepaid expenses and deposits outstanding as at September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016

Deposit on research agreement (Note 11(c))	$	97,723	$	54,770
Other prepaid expenses		-		15,614

	$	97,723	$	70,384

XML 21 R10.htm IDEA: XBRL DOCUMENT

4. Intangible Assets

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Intangible asset transactions are summarized as follows:

	Patent Rights		Patent Application Rights		Total
Cost
Balance, December 31, 2015	$	30,000	$	41,760	$	71,760
Additions		-		33,421		33,421
Balance, December 31, 2016	$	30,000	$	75,181	$	105,181
Additions		-		55,347		55,347
Balance, September 30, 2017	$	30,000	$	130,528	$	160,528

Accumulated amortization
Balance, December 31, 2015	$	1,500	$	-	$	1,500
Amortization		3,000		-		3,000
Balance, December 31, 2016	$	4,500	$	-	$	4,500
Amortization		2,250		-		2,250
Balance, September 30, 2017	$	6,750	$	-	$	6,750

Net carrying amounts
December 31, 2016	$	25,500	$	75,181	$	100,681
September 30, 2017	$	23,250	$	130,528	$	153,778

The remaining 50% ownership of the Patent Application Rights was acquired from the Governors of the University of Alberta in exchange for a future gross revenue royalty.

No amortization was recorded on the Patent Application Rights to September 30, 2017.

XML 22 R11.htm IDEA: XBRL DOCUMENT

5. Credit Facility	9 Months Ended
5. Credit Facility	Sep. 30, 2017
Debt Disclosure [Abstract]
Credit Facility	On June 16, 2016, the Company executed a line of credit arrangement for an amount of up to $250,000 with Pleasants County Bank, West Virginia. Pursuant to the terms of the line of credit, interest will accrue on the amount of credit outstanding at a rate of 1.5% above the prime rate adjusted monthly. The Company’s President and CEO pledged personal assets to secure the line of credit and the Company pledged its patent rights in the provisional patent application numbered 62287857, dated January 21, 2016, “Use of Anti-Aging Glycoprotein for Enhancing Survival of Neurosensory Precursor Cells”. As at December 31, 2016, the balance outstanding was $nil. As of September 30, 2017, the line of credit was canceled and the pledged assets were released.

XML 23 R12.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Common Shares Issued for Services

During the nine month periods ended September 30, 2017 and 2016, the Company issued shares of common stock for services and other value rendered as follows:

2017	Number of Shares		Value per Share			Total

January - September 2017		-		$	-		$	-
		-					$	-

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

7. Stock Options

9 Months Ended

Sep. 30, 2017

Stock Options

Stock Options

As of September 30, 2017, 27,200,000 options and no shares of common stock have been granted under the 2017 Plan.

Stock option transactions are summarized as follows:

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2016		28,900,000			0.06		0.04
Options granted		27,200,000			0.05		0.03
Options expired		(1,000,000	)		0.10		0.03
Outstanding, September 30, 2017		55,100,000			0.06		0.04		2.77

	September 30, 2017	September 30, 2016
Risk-free interest rate	1.05%	0.56%
Dividend yield	0.00%	0.00%
Expected stock price volatility	125.00%	125.00%
Expected forfeiture rate	0.00%	0.00%
Expected life	3.46 years	3.94 years

The following non-qualified stock options were outstanding and exercisable at September 30, 2017:

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
	$
February 25, 2020		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		15,000,000
October 05, 2018		0.08		300,000		300,000
December 31, 2020		0.05		16,200,000		12,150,000
August 31, 2021		0.06		11,000,000		-
				55,100,000		38,050,000

XML 25 R14.htm IDEA: XBRL DOCUMENT

8. Warrants

9 Months Ended

Sep. 30, 2017

Warrants

Warrants

Warrant transactions for the nine month period ended September 30, 2017 are summarized as follows:

Number of

Warrants

Weighted

Average Exercise

Price

Balance, December 31, 2016 and September 30, 2017

6,500,000

0.11

The following warrants were outstanding and exercisable as at September 30, 2017:

Number of Warrants		Exercise Price ($)		Expiry Date
	500,000		0.25	November 8, 2018
	6,000,000		0.10	April 22, 2020
	6,500,000

XML 26 R15.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity

9 Months Ended

Sep. 30, 2017

Stockholders' Equity Note [Abstract]

Stockholders' Equity

During the nine month period ended September 30, 2017, the Company:

a)	Issued 8,000,000 shares of common stock to investors (which included both the President and CEO as well as the CFO of the Company) at $0.04 for gross proceeds of $320,000.

b)	Issued 4,400,000 shares of common stock to investors at $0.05 for gross proceeds of $220,000.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances

9 Months Ended

Sep. 30, 2017

Related Party Transactions and Balances

During the nine month period ended September 30, 2016, the Company:

Recognized $407,780 in share-based compensation associated with stock options granted to key management personnel.

During the nine months ended September, 30, 2017, the Company:

d)	Recognized $297,412 in share-based compensation associated with stock options granted to key management personnel.

As at September 30, 2017 and December 31, 2016, the following amounts are due to related parties:

		September 30, 2017		December 31, 2016
Clarence Smith (CEO)	Accounts payable and accrued liabilities	$	-	$	81

Amounts included in accounts payable and accrued liabilities are non-interest bearing, unsecured and repayable on demand.

XML 28 R17.htm IDEA: XBRL DOCUMENT

11. Commitments and Contingency

9 Months Ended

Sep. 30, 2017

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingency

As at September 30, 2017, the Company has the following commitments:

g)	Entered into a Material Transfer Agreement effective March 31, 2017 with Proactive Immune Sciences Corporation (“Proactive”) for a term of 1 year. The Company will furnish AAGP™ at no cost to Proactive so that they may test and evaluate AAGP™ for possible use in Immune Cell Banking.

XML 29 R18.htm IDEA: XBRL DOCUMENT

12. Subsequent Event

9 Months Ended

Sep. 30, 2017

Subsequent Events [Abstract]

Subsequent Event

Note 12. Subsequent Event

Subsequent to the nine month period ended September 30, 2017, the Company:

XML 30 R19.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America (“US GAAP”) applicable to interim financial information and with the rules and regulations of the United States Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed, or omitted, pursuant to such rules and regulations. In the opinion of management, the unaudited interim financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the year ended December 31, 2016, included in the Company’s Annual Report on Form 10-K, filed February 21, 2017, with the Securities and Exchange Commission. The results of operations for the interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.
Use of Estimates	Preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The more significant accounting estimates inherent in the preparation of the Company's financial statements include estimates as to valuation of equity related instruments issued and deferred income taxes.
Cash	Cash consists of funds held in checking accounts. Cash balances may exceed federally insured limits from time to time.
Fair Value of Financial Instruments	Financial instruments, which includes cash and accounts payable and accrued liabilities, are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. The Company measures the fair value of financial assets and liabilities pursuant to ASC 820 “Fair Value Measurements and Disclosures” which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. ASC 820 establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The policy describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) Level 1 inputs are used to measure cash. At September 30, 2017 there were no other assets or liabilities subject to additional disclosure.
Income Taxes	The Company accounts for income taxed following the assets and liability method in accordance with the ASC 740 “Income Taxes.” Under such method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. The Company applies the accounting guidance issued to address the accounting for uncertain tax positions. This guidance clarifies the accounting for income taxes, by prescribing a minimum recognition threshold a tax position is required to meet before being recognized in the financial statements as well as provides guidance on derecognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years that the asset is expected to be recovered or the liability settled.
Intangible Assets - Patent and Patent Application Costs	The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures are recognized in profit or loss as incurred. As at September 30, 2017, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the patent application costs as at September 30, 2017.
Research and Development Costs	Research and development costs are expensed as incurred.
Loss per Share and Potentially Dilutive Securities	Basic loss per share is computed by dividing the net loss available to common stockholders by the weighted average number of common shares outstanding in the period. Diluted loss per share takes into consideration common shares outstanding (computed under basic earnings per share) and potentially dilutive securities. The effect of 55,100,000 stock options (September 30, 2016 – 28,600,000) and 6,500,000 warrants (September 30, 2016 – 6,500,000) were not included in the computation of diluted earnings per share for all periods presented because it was anti-dilutive due to the Company's losses.
Share-Based Compensation	The Company has granted warrants and options to purchase shares of the Company's common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance. The Company accounts for stock compensation arrangements with persons classified as non-employees for accounting purposes in accordance with ASC 505-50 “Stock-Based Transactions with Nonemployees”, which requires that such equity instruments are recorded at their fair value on the measurement date. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period.
Common stock	Common stock issued for non-monetary consideration are recorded at their fair value on the measurement date and classified as equity. The measurement date is defined as the earliest of the date at which the commitment for performance by the counterparty to earn the common shares is reached or the date at which the counterparty’s performance is complete. Transaction costs directly attributable to the issuance of common stock, units and stock options are recognized as a deduction from equity, net of any tax effects.
Related Party Transactions	A related party is generally defined as (i) any person that holds 10% or more of the Company's securities and their immediate families, (ii) the Company's management, (iii) someone that directly or indirectly controls, is controlled by or is under common control with the Company, or (iv) anyone who can significantly influence the financial and operating decisions of the Company. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties.
Recent Accounting Pronouncements	In August 2014, the FASB issued Accounting Standards Update 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which provides guidance on determining when and how reporting entities must disclose going-concern uncertainties in their financial statements. The new standard requires management to perform interim and annual assessment of an entity’s ability to continue as a going concern within one year of the date of issuance of the entity’s financial statements (or within one year after the date on which the financial statements are available to be issued, when applicable). Further, an entity must provide certain disclosures if there is substantial doubt about the entity’s ability to continue as a going concern. The requirement is effective for annual periods ending after December 15, 2016, and interim periods thereafter, early adoption is permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Update 2015-17 – Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. This accounting pronouncement requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. Currently deferred tax liabilities and assets must be presented as current and noncurrent. The policy was effective for periods ending after December 16, 2016. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Update 2016-09 – Compensation—Stock Compensation (Topic 718) Improvements to Employee Share-Based Payment Accounting. This accounting pronouncement, which goes into effect for periods ending after December 16, 2016, addresses the simplification of several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Update 2016-01 – Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. This accounting pronouncement, which goes into effect December 12, 2017, is far reaching and covers several presentation areas dealing with measurement, impairment, assumptions used in estimating fair value and several other areas. The Company is reviewing this update to determine the impact it may have on its financial statements. Accounting Standards Update 2016-02-Leases (Topic 842). This accounting pronouncement allows lessees to make an accounting policy election to not recognize a lease asset and liability for leases with a term of 12 months or less and do not have a purchase option that is expected to be exercised. This standard is effective for interim and annual reporting periods beginning after December 15, 2018, with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its financial statements.

XML 31 R20.htm IDEA: XBRL DOCUMENT

3. Prepaid Expenses and Deposits (Tables)

9 Months Ended

Sep. 30, 2017

Prepaid Expenses And Deposits Tables

Prepaid expenses and deposits

The following summarizes the Company’s prepaid expenses and deposits outstanding as at September 30, 2017 and December 31, 2016:

	September 30, 2017		December 31, 2016

Deposit on research agreement (Note 11(c))	$	97,723	$	54,770
Other prepaid expenses		-		15,614

	$	97,723	$	70,384

XML 32 R21.htm IDEA: XBRL DOCUMENT

4. Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible asset transactions

Intangible asset transactions are summarized as follows:

	Patent Rights		Patent Application Rights		Total
Cost
Balance, December 31, 2015	$	30,000	$	41,760	$	71,760
Additions		-		33,421		33,421
Balance, December 31, 2016	$	30,000	$	75,181	$	105,181
Additions		-		55,347		55,347
Balance, September 30, 2017	$	30,000	$	130,528	$	160,528

Accumulated amortization
Balance, December 31, 2015	$	1,500	$	-	$	1,500
Amortization		3,000		-		3,000
Balance, December 31, 2016	$	4,500	$	-	$	4,500
Amortization		2,250		-		2,250
Balance, September 30, 2017	$	6,750	$	-	$	6,750

Net carrying amounts
December 31, 2016	$	25,500	$	75,181	$	100,681
September 30, 2017	$	23,250	$	130,528	$	153,778

XML 33 R22.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services (Tables)

9 Months Ended

Sep. 30, 2017

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Incentive Plan, Issuances

2017	Number of Shares		Value per Share			Total

January - September 2017		-		$	-		$	-
		-					$	-

2016	Number of Shares		Value per Share		Total

March 2016		100,000	$	0.07	$	7,000
		100,000			$	7,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

7. Stock Options (Tables)

9 Months Ended

Sep. 30, 2017

Stock Options

Schedule of Share-based Compensation, Stock Options, Activity

	Number of Stock Options			Weighted Average Exercise Price		Weighted Average Fair Value		Weighted Average Remaining Life
				$		$		(Years)
Outstanding, December 31, 2016		28,900,000			0.06		0.04
Options granted		27,200,000			0.05		0.03
Options expired		(1,000,000	)		0.10		0.03
Outstanding, September 30, 2017		55,100,000			0.06		0.04		2.77

Schedule of valuation assumptions for options

	September 30, 2017	September 30, 2016
Risk-free interest rate	1.05%	0.56%
Dividend yield	0.00%	0.00%
Expected stock price volatility	125.00%	125.00%
Expected forfeiture rate	0.00%	0.00%
Expected life	3.46 years	3.94 years

Schedule of options by exercise price

Expiry date	Exercise Price		Number of Options Outstanding		Number of Options Exercisable
	$
February 25, 2020		0.04		2,000,000		-
February 24, 2018		0.05		1,000,000		1,000,000
February 25, 2020		0.04		4,000,000		4,000,000
February 28, 2020		0.04		5,000,000		5,000,000
June 30, 2018		0.10		600,000		600,000
December 31, 2019		0.08		15,000,000		15,000,000
October 05, 2018		0.08		300,000		300,000
December 31, 2020		0.05		16,200,000		12,150,000
August 31, 2021		0.06		11,000,000		-
				55,100,000		38,050,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

8. Warrants (Tables)

9 Months Ended

Sep. 30, 2017

Warrants

Schedule of Warrant Activity

Number of

Warrants

Weighted

Average Exercise

Price

Balance, December 31, 2016 and September 30, 2017

6,500,000

0.11

Schedule of Stockholders' Equity Note, Warrants or Rights

Number of Warrants		Exercise Price ($)		Expiry Date
	500,000		0.25	November 8, 2018
	6,000,000		0.10	April 22, 2020
	6,500,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 36 R25.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Tables)

9 Months Ended

Sep. 30, 2017

Schedule of related party transactions

			September 30, 2017				December 31, 2016
Clarence Smith (CEO)	Accounts payable and accrued liabilities		$	-			$	81

XML 37 R26.htm IDEA: XBRL DOCUMENT

2. Summary of Significant Accounting Policies (Details Narrative) - shares	3 Months Ended	9 Months Ended
	Mar. 31, 2016	Sep. 30, 2017
Warrant
Antidilutive Securities Excluded from Computation of Earnings Per Share	6,500,000	6,500,000
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share	28,600,000	55,100,000

XML 38 R27.htm IDEA: XBRL DOCUMENT

3. Prepaid Expenses and Deposits (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Prepaid Expenses And Deposits Details
Deposit on research agreement (Note 11(c))	$ 97,723	$ 54,770
Other prepaid expenses	0	15,614
Prepaid expenses and deposits	$ 97,723	$ 70,384

XML 39 R28.htm IDEA: XBRL DOCUMENT

4. Intangible Assets (Details) - USD ($)	9 Months Ended	12 Months Ended
4. Intangible Assets (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Cost
Beginning balance	$ 105,181	$ 71,760
Additions	55,347	33,421
Ending balance	160,528	105,181
Accumulated amortization
Beginning balance	4,500	1,500
Amortization	2,250	3,000
Ending balance	6,750	4,500
Net carrying amounts	153,778	100,681
Patent Rights [Member]
Cost
Beginning balance	30,000	30,000
Additions	0	0
Ending balance	30,000	30,000
Accumulated amortization
Beginning balance	4,500	1,500
Amortization	2,250	3,000
Ending balance	6,750	4,500
Net carrying amounts	23,250	25,500
Patent Application Rights [Member]
Cost
Beginning balance	75,181	41,760
Additions	55,347	33,421
Ending balance	130,528	75,181
Accumulated amortization
Beginning balance	0	0
Amortization	0	0
Ending balance	0	0
Net carrying amounts	$ 130,528	$ 75,181

XML 40 R29.htm IDEA: XBRL DOCUMENT

4. Intangible Assets (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
4. Intangible Assets (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization - intangible assets	$ 750	$ 750	$ 2,250	$ 2,250

XML 41 R30.htm IDEA: XBRL DOCUMENT

5. Credit Facility (Details Narrative) - USD ($)	Jun. 30, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Line of credit	$ 250,000	$ 250,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

6. Common Shares Issued for Services (Details) - USD ($)	3 Months Ended	9 Months Ended
	Mar. 31, 2016	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of Shares	100,000	0
Value per Share	$ 0.07	$ 0
Total	$ 7,000	$ 0

XML 43 R32.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details) - $ / shares	9 Months Ended
7. Stock Options (Details) - $ / shares	Sep. 30, 2017	Sep. 30, 2016
Outstanding, ending	55,100,000
Weighted Average Exercise Price ending	$ 0.11
Weighted Average Fair Value, granted	$ 0.03	$ 0.05
Stock options
Outstanding, beginning	28,900,000
Options granted	27,200,000
Options expired	(1,000,000)
Outstanding, ending	55,100,000
Weighted Average Exercise Price beginning	$ 0.06
Weighted Average Exercise Price, granted	0.05
Weighted Average Exercise Price, expired	0.1
Weighted Average Exercise Price ending	0.06
Weighted Average Fair Value, beginning	0.04
Weighted Average Fair Value, granted	0.03
Weighted Average Fair Value, expired	0.03
Weighted Average Fair Value, ending	$ 0.04
Weighted Average Remaining Life (Years)	2 years 9 months 7 days

XML 44 R33.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details 1) - Stock options	9 Months Ended
7. Stock Options (Details 1) - Stock options	Sep. 30, 2017	Sep. 30, 2016
Risk-free interest rate	1.05%	0.56%
Dividend yield	0.00%	0.00%
Expected stock price volatility	125.00%	125.00%
Expected forfeiture rate	0.00%	0.00%
Expected life	3 years 5 months 16 days	3 years 11 months 8 days

XML 45 R34.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details 2)	Sep. 30, 2017 $ / shares shares
Exercise Price \| $ / shares	$ 0.11
Number of Options Outstanding	55,100,000
Number of options exercisable	38,050,000
February 25, 2020
Exercise Price \| $ / shares	$ 0.04
Number of Options Outstanding	2,000,000
Number of options exercisable	0
February 24, 2018
Exercise Price \| $ / shares	$ 0.05
Number of Options Outstanding	1,000,000
Number of options exercisable	1,000,000
February 25, 2020 One
Exercise Price \| $ / shares	$ 0.04
Number of Options Outstanding	4,000,000
Number of options exercisable	4,000,000
February 28, 2020
Exercise Price \| $ / shares	$ 0.04
Number of Options Outstanding	5,000,000
Number of options exercisable	5,000,000
June 30, 2018
Exercise Price \| $ / shares	$ 0.1
Number of Options Outstanding	600,000
Number of options exercisable	600,000
December 31, 2019
Exercise Price \| $ / shares	$ 0.08
Number of Options Outstanding	15,000,000
Number of options exercisable	15,000,000
October 05, 2018
Exercise Price \| $ / shares	$ 0.08
Number of Options Outstanding	300,000
Number of options exercisable	300,000
December 31, 2020
Exercise Price \| $ / shares	$ 0.05
Number of Options Outstanding	16,200,000
Number of options exercisable	12,150,000
August 31, 2021
Exercise Price \| $ / shares	$ 0.06
Number of Options Outstanding	11,000,000
Number of options exercisable	0

XML 46 R35.htm IDEA: XBRL DOCUMENT

7. Stock Options (Details Narrative) - USD ($)	9 Months Ended
7. Stock Options (Details Narrative) - USD ($)	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Aggregate intrinsic value	$ 392,000		$ 110,000
Weighted average fair value of stock options granted per share	$ 0.03	$ 0.05
Common Stock
Common stock granted	0
Stock options
Common stock granted	27,200,000
Weighted average fair value of stock options granted per share	$ 0.03

XML 47 R36.htm IDEA: XBRL DOCUMENT

8. Warrants (Details)	Sep. 30, 2017 $ / shares shares
Notes to Financial Statements [Abstract]
Warrant outstanding, ending \| shares	6,500,000
Warrant weighted average exercise price \| $ / shares	$ 0.11

XML 48 R37.htm IDEA: XBRL DOCUMENT

8. Warrants (Details 1)	9 Months Ended
8. Warrants (Details 1)	Sep. 30, 2017 $ / shares shares
Number of Warrants	6,500,000
Warrant One
Number of Warrants	500,000
Warrant Exercise Price \| $ / shares	$ 0.25
Expiry Date	November 8, 2018
Warrant Two
Number of Warrants	6,000,000
Warrant Exercise Price \| $ / shares	$ 0.10
Expiry Date	April 22, 2020

XML 49 R38.htm IDEA: XBRL DOCUMENT

9. Stockholders' Equity (Details Narrative) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Stockholders' Equity Note [Abstract]
Common Stock, Par Value Per Share	$ 0.0000053	$ 0.0000053
Common Stock, Shares Authorized	400,000,000	400,000,000
Dividends declared	$ 0	$ 0

XML 50 R39.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Details) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Accounts payable and accrued liabilities	$ 19,818	$ 45,295
Clarence Smith (CEO)
Accounts payable and accrued liabilities	$ 0	$ 81

XML 51 R40.htm IDEA: XBRL DOCUMENT

10. Related Party Transactions and Balances (Details Narrative) - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Related Party Transactions [Abstract]
Share based Compensation	$ 407,780
Payment to CFO	$ 54,000	$ 54,000

XML 52 R41.htm IDEA: XBRL DOCUMENT

11. Commitments and Contingency (Details Narrative) - USD ($)	Sep. 30, 2017	Dec. 31, 2016
Commitments And Contingency Details Narrative
Prepaid expenses	$ 97,723	$ 54,770

EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( %IQ;4L?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 6G%M2V;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !:<6U+5_6;J^T K @ $0 &1O8U!R;W!S+V-O M&ULS9+!:L,P#(9?9?B>*&K&!B;U9:6G#08K;.QF;+4UBQ-C:R1]^R5> MFS*V!]C1TN]/GT"-"=+TD9YC'RBRHW0S^K9+TH2U.#('"9#,D;Q.Y93HIN:^ MCU[S](P'"-I\Z /!JJKNP!-KJUG##"S"0A2JL4::2)K[>,9;L^##9VPSS!J@ MECQUG !+!*'FB>$TM@U< 3.,*?KT72"[$'/U3VSN@#@GQ^26U# ,Y5#GW+0# MPMO3XTM>MW!=8MT9FGXE)_D4:"TNDU_KA\UN*]2JPOL"L&PO=&AE;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S M:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N M+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X M%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53" MQ,!J9S]6:\?1TDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@ MX_%X.+;+THMP' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMH MG J-6T_3:W?=TXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2 M%;7E0-,@ %AP=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9R MG9 %#@ WQ-%,4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S M>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,B MUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C? MC8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SCFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1 MVC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE M"0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ MZK:4OK4F.$KTL@'37[]EUVY".E,%.70[@:0KX#;;J= MW#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B M(>ZAAIC/PT.'>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)5 M8#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6Q MP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>; MG*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4< M!A87,N10[I*0!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E M$A2*L P%(1=RX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TSU#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+? M.7#;.MX#7N83+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4 MJUJE9"L1/TL'?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5 MBZPYC0IO0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%0 M2P,$% @ 6G%M2VM2_OV) @ 2 D !@ !X;"]W;W)KLNUOVM)JGHH#6M^^ M_0!]SLEU_RC@.?=PX1XA[[EXE25CRGMKZE9N_5*I[CD(Y+ED#95/O&.M_G+E MHJ%*=\4MD)U@]&))31W@,$R"AE:M7^1V["B*G-]57;7L*#QY;QHJ?N]9S?NM MC_SW@9?J5BHS$!1Y1V_L&U/?NZ/0O6"*%F)EKCS&MI MG][Y+A5OQBAZ*@U]&]Y5:]_]\"4B(PTFX)& )P)._DL@(X%,!!39Y(>9V50_ M4$6+7/#>$\-N==04!7HF>C'/9M"NG?VFLY5Z]%&$>? P84;$?D#@&0)-B$#' MG@0P)+#'#AW_*W!P$006(& &Q-+)C![!] BD1Y8>S>CQ8@%<1 (+Q*! [-#3 MA<" B"VB'588X0QE&U@F 6421R9;R+B(%8$4%$@=.EJ6"@!9J94,E,A<_J)8 M]@!DI5HVH,3&Y4<+"0 2PQ(HA#T5NA&2I:L 3+JBLN)VOO#[/1Z9JPP_9<^PL?[AA?J;A5K?1.7.G3T9YA5\X5TY,)G_0T M2GVMF3HUNRK33'5;#&?[T%&\&^\MP71Y*OX 4$L#!!0 ( %IQ;4NRK%J2 MT0( (@* 8 >&PO=V]R:W-H965T&ULC59=CYLP$/PK MB/<>_L*&4Q*II*I:J95.K=H^^Q(G00Y_OO:P"'.7JY] =O,[,XN,-K5 M3;=/W4DI$SW75=.MXY,QY_LDZ78G5G.K9+[GE17 M"4&()[4LFWBSZL\>VLU*7TQ5-NJAC;I+73\8=))O5 M61[5=V5^G!]:NTNF*/NR5DU7ZB9JU6$=O\?W6\P=H4?\+-6MFZTC5\JCUD]N M\WF_CI%3I"JU,RZ$M+>KVJJJW-:QUD<[=5!7BKS3=\^J;&@-([&ZK^HJZHLW"FQ.7:ZZOIKM+MT1M=C%"NE MEL_#O6SZ^VV,_T*#"60DD(F V9L$.A*H1T@&97VI'Z21FU6K;U$[O*VS=!\% MOJ>VF3MWV/>N?V:K[>SI=4/R57)U<49(,4#('/(:L0T1%$V0Q.:?1!!0!.GY M=,[',)^"?-KSV9SO22P&B.@AS0#).&9^)0!,8#1KR2LU#%3#0C744S- TEF: M7 CBH;8A2B":,5A+"FI)0RW,TY(&65AF>Y-Z8@ 8PPQ36 T'U?!0C9>FX$$: MG%(A,D\- +/.E2U\-0)4(T(UW%,C@C2<"L[\%Q7"4D90OO"F,E!-%OX# N;G M(#\/J_&:5N1AT_(,^ZT-42PE>0IKP0AV%12J"6P%_9<< /:6G@67PT%WV8)# M8=BB, DJ8MBOB(054;_N+80B8N$_PK#AX=#Q?"LK1LP\#T6$D0QQ7U&()#G& MJ5CL,FQ\.'0^_U:[( []C6.1 M$=\& 1S+NM3&3A?] M#'#0VB@;$]W9^DYV+)PVE3H8MQ1VW0ZST; Q^CS.?-/H@20UG--&Q';I93M$2&1E5 3L6,M-.JD8+PF4BWY%8F6 M \F-J:;(V>>1.PF:=7 F5OB5M>$_ST!95ULN_;+QF-U+:7> M0$G4DBO\ /FS/7.U0F.4O*JA$15K+ Y%;']TCVFH]4;PJX).3.:6KN3"V)-> M?,UCV]% 0"&3.@)1PQU2H%0'4AA_AICVF%(;I_.7Z)]-[:J6"Q&0,OJ[RF49 MVP?;RJ$@-RH?6?<%AGH"VQJ*_P9WH$JN252.C%%A?JWL)B2KAR@*I2;/_5@U M9NSZDR <;-L&;S!XH\'U7S7@P8 7!M23F5(_$4F2B+/.XOW':HG^3[A'K%YF MIC?-NS-GJEJA=N^)'T;HKN,,DE,O\282;ZY(UPKLC!*D\H\0WB:$9_QX"K'? M]N--/S9^?^H_+(KH)05_F-#DS2FB[Y79=W.XV/7 MG9Z3I-T>396W3_9D:O=G;YLJ[URQ.23MJ3'YKC>JRH01DB957M3Q8M;7O3:+ MF3UW95&;UR9JSU65-_\M36DO\YC&/RH^%8=CYRN2Q>R4'\QGT_US>FU<*;EZ MV165J=O"UE%C]O/XA3YOJ/ &/?%O82[MY#OR4MZL_>H+?^[F,?$9F=)L.^\B M=Z]WLS)EZ3VY/+Z-3N-K3&\X_?[A_?=>O!/SEK=F9_C"C(!E'H_J_S+LI'>XS<3&VMFS[9[0]MYVM1B\NE2K_/KR+NG]?AC^* MCV:X 1L-V-7 Q7YDP$<#_M- /#00HX'XU0AR-) @0C)H[QMSG7?Y8M;82]0, MX^&4^V%'GZ7KKJVO['NG_^?:LW6U[PO)9LF[]S,BRP%A4X3?(NL0H549* MO@%9ATRC$%H\P%THTBBBF2H2 %% R(G0:@+ C4AE.*" E4AI83@ M(.(&H8@0=P9DBNI*0UT:Z$J#*())D0%=(<6S-(5#-Z0HR30#LVR#8$)E2N'* M%*I,AF46DZD):",$N- M)$TD![-PA6!9QE,)M(68U(HH.!X13 G*-*XM0[5EH38P.999$.8WEF4T@TLI MP@G.@K37"$<)H8I"?1A(1:;UG<61$GPG(L'RFK(['N[L931L)3"'EB,#98$V M0BBXPF*.!.=@:F\>>KH5A>Z-+Y2%H@04Q8*5W/<]"_H> ]'.QT#73"F1% K$ MR(?=CV^NE(461^K6_=/1GV)_NAQO+WWES*.HV>K.=.PGWY]6] MM9UQ"LB3R_WH+DG70FGVG?]4[KL9;@I#H;.G\1:47*]BB_\!4$L#!!0 ( M %IQ;4NL^2>*T@( &@* 8 >&PO=V]R:W-H965T&UL MC59M;YLP$/XKB.\M?L$8JB32\C)MTB95G;9]=A,G007,P$FZ?S]C*$U\;K)\ M"+9YGKM[SL?9DY-J7MJ]E#IX+8NJG89[K>N'*&K7>UF*]E[5LC)OMJHIA3;3 M9A>U=2/%QI+*(B(()5$I\BJ<3>S:8S.;J(,N\DH^-D%[*$O1_)W+0IVF(0[? M%I[RW5YW"]%L4HN=_"'US_JQ,;-HM++)2UFUN:J"1FZGX2?\L,*68!&_^,_ELS>IQEO!) M=.SL#)!Y#R'GD/02LH"0F%Q"EAXKV25DY8'@$1(9&:,6XM5"+#\^XW/D:.DA MS$(J"R&49XS$E/H]4:\G"CUAQU,/X6>>,.'4R1L$D0QC9B)RL@>!=R1-""(@ MB1 99PG/,K^\V"LOAO*<[9S'()$ILC^_'^;UPZ ?)T-S!N6X260@%(JSC#EE MO(0PISA6'D/D8TF)5U(")<6.I 1(<@)9)" 0EG+$7440YBJZ:>A"$?+ M@0,W<7RE&%*OG_1V,:3PJ,+(?V8@N%5.PYH/F(O\,42O=%K\P0&%H;/$ M=89ALZ74Z8P+#XHB$I,4.?:6'N0=R1*2F'[@GED0FF">$N:(C,X.Y.X.]ETT MN[QJ@V>ES=EN3^"M4EH:F^C>9&UOKGWCI)!;W0VY&3?]W:>?:%4/][IHO%S. M_@%02P,$% @ 6G%M2RV\;]W% P S1 !@ !X;"]W;W)K,9Q8J\ ::&J[J2KM.KIKJ^S8"!J M'K@D+.VW/^=A*>N9T+Z!Q/QG_!_C_/"PN-3-M_9H;1=\+XNJ78;'KCL]1E&[ M/=HR:S_4)UNY3_9U4V:=NVT.47MJ;+8;@LHB0B&2J,SR*EPMAK'G9K6HSUV1 M5_:Y"=IS66;-C[4MZLLRA/!MX$M^.';]0+1:G+*#_=MV_YR>&W<77;/L\M)6 M;5Y706/WR_ )'C=H^H!!\6]N+^W-=="7\E+7W_J;/W?+4/2.;&&W79\BVJ\LIB[-29M_'][P:WB]3_K
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�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end XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 53 133 1 false 19 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://protokinetix.com/taxonomy/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS (Unaudited) Sheet http://protokinetix.com/role/BalanceSheets BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://protokinetix.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS (Unaudited) Sheet http://protokinetix.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Sheet http://protokinetix.com/role/StatementOfStockholdersEquity STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://protokinetix.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - 1. Basis of Presentation - Going Concern Uncertainties Sheet http://protokinetix.com/role/BasisOfPresentation-GoingConcernUncertainties 1. Basis of Presentation - Going Concern Uncertainties Notes 7 false false R8.htm 00000008 - Disclosure - 2. Summary of Significant Accounting Policies Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies 2. Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - 3. Prepaid Expenses and Deposits Sheet http://protokinetix.com/role/PrepaidExpensesAndDeposits 3. Prepaid Expenses and Deposits Notes 9 false false R10.htm 00000010 - Disclosure - 4. Intangible Assets Sheet http://protokinetix.com/role/IntangibleAssets 4. Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - 5. Credit Facility Sheet http://protokinetix.com/role/CreditFacility 5. Credit Facility Notes 11 false false R12.htm 00000012 - Disclosure - 6. Common Shares Issued for Services Sheet http://protokinetix.com/role/CommonSharesIssuedForServices 6. Common Shares Issued for Services Notes 12 false false R13.htm 00000013 - Disclosure - 7. Stock Options Sheet http://protokinetix.com/role/StockOptions 7. Stock Options Notes 13 false false R14.htm 00000014 - Disclosure - 8. Warrants Sheet http://protokinetix.com/role/Warrants 8. Warrants Notes 14 false false R15.htm 00000015 - Disclosure - 9. Stockholders' Equity Sheet http://protokinetix.com/role/StockholdersEquity 9. Stockholders' Equity Notes 15 false false R16.htm 00000016 - Disclosure - 10. Related Party Transactions and Balances Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalances 10. Related Party Transactions and Balances Notes 16 false false R17.htm 00000017 - Disclosure - 11. Commitments and Contingency Sheet http://protokinetix.com/role/CommitmentsAndContingency 11. Commitments and Contingency Notes 17 false false R18.htm 00000018 - Disclosure - 12. Subsequent Event Sheet http://protokinetix.com/role/SubsequentEvent 12. Subsequent Event Notes 18 false false R19.htm 00000019 - Disclosure - 2. Summary of Significant Accounting Policies (Policies) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies 2. Summary of Significant Accounting Policies (Policies) Policies http://protokinetix.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 00000020 - Disclosure - 3. Prepaid Expenses and Deposits (Tables) Sheet http://protokinetix.com/role/PrepaidExpensesAndDepositsTables 3. Prepaid Expenses and Deposits (Tables) Tables http://protokinetix.com/role/PrepaidExpensesAndDeposits 20 false false R21.htm 00000021 - Disclosure - 4. Intangible Assets (Tables) Sheet http://protokinetix.com/role/IntangibleAssetsTables 4. Intangible Assets (Tables) Tables http://protokinetix.com/role/IntangibleAssets 21 false false R22.htm 00000022 - Disclosure - 6. Common Shares Issued for Services (Tables) Sheet http://protokinetix.com/role/CommonSharesIssuedForServicesTables 6. Common Shares Issued for Services (Tables) Tables http://protokinetix.com/role/CommonSharesIssuedForServices 22 false false R23.htm 00000023 - Disclosure - 7. Stock Options (Tables) Sheet http://protokinetix.com/role/StockOptionsTables 7. Stock Options (Tables) Tables http://protokinetix.com/role/StockOptions 23 false false R24.htm 00000024 - Disclosure - 8. Warrants (Tables) Sheet http://protokinetix.com/role/WarrantsTables 8. Warrants (Tables) Tables http://protokinetix.com/role/Warrants 24 false false R25.htm 00000025 - Disclosure - 10. Related Party Transactions and Balances (Tables) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 10. Related Party Transactions and Balances (Tables) Tables http://protokinetix.com/role/RelatedPartyTransactionsAndBalances 25 false false R26.htm 00000026 - Disclosure - 2. Summary of Significant Accounting Policies (Details Narrative) Sheet http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative 2. Summary of Significant Accounting Policies (Details Narrative) Details http://protokinetix.com/role/SummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 00000027 - Disclosure - 3. Prepaid Expenses and Deposits (Details) Sheet http://protokinetix.com/role/PrepaidExpensesAndDepositsDetails 3. Prepaid Expenses and Deposits (Details) Details http://protokinetix.com/role/PrepaidExpensesAndDepositsTables 27 false false R28.htm 00000028 - Disclosure - 4. Intangible Assets (Details) Sheet http://protokinetix.com/role/IntangibleAssetsDetails 4. Intangible Assets (Details) Details http://protokinetix.com/role/IntangibleAssetsTables 28 false false R29.htm 00000029 - Disclosure - 4. Intangible Assets (Details Narrative) Sheet http://protokinetix.com/role/IntangibleAssetsDetailsNarrative 4. Intangible Assets (Details Narrative) Details http://protokinetix.com/role/IntangibleAssetsTables 29 false false R30.htm 00000030 - Disclosure - 5. Credit Facility (Details Narrative) Sheet http://protokinetix.com/role/CreditFacilityDetailsNarrative 5. Credit Facility (Details Narrative) Details http://protokinetix.com/role/CreditFacility 30 false false R31.htm 00000031 - Disclosure - 6. Common Shares Issued for Services (Details) Sheet http://protokinetix.com/role/CommonSharesIssuedForServicesDetails 6. Common Shares Issued for Services (Details) Details http://protokinetix.com/role/CommonSharesIssuedForServicesTables 31 false false R32.htm 00000032 - Disclosure - 7. Stock Options (Details) Sheet http://protokinetix.com/role/StockOptionsDetails 7. Stock Options (Details) Details http://protokinetix.com/role/StockOptionsTables 32 false false R33.htm 00000033 - Disclosure - 7. Stock Options (Details 1) Sheet http://protokinetix.com/role/StockOptionsDetails1 7. Stock Options (Details 1) Details http://protokinetix.com/role/StockOptionsTables 33 false false R34.htm 00000034 - Disclosure - 7. Stock Options (Details 2) Sheet http://protokinetix.com/role/StockOptionsDetails2 7. Stock Options (Details 2) Details http://protokinetix.com/role/StockOptionsTables 34 false false R35.htm 00000035 - Disclosure - 7. Stock Options (Details Narrative) Sheet http://protokinetix.com/role/StockOptionsDetailsNarrative 7. Stock Options (Details Narrative) Details http://protokinetix.com/role/StockOptionsTables 35 false false R36.htm 00000036 - Disclosure - 8. Warrants (Details) Sheet http://protokinetix.com/role/WarrantsDetails 8. Warrants (Details) Details http://protokinetix.com/role/WarrantsTables 36 false false R37.htm 00000037 - Disclosure - 8. Warrants (Details 1) Sheet http://protokinetix.com/role/WarrantsDetails1 8. Warrants (Details 1) Details http://protokinetix.com/role/WarrantsTables 37 false false R38.htm 00000038 - Disclosure - 9. Stockholders' Equity (Details Narrative) Sheet http://protokinetix.com/role/StockholdersEquityDetailsNarrative 9. Stockholders' Equity (Details Narrative) Details http://protokinetix.com/role/StockholdersEquity 38 false false R39.htm 00000039 - Disclosure - 10. Related Party Transactions and Balances (Details) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetails 10. Related Party Transactions and Balances (Details) Details http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 39 false false R40.htm 00000040 - Disclosure - 10. Related Party Transactions and Balances (Details Narrative) Sheet http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesDetailsNarrative 10. Related Party Transactions and Balances (Details Narrative) Details http://protokinetix.com/role/RelatedPartyTransactionsAndBalancesTables 40 false false R41.htm 00000041 - Disclosure - 11. Commitments and Contingency (Details Narrative) Sheet http://protokinetix.com/role/CommitmentsAndContingencyDetailsNarrative 11. Commitments and Contingency (Details Narrative) Details http://protokinetix.com/role/CommitmentsAndContingency 41 false false All Reports Book All Reports pktx-20170930.xml pktx-20170930.xsd pktx-20170930_cal.xml pktx-20170930_def.xml pktx-20170930_lab.xml pktx-20170930_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2016-01-31 true true ZIP 59 0001079973-17-000662-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-17-000662-xbrl.zip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

L48>'P^>RI!-.5'P@W_&=GPL9BL.# MJ"@!?PIS#&/>=^PID^=O(*?"5DR$CV2(B;>!G6T*))AJ0 DXJNP+PYE 4+^7Q\U3/E]F;)G)+U<]9=QD>K#9(U<]#H@[;D!X M1.\L3E6ZKBE?() **[97!)D),=Q6(5CBWV$3"3&YDY^/RL "/Y(IJ!QC(TG8 M?H)U)@N-DACB]%"%J-PJCO,(I%-CB#CYW+?CO&A4G2&H;-HK CZDC 0M'VZ> M*GG51@"AN&T@C%^0V$&3:E1N2UAY<9#,:("%(WZ M0V*\)$D@>T+,0ETRN0&-*.(5?UBG"$%:BJKN?R>2MHR^5M4"JUY2H];F5>3S?$A M,&1#T0SDH?&==C9>+*+4.*Z>YD6\5%XK/"&,,-%--!G[)?<8$\X1D1C!/4', M/=EP&^/)5[#6X;"CR])*ZC+FB22M%TN*^R(5 NA==B[XBR]%B>90C"/K,?DQ MR(9AXM=>RJA^7* 0FR(<&W'ZD27PO(P/GKH(SMI2$JRP5$T##SEA4\6B;"J\ MC9&5'-DK.5+"+3UJ05NA@DCSG-%E&YIZV\834C39HL [T6$K+BA&OA;R(*,# MLO(X%MML6IVJ&:! /Y7I= $GL1@BNEETZ+ MY;-(%U/* [8P7,V[U"0AM:U0N2%F0H'O4I(]<\;FPB9RK$@>A2P0>64KG?2< M\8G[*H>( TPI#%DTVJ*)6RLJ'.F&N^3Y\;SJ1*D9?*F*+Q%1[ BJ5G)QXOCN[P:,A3'FRQDP)7AV*E^!2QW&I>.B'4K#IA(CL >=!;=%$TA)"F/Y M2%*S]T+\3H?!T.#*VS$63T]AH/F;)697GS?=\8LLG9#]= MJZ:.HGA1VN$'%F(MVW+?F"W$BBM@JHM/[\$ M\OPM5NU&F!S[T*9B9] MG.:O M>(=!NB*4JSY[AHU#J.&!,;,=RKAY8<,$Z7>5#,&NI9#$,L+Y2S% MG[!&SO<<&-8.Y >'!]+PP4"$F80 B0>6RG2I=/J%_4 +ARF%-^)IIN&J]6E4 MIC-U*/,9%G!6G#FL?>R2HW-&%22D]B9E^XWNN M%XE^@4])+7QTM7%T!U]@]'+ $QL^C&_?2I,GP1'!WSK#W MWKM4X>HWF:'(M0&5AX @O:M*9Z5JV!:)]ZU?JY'/-._E(WT8F 1(P MZ41 [@/C.R04U*#*>U2*5ZF&!,&9X7)%2A_C'8/.9,>@* 4XC]&B 9>3H!@W M"H"]]%$+!&96E0T+.\&:A>4Z8E ZZ W.F3E8V.R,IEFW1*02%4PT-/66?J@UA;S+#=8&C? DX3:6H; QY M"F]XIH_4P"8!I.;$:R^^>G/;Q+3YEZ^UM[SH5[N]QTSHZU16,E(I3ASF^?0\ M=3O5\T79FS+1'9E3S]T&L..S6>HBSVK"EH-6HC4L[\NG_!K3-]TZ0>9WGVO7 M<4_9I93^%=.3Q$Y83%B?GPN 2=5<(BQ"GIA[FB;MQ%+-D@[RH MQPIWGCRK%D?$&QE*D\S4D>48HH0BL+$5H"K% 28:TF:.9PBQU6^D[2<*-RN! MTKE8CV+3![*!CPQ?)O49J<*7;($#V0[BM 268_.47A[X39>/=>)#MNP((G58 M50!Q=5]0FT!QS+1"I0B5OB14N9T1THV+B0$=[<4M6#@D5Y<]V*IP"_JB)LD# MW7]/A^Z3L<=)W4KRY6]J:TYN\ZZ3.&V%M"5"U9-IU#86I?L\D$C21\U!'S"3 M1GRGZ2_-].JC$/56/:\?EQNK2=Q]+$E*+R$N$!YMT$8E^%ZYOZ-03])L)U-I2%,"ZG524"/N@AF[%EW]P75<8^_L MH(/.N'8)]!>\1ZD0ZW;/.5]BW,)+Y***ZZS4]+M5BH?^CS'NG?Q.06)WML,RJ-MA??P:+?[T[-D4IS/CS\B9]%7EAP? M-@?J4"&)!GOL&VV")WW^V<0+0V_V6IO@4;.FGP\!".KPF+?0T"HQ"Q^YRHE, M#['I_ORL]VRGI:59&".JS(\#KD@,E3!G>)$(\0D]LLQ_!# ^&0=;\Z%WO4?? MF/_\C/^[<@75H^U)T6=)$32///2GOY/X5D3\JDE;?+Q2V&Y7NXYSY&@3X, [ M'TP.ZPS@]_S7VG]=7[]__^'#LW*\%>\R%Y<_K3^;VBB*M(NC#15?O6#<^8P; MP?SF'UU_8;Y\651&-\BDW!U_JDPW9D;D M &M']I,GWW#0&8VZ!R1?277S>&^'K+2R$?9PO)/2'KJ3WN&7-V8=BXHHFPON MWFRQALZ_ Y.?U<3?]>+IL%38([FWIJL^[%SH@X80=R]VT]ZMU'T,LY(#CM_( M?S+HV\LVGJM*>N<]U"68N>*P>K768:?:GV6Y&:*F.@P-)%O+(64Y9-3M]"_K MVM9W(EN.EGO%"Q/NU .:78]:LDHAI_.9%M8I3(W*+4Q/K&)NWWPTYR@ MKK.475I]M0Y*6B]W M(,V(<]T *"PT;_FG&=+]U<.+FALGU;E>4EF=OT/4$A^A>AVT3 B:I'IG5Z/P M^$^^VM6>[FKW$IV+3;MA;[=335$4T5E*.1I6Y+^UQV!I8/K4B*RF#:,]Q:R; M? .],[IHR7>LY!L=FGPE=X>F'$*/Q>U&[;ES>^Y\*N?.#9U_%]NBWQGT])85 MFAO>.!7B[LG)J<.Q*9Q"O3]W=W]&5!/=EF;E.!P-14;#CGY9CSYH*;)=DECW M("1I78H&6! -G;]U*9I A4//OTO6_K#3']15%'C*K' ,+D6CB+LGEZ)L/MFV M;L?VE;5M-N"!L@%K/9II(-E:#BEMX0.+#'N7+8NT++*212X:RR)[133N'ZM<8FCWE8ZB& MSM^X?>:TN> 8#B.;).%'ZTNTR8W;L-Z@]26:19#6EV@0,0XB':TOT13;H:'S M[\#0O4YOV!1+H^6$UI>W$0FQ@Q.(ULC19]+?K:7*&-R8R?6*B9AN\OZ,K( M&=[ R>ME)_$Z&A7L/PWV:-'7HN]HE-,!K?;N3C1EBHUQVS;4.W1!5MZ_1K/+1I(MI9#2NO#M@"]99$-+#+L=T:C1K)( MSK::7&H5?[7C-4QY\U=_V=-^9EEM +R+? P)A?=,6S##UYAK,6NYM*Q#D.!3 MU]YL;K@+C2XW@4=M-_0TP]7&00"#TQWFWE3C5]P$\(.E+5]WH[U@TRDS0_N! M:7\WW,CP%YJ8Z*7V F?A&+GL];KQ;3GQ^/%O^IN7!-:C'=[3"CZZL+ P"K5/ M-(WA:!:@Z-:TF6O"'P3!7Q&#/RT&6(L80*+,]/'3[5@=7)MZ/HUKI-9F DL; MMJO-E34:CD.@D(0%^()GVE0ZC->F,8(P?V&!.N.Y]E5!,0Z,,&GWAH47-S_8 M7A0X6=1K@%7F!A38D]?($RP2>DD+ 'D<,<[05XLOCO^\CW F $ MO'D.4**PJ&N[3)N!"-QKT"?Z%? M'PT?D11H+^@7>!!?CWR M@SN#=\(+D06S'/_P2:ZZYWD7AXD/1J@PI;/#[%'4VLD&05B!+*".E90!P(:CAJ6'[ MVH/A1(Q ()DG6>^@SVO>PZI(WW@F;[<0Q,@0&L4T@GN\,#*PP6K@TR"6.HD0 M^FP&+(",^ERHD0DCG1B/*H82""1 "V@G@1KX8\>V"O(-:FITEH9\ P<;49X M7:;V_++7Z0Y&J"XL&S1,"&\&L'B?.? J2HVW@BD$FKC4/!\,.KW1"*$0^ 6 M36:QMM& IZJ.OJ:(O:0+$FP3*#F,2;QF_A79B-JI[\WHG5^1]*[GQ\+SS056 M]P,[7. W8V>"2@8)G9)X0YM&803$NH,]"^G^P%R05]];&$ZX.%4:%-L2+C9N M"0+'H"$4"Z3$3I"["[BP.%2>4<"F$3?+[-G M4G:";P%IPS'\=#:^P[7^ZBQ,#T8)0:L01.]=X *\8E6[C?P'&[0;OO&)H?$" MIH('-NT-:(3(AS^U:[R15=E%"*KL]H-4J60+6CM0WA;$Z22W(6EY*;.L5H!Z MOS.XU#'5@EN$,!/7MH\19T6&[B>6T + EW6HBNY&[K M7<[9ZY]_\]R[K\R?O6.3L&$7/G]VM;]'P#Z@G;B.2HD#&$1F1"8(X:(4S ^A)V&6NS&849 UMHU/K;0WAKN]X[V M3P9.V!\VPFL;JIC=@+:(#.XH(5B@+&>!% K$@U0!_4H"$F 2A.L%L,T?=A\ M!/T3T 3X7A0&0$J+S")8C0;F#8VFGP]_THP):$AZ$8S!&>,_&A;B3B@(DCAG ML4(O2 6EC]X$J/G0?G)#TL37[S]K<]"P=X!8$-B 7'.#F E7&J"69#GKXS:P M0AXQ"-?I\#(W^*6-+[Q*5/5VP/U_\8"A\+\;(]WN7H<@BNHD7VH8Q$ M].3N57Q#B/WMG3:%<]@%@3 *>I=W5%KAA*?1IPB*&N"Y:SL*=;CHDT&SRD'. MX!L',7%HW XE\B7E!,%(*X-Z!\YF5J["R)7^K(I(M,CG*9(7L$/T^<*HY1I= M1'^++LA;G.>&!Q""ABF3=:&)(+LI$3DD^@F[R_J'^W2*&\<=-XT[;B5E?.52/G;"YZ[Y0#5E*YT4I.U]X1M% M3QK;9XII6F%N47R%[DZ9N$4GJ7S$G>XFKJL.K\8[H/=(I?UE9[3$;(G9'&*6 MW!ZJN=VO7V.WBOZ:CAU[R?:J=[E;SM] [CPAICBFI3Q=*CVQ1,UFR&W._G+B M.9EM>+-QX)R!R^YYMZ[KW5OB MU4V\T8%%KZ22/XK(\Z'#O(>>O[%[P;'RP3&%7Y\(29Y8&+G.;:*QH60G7,I> MWC$Q.9OG?(N9N_>> X0+WO\5V>'BDQ>RG!J*9F0T?TTE(VM&%-Y[/O")4HLZ MX J%I<3P"*GG,NT!\*Q-(A0-F-+U0GCT >;@MWIC'2L\@>G;O'S@ M7$1 ER; ,EA\.X@F_\8")^IWL-!\9K'9G$H*,"W;=K_#6+P0 *R9I H!2.#" M Q95="PX#%3+@)7/2P.\-Q%IKQ8-@.'65@1CD^J%G,= Q,)9\L M>+V!9_A4_!WGVB?E$\?EA*D0 Q!8O(8OJF4/Z=S['(X]H^*)E\==+T:S M[-XNX9C*!K8X+8LC7?F;KQ@17:ZBAW9%MUCC94E#0,!R-2H!S$XAKH^\_N0R M;C>PHA(%-P-040'J NT%+]>T7=.)D+U@EQ>-,9:JP RL'$*M8 SW(?/F5X% M+[$R#?>& 56[\*IJT*4F8Q;?-_H]@NQ\)2KW:#Z<("_OQ#Z38V'P06=0@L$% M2PY7L62OV2R9V+:%C=&L%2N,WQO##Q?4O,4PT5;)JP7>IQV[]89W<8H;WF8Y MZ^T>$U4/5!JQ1ZX#<']ZY7VZL07VCXF<,-64BY>$8]>=N/F9)0JPTTW0+I*N M-L5JJQ^QHQ'8ZMC=!NO )^1)<<\5"T*QUMOU9C:57<=5X<_U=$%I>.][T1TU M\5JRCWD+G&0IAA-X@ U[CJX4%J-2J3I,0![,E&$U-TS[Z$6.15TEBB_FN0@0 M4A,BZBZ"#@,'4K.G\42B Q[W4-''S )OLK M1A>?\ZX.9.%&@]K*47-HUQ!PB[0QJ'B3&\/5 #X5D<,* F@X)XP?:]"J[B#!EAC;A3$'=CBE92 $[O[*07T MMX9#R.9]Y\03"]G=0W;T6-T8"ETTW[,B$_[FHI#N[H%4D U>X@6OZY(0/]0A M-% K*6#/.VPA T,/$V.6NYWD9@>R^14I7Q);:0#D]=#20&AL9TDPKKAPJ>VS MNI=*^ZP7N+]JHZ5>*A(&:K$5H1N.M@8OWH815W7F:)YM4<-^V>Z2-1C:3VZ7 M1-=2[HO!NHU1=#4AA8\23*WV2NR,&?X&6%"_!GD*=G :"C898"S:%N)\PX%HNQCPP&*FQ6F63MMTJ;H@V\<. MD@@*]K+TO2D+1!L;8);@.': 5DLKZLX\"2T=!_VQS][6>CH9)R/XY^OT#7Z, MWT,9% UR]":HG%.VY%HY5@3".DXY_L),[\ZEP]OG@^ZH,[KLXLY"7'PVP=/K MQ!I"&\'(]+9.BY;<[4&HOK,%,)5KB%9XO*6;RYSC8.W]=@-;:@/629U%GF(< MLCUX.ZQG-&I<_'#4Q@^?@XQ+TJ$)XB:"??E)B/D M5&*WQ7:Z3,=;8KQ%M-0!XCV M-E))/1W+O$K*MI;YL:K@1L3L#QJ>[UV-.@.]UX;G:PS/CU<:] MU(^9>W.WUQS@BS);^UQ=SSV-((H(@:A'6T:.>4&0Y)@8HIN.>Q;?7#QA!IZK M=;3(Y1>FL"3$!'ND\'\5Y$KS<:J=7@02NUZ&K-._^=&LKBT5E M<=BDI*DRP%0IB]=@@AL3SS=(L+Y(,V<-9A/;T%XH8W][>YT:&G6"$>_L M/9Z&NEQKBR"E'0S>/C-)D[P>O].>ZQ=7)/TOGNL Y6!P^9(MJCNLV;%UZ'BXWPV[)3T'GN=T9+W"*)FNS;ESTL5 MI@NU(3T7B^_N^.59Z)U1AC[?X!7G)'(=M(D\_.K1#C9++TBCPPQT$);%F(MO M)^/>SJ.)8YL\$8CLD=BMS1I4MO!VU/JZ]6TH$9786E564HA\6+*C?.&Z]X8_ M:2_TU# OL2X ;+R^+$'VL/7S:D\O\[J<9KM>)MQ2AE_J@)6 M!KHWX@ <)I?BB#8JVA"8 30YND^@UT# X=GL3./$0DN5[:;FA=% WO\=N;P" M6,0;2=7.4?%2_4O6*V2SN>,M2)72P!Q?.2!E^\9D:K\"5!H\.+X*V$R)#\+K MLS#R7=+IO* 9OY]&\"43K7Y]++**@$.R*/G"R9G"@ 4\\P KF/K>+*E9-GP[ MP 72M]096X6JU2.'U2/38],C&ZVQQ;:VV" GDM]@6VR7DX:M[DF0" M]P^0& M#6@'&U/U2^&9?-PLKD$3^9Y!),1851RE6HK8M=KBD(4E=XTO+,EHB]]!PGR4 M7CH>GP*_C5>Z6&71UIK E8Z1K//[U1HPTN.R]08W@8HPYH/A5 E[@\<+N\)Y*7T#> M,":,6H!A%Q+TE+)#D>: [=U&/L7*:[ %Q"JO\8:*MP9=Z',:)1S_,"(2O[SYH5]VS M7N\ 2JA 63/ (L/'\%L\UYR-U MXHD15-NUL%D/+0\DT ZY!..%6?8,!(RA@TV +Y!$! 9%@@W;0?! CA$[&Q!C M3[DE(=*'. (XM^#,\*228[1*M:!BF#!ZTF$Q/DS[P784W-)WPC7"@7G_!@PC MHQUDL=AJ49L]X'*Q6,\A/R;F>$2F8&HRUHC%3<^WOC,VE]>%^>ROR/9)'Z= M_^3AE5GVC-!,MUR!B\/\,+F7:ZU O8%W4%B(=?A -D4R0)("O/=+#A:*R],2 MIRBDV[7H- ]=+UQKO*25\@N/ U[L&6Q%-*4DB'#4E$OE(I>, [S82V"3Q4 D M[<72'$_,)0B(D VY#) ;P3N+SJAL5H+0B BK9ZPG%R<1H<(RE5OBF<,JT.= M:L?F>(P-C)C!N'.PY[4[Y@*'T$5RIHEJT)*G*-]< N(VI%8L&,28P<+,S+'5 M+0'TZWA\DS(9#-X$3/ );0# P,F";()-%,:Z5L*??N2(HQ"?W44R)IL$5120 M;C'=4&0EBHS%]S]$CQ7B%PI7G-.>X*/-ZBPZ2M0D#<#4\T(7(Y]6S%YXZ2 \ MXE!B2')NDT>5F YB$R5D^Q8=6]'2[RG@S/(."O^?* M"6 0@6+]= ^@82'[\N]=!M9D M@#L6:E&Q+Z!+!YX<[&0("@$2;U3H0<7DE%-RIRV0KS$+:):9"/<-:D7'28)J M./+) 015#K3J@&9$O-+%@;&'B@3%EGB.]\@1 L(6L/PEPA8L^N>!PVOEAL)6 M=9>1*$0/$1/'C57"&_,I B:<:]Q !>[6A,@O.BD>7 7)V'4CTNW<5'+15)J! M8W;VCX[&C9@/;.*C.\J+I'5Y7!FO+RU46JY ?4V3DN\Q)*=R)5G*RCLX);_8 M)%-D>X(9W#51B@:X7@*OL X9DH398'*FU-6"^!VG$ 30'C.]-8O%XJ M. N":"8.5&@[-\CYU&(S3I;7HYS"_L[9/9T\+M@_T;&R&1;0002!<]\+N?$M MCLQX)D*^>.6"(T+ W*,4Q^T5QG8GNCU\26P?J!.Z><9L]16-%[O\G6*^J%>*1+<@= M:3$.H\OCXNX'F'3E1XE](<\I*0PW14O=4JQZV?LJ(UAI$5E*UC>"^[%KX3]X M& O0US]:N:4K>96Q'=J!3 -,!NYW8 Q*#JUH M/C 5;- 5 =JOOO=#"!#9-+P=KF@;(MT=]-O#,XJ,<3M$""G%H^(U'/>MQ,6B M2S-F<)LY-@+C_L&QFN)DRU?QJED[OKW6+GM=-?B#;*P1'VN_\YD2C9\XA*FP M#R_3\[V1)\+70@9_REM@\#-0%JI-@ M3+#]H[+DF0+@>;P895(T59+'[VU0"KYYO^"-:SC8\;:,Y1Z8;[+@N_(/[J"3 MZN,2I-EGX#=&AZ3'/ZL"!?T7D?U!^"@]! MF;&Y"\-^1SE ?J,&Z'@Z(NT?:K6=+NO?_UIZ:]9"&:/ 8([AKQ/J>,F:7"XU M:4_8A=RZF"D/M-!^:J%9\%2I(8A>X.+9#WC%H5;S]]H4_$NP\2@$>B<'X!W M>-\O:3>_/''FEPK(7]8 B"CN@X]SFWCQ\/ CX_%A[N?E2H,61)-_H]^!AV-) MGDBBD7-MIT)F4-9V^D@F[U?C1R/-5'7WC>T@4B>)I6XE=:9QY#Y'5G'[!A4CP-[V&B0VI Y;K2OW!U(MMVEDP>*4?'A.XDW <"M4QS(07[27R\. M+O&\'@SKHWW.\+S!)/\PA*TI"N.X-+EF_+<)"Q\QG+;":20HT#!8_?;?2E\4Q85^#;7HN3F$1,A3\E6<8%!<55I+B!-Y%-J%<];XX?V.T/_LT MHB-RU4,.2AKG<3]U7CN(1\8C!."NG+DS+ -\..&1 @S'X99/2. 613239"%/ M$BV! .\CQ^-A!0P\)1 6C% "+)3'&1/&4SUBXMHK:2.L,[!2\$37"&2^O[(J M*BY70.JHUE<'%QT$Y'3S'^.32"I>D*<3'14=(J-.B5YULC$+(CT>QM.4:DZ* MPMXK^<:/+41+B^B,%. PY3F83QX'!BE,T0X268:L/_@YWH0$P03N^!F7/$+G M,XO3HGB8"9>H!THM$/*4R#^\@"G-N;ISE1I<5I>AX=[A@?R8EOX!TX[8;YA/ MUR0W4Q5'[]&EXVD!MZ29R@%!-X28*6*ES"2^6;YH>X74#.HYV<)>3XNQKE;XGM(II%//8#*L\/ M[?\D)R'9!VQ E>W'NA)D /6;=AM-N (.>4@-=F+N#M'$# MLCN <7V&]_,H^AS+=;R9;0*/NN"NX24QLXEGV8ER0 6+8LQ7Q[4)IQC#]5RU\S/E M#'^1;8#GZ5.2:=*K#X7-9T@DG*CZ0[^2Q. H9BH,LY0 #>1HY M">\[]I3).#L_'J>-.18^DB$FWO895:.X\2$*;<9"_6>)A4XY08$5*#0>GK#1 MN;,J^$$)!#4[^4IRY3/EQE;-(Z/5SUE?/-_L-DC5ST\!]2@DREG<:K2=4W' M9(%46/'.*\A,B.&[+L$2_PZ;""9DB',0Z2GRJ'-!Y1AO]\**$:PS6? +1^0! MATI4;M_%QV?2/#=$X!.\?-"F/.2%JC,$E2WN1#63=>8=8IPJ><>J1!"#YVXF M\0[)$ZK!OS2P1.#,P1P9GE$=*P"),X5''I9J[E.GN\+X$$GA!N8GI$559AJ) MO*081$\<)BT9+&07!!ONNETR!S>8>5F[4%96CUWK79+4_9Z?PS7),ORR*O]< M8,EG\O30DIY)CM&@]K;:N/ LKMX;/B:-!S?,O\4*MT9&'O (W>1V4]+^P0XH M@RX2^6V6S9/ZX["#"SJ*FUH/ANU(3UVMED1K ],E12K3(T/10:T#$F/&<[!%X&\M#X3@J-M]7!ZRA]*1RKIGD1 M+Y6GFR)?"\ MC ^>J.$XRRD_PD#AMVC9HM@4D'86(RLY>E..P(4WDB=]&T0I*WGTS%L,VEXK MMS9$F2# (,3C#1\8#<../Y-TEJJ/WNO]'R15";B"Z:1GM,\ K6$7EANHY?_ M"5)RR;,'@%YTCZB?9-DF94QY!3I?4P>!\1PIYE- DU7%20*TY?#D5*7]*7_OD^?&\ZD2I&62!,CUIX,6D=BE M))_$L2_?DBGW>&BQ+&1*X)Q;*110^YK^A41AU0U'=NIPCDL=QNSB/%Y--#\E MHXG76JB0DA3&\I'D(>3*WW:[@SRV20,.>Z%_)\*$Z5!-;+XB;&IR8([!L84% ML62$*';P>R)E(QV :]4Z4'05"@C\P*B&*65+"SDKS8E<9R'1,EL8(6>9/>EQ MTI134I."X< 2Q6.W4,TTYB.'2119Z<3+RPN93S4"*,8360.,\16?%SD#CZ.% M&[^:N H4(##,^^2D)359S%3J<&E/7YE:.%8.Z/Z35=C*M?/N,S!D ^A? )MC@@2X7QA1,SE4=\E5%"1.>R7%G M+-_+V"BQ4L3GW\,?*[M=-\F?&*G!.I>!=!NLB ZP%[-F.63=6-QLQVZ%SVA0T3I-]5*E@$"/A,X,V8 MYXK[H6/FH9/M^).X=!F&M0/YP>'1"GQ0EF4*;I)7-&R0QTP[4*J><2U?'_+Q9B(@=Q,HU/MLU M1,Q/I9SZCCR!$R<'_+ RO+ (624:N--@"5$V87,G1L?)N3 M]L>WSK"Z^%VJ^N&;3.3@XD#)I,!)[RGI,UW<(\[J@>#7LOTS:;%?/>0C^ Y& M4G&&BG^"$.(=!25[FN2331#& _8[DH0P# MRXLFH>#(%:N6(B^OA4(!X/1Q= MTIZI,POC=C4=LOG ?K!$*SD[X#VLPC ^_90_$7GMC*18MD6Q3HI'&=I,=N' M$U0S7.=YYTO :5INB=+3\A3>\$P?J9$A496:I YJ+[YZ<_ 11X/NR]?:6UXT MH]W>8\+8=2IY"ZD4YU?QM$.>X9:JHU7VDHQ[+%,/N1&9[C@0G[M3M_=EKY_. M>'A1EJ'^&M,W77\GT^#.M6O^(C>N8GY\+@$GE9Z/ M\?*42*V7(P(!I8@:(>:*@W9DHM#())$-\G$!ELN2?.3%3?7>F^6@:BP\^N5+ M[>,,];S8.$ ?OQ>!(XW"$CS,I-T8"V+7!*P-0J0&:^\\>4PF3J$GZ:B_4HEFX@*Z5E4$AI1Z(F M#6>30\F@$#'H0'8S$^&T= 9Z)SZZR(X@DM54K1 7" 2U21G'3+OI*$*E+PE5 M4ERHI/VG#BT^$P,ZVHM;,'M(KBY[L'_AOO1%3#H@J[8>2G-_DR]_4 MUC;<$%XG<=H*:4N$JAZ-I_'FF2#&DKQ#6)Y4ELQH#TI''>+&4[;A%3BN(-G&NI=PQ/#$OR M#KYH3+MI.1?&_S MHC*2"C3CPM; 2O-Z[^PW3*@5 1F^(UP.>B\WF4<&9A0'E!2,QQFRZ-]()78) MZX)A,U=*,O1(1\5Q-%!4#J7S)HFYZ<(2:EE%\,E4P;B/7"]N;^W+U&0+G Y5 M"<;GU$)I\AY52XGMHDTT-^R%(1][F5E?(\^OS!;_J[>,Y#L@EW'/ZI27D;@8 ML3V\(U(BK!-\G0=V.N?[^!37;9U5Z'*\^SG9J.:9+_(KW MLUS3XW--[\RM+M#>V\6[Q2#;[]W?;+_%>TD6G%]^*V M],FESY(B:!YYEA7?BHA?-6F+CU<*V^UJUW&.'&T"''CG@XUAG0'\GO]: M^Z_KZ_?O/WQ8U^(Y5S[%+G-Q^=-.'92%F8)V4])3/+DNA6XXT?47YLNRO:!7 MR:3<'7^J3#=F1MR\YJKN?)<3]S,D*'5G.[_QJB8%6#NRGSSY^#5C!R1?277S M>&^'K+2R$?9PO)/2'KJ3WOE,D8^L8U$197/!W9LMUM#Y=V#RLYKXNUX\'98* M>R3WUG35AYT+?= 0XN[%;MJ[E;J/859RP/$;^4\&?7O9QG-52>^\A[H$4U@< M5J_6.NQ4^[,L-T/45(>A@61K.:0LAXRZG?YE7=OZ3F3+T7+)34(B0;;4H4KJ M."93;O\5!V[8\4NV$THJ'8.2&.,CF;APGA_7!'4=ENR2#-2>H!PF0K^=;U N M2)^^^W2/RN3HJ5."\>3@TQ9-_D&>F=TT9+O6,DW.C3Y2NX. M33EE'HM;#]J#Y?9@^50.EALZ_RZV1;\SZ.DM*S0WO'$JQ-V3DU.'8U,X1WI_ M[N[^C*@FNBW-2F(X&HJ,AAW]LAY]T%)DNRRP[D%(TKH4#; @&CI_ZU(T@0J' MGG^7M/QAIS^HJ^KOE%GA&%R*1A%W3RY%V82Q;=V.[4MGVW2_ Z7[U7HTTT"R MM1Q2VL('%AGV+EL6:5ED)8M<-)9%]N H-C%RT MQ#@>Z=B3D5C#46363&Q/(YMV#M6O,31[RL=0#9V_M+-(L@K2_1(&(<1#I:7Z(IMD-#Y]^!H7N=WK IED;+":TO<5Q< M< R^1),D?"^^1)O56/U4^S/-:DU(NNB,:I.%!E*M99"F;((-I%C+'">C/?;B M(#8Q8G :V1HM^EKTM;E"&Y,9/[%0,PW?7]"=D#.\7I/7RT[B=30JV'\:[-&B MKT7?T2BG ^1:MZ>.59RK](;ML6.S*-*V5&D:1?1NMW-QHBU5:H[9MJ':HPNV M]/HUGELTD&PMAY36AVT!>LLB&UADV.^,1HUDD9QM=>G6JK5W3\E;JJ+@[,XP MYLH55[?WAL_>&@&SKKT97G-%"3CT;3".PGN/;H+ZY@+PMR&,]'F.O]\XAAN\ M7;S_P7S3#MB-;YOL"TR_Y6U7^[_%J8B%D\^;:XZQY0ORI1VNLLECAOW=EQ,; M/9MNRXGODNC'Y*GSSIA/$=IE2Q(Z\;57*?IN&,:;:IS!=Y3U'?-)]HR\/PPG M8COC;@YV,2'O2>&NBLN**LE_*>7SWQ$XA[**35#[B3I=ZU)7 4N/E*7NDTO[DNN\E3%+O4),<4Q+>;I4>F(1SF;([=I@9OS5CG?* MKX^?[7F6-KS9N/#F1:'P9L6QJEZ)6%6!BKVG'#L])CS=PV3WOUG4O M4DN\NHDW.K#HE53R1Q%Y/G28]]#S-W8O.%8^.*;PZQ,AR1,+(]>Y31Q3*/EO MK_:73ELZ@3<9/!B;H?U@AXMT2O#))NAN'R@JH0KJG62+\%?E(?J5*^"!9,V; M)I*PEWF)I37!T\KXX??$O9OC!R\/A1I6$-\*<*7_$D$9[MT3VG1_88L^BA43(&L MJF+VTWZT$?LQM_W"VN@(+.JMK.A2&O"%CMJO@O.]JOB@L#U_HM0KJ]#T_1"N MR0AL&$6VWF*. (%'%H^KV]*60XEC[?[%3U7FAJ3<^IV;5"I%^#6TE-O/Z/U" MP^^P'0Z'G6J2T$X!V\VCY=ZB**>$Z!,@X[9QH5-"]+&3L7<^VK50H"I4Y)@% M:G?-ZE+NBB3QW1B+&2!R_&CXECHBYBG0-.,@B&;\NZ-*Z%O#=1MJ!H8K*5SE M[9IJ_5=O4'C&"G,05B::[B>]+M^B+%@BOX&$O6$!A.ZB3I:@7[W5[R\81LNQ M78LAD3#":KM%U_/%#KZ?37W&-!O1P()0\XVP<&WWKI%P'8#]:5^3=<^'%ZLG MVY?3M@.QWH&NA_:;1NLJ,0J?<_YLS$1+* $HGGF!VJ M/7@.[*H.;-5[$ZW><)^$VS3=$8A73+BIYT^9'48^VZLR?)*"5G"SWI&BCLRD MK"["OT.XIW\^N- 6F$;4))BN!AM@VL%_V=[;D+X,W3V@#(V#W'L.H"-X_U<$ M>O63%[)_&CYF!@2?_2^X]L0].CW?);?&>+L>.D5KY';OK5.JC'!S,Z3*/:/& MU2))AB[D(NU8 GFJS+,_+I$E!'MF$E&PH,F"I#U/OW/Y4U4LM-9HJ;QWS\7E M3P4*V4LV]'EK.(9KLIQT6LT OZ^V*^.4$&>=!>RE(JG[ :5H!+K:EA,7>+/H M/KJ@[(V>C6&;HB2HHR-.K8?$W7.]GGLV=Z#C!I>@&J-]S7%&H0&/Q?I?3Z7< M?:JBVI>,D]W3YX6Y,K:,M92M6E\:TFG6N>YR)I$N1-=>/*^[.&DO)-B?V7ZP MH[#WF#B\T-[)&..2_5R_1;NT U2]:?>[NW2*VY.55+VETOP1=R-,%XR:QE-% M==?ZPUV6^\E[X'[7);E=JR]O+2FQI5L+E@MZU-5SK)J0\T5%-0"-Q]'I3;2; M&W.T!">%4B-NQG/?=K1>#Y5,;S66]F<6-.H6\ ;'6QJ%I].<:I\-0O>P\-6J MI+YTTG+1DM5AER_, 9?%NC'\]]2:>(#YTR1_W2 R9$^<"]?2L)B:X:#(3U&\@IESK MXEGLFW%\[1@^7GNSF:AANXE\_#;\ZMWX]@,,>0-0,\P3_3R= M@OWNWO%^]@4=B3\%I'\J4_Q.9L S+7)M_GI (S[3+&;:,\,)?G[V\=.'9[\, M!EW\GSBQW@G:*M8]GN&^4M2!2E87!9:Z-/"M>KW=U\6AV?NZ"M$S9\7]XU[M M&-Q=%"?#N3%LZZ-[;$ 8?7=.)+ 8$D5;?#3?ZQJXUYB;?;XG%5X7H]O7+2[FT MG0':P_HNE/5=%%A?M_+%R:T*WO:9$3!P ^G?9)0OX!@"&U"L:7<*=9/=LPRM9ZN_@6H +Z/&>^ M$>)&P?,2JR+)X'(PTO5D$<6GKQ;PTKB_& Z&^F45@.?WMQCC><0=[=%O%_DE M9#SI4!28!>,'PW:0S!\\_U<\RT@M$O_@2P>W]^_?QG7_]31K_IN[6+&*5IMF/SK\CVV>?PGOE@ M+EH16H;BU2KVY.&P/Q@E@!:;N#IPTY9T*778&P[ZO?[PJJC)T82E%6&L52L= M#=:+2W_0TQNUVB:#NRZ>6HCO-E#C@'R7M[0:^:X2!;)&/XY-,YI%='HVGGE^ M:/^'(-_)-AX,"^XL*R:O&/P2UO/%:-A R(O8UWHC<5ZE"=[,%6YOI3=32BHS MY!NXMLH,_0:N;7M'H)DZKS)?H=*UC2WLGH([\ ?/7[F$K1,C5$*LG&HGF.IV M"/HIIW)_:ZC1 CO$>@Z.X[H-^'WP^IXM]6W6LT8C?6+AC@'J[D7!:!1,M0-@ M98+3P_YH5"QN4PE,VQMGO6%1ZZQ20/<8@JR2Z-L@N-\K:'94"N@^0X\Y@*NZ MX/,T^T(-1L3:^7:'KNQ)_=ZA&Y6!;K1/X$8*<$4(NP5PO->5TMMVNT+([?O, M].'1[NKN@Y]=I:F@N+N@HX7W3'OK&;Z%'9S>V3XS0\\/*!$: M87ES;*6,WR'0&JU5XXOEW0GIB[>>&P7:C6.XV@M\EB>=7_9Z7:J=HU_B[_0W M+\^U)"W]:RXT9C "S0YA\M V[3FHF4"+L,OZ?VSW3F-4X@K(3_(. M\/FYX8>>CZF,YQ36GW26BA.M=^1WNL;&%4URVJN0HH9=W<^ MNT.DN7$S,)X@ LQBA##4@@"9,,VF- *0/ L>2Y/2#I M14<0^7X03?X-.-=" M#YA FGE$19%MA(/XS';/$QQH7]/C\E12@.71XQRTF,,G@-'CT_Z*8-W3!?&:BP6)L/V(WOYB!+&>6\X=VJ#7TX3P?,3R1==PM"_L@;D1 M2I/%I'3I5Y<@@3"L,>.3&=APGDV9[_.94S.N@?;QWC;OZ6W7"S?#+D8B,'*F M=#WWC+]GPW?QM'7R[[ZY=DST7^ZF"O^-K^9.H\G%XAS)E?"N2>EC@@WN#<#J MA#%77DR>Q^"GK %24FQ8,S#3 KQ-QM(FBV2+D7P?*_:.YOF:0;BTPY"!)IG/ M/9L0J+Z7V@Q4_O\("EU42R#O6@SFQ+E![3[>>]JC[3A EI@H*D$]7]!N@ML5 MKAJG2R"Y-P+ZQHC">\_'?019P+(#TV?9^1C,!K27R@ ?%*,N@8"_P; $0J(L M\]Z$\9/WLMI-P9@3>*A@%6 ,[8$%F'B)X[V"A2K7602BB N_DU-)!L=')21B M7HZ5$-@"*142O]!:F0$*AS\,8 (X#*_!IC:$F*7'W[,BOH-*9"%#R8(\D\X0 QITRX"]-LRII%2 ( M UE=';XYQ?2!20&K%FS,L!P?.(ES+>S_&,_E7(Q[#3>OYB",@ P<#9C9L!XX M>Q#EB:A"5:3Y) ^^$U6>H,%(,AZ09&0L@3J\Q]S8#DDB-<.8\$#13O/\.\,5) 5\PI:8HG+0(6"H.!FE MG1>X\6U6ZDA>(2$4".4Q",V0J# 27058E?)YYJ>Z;2&ZA&TN$&.$Z54*(8>M M-/"'W8F?#1:,0HOX/A*^)SR;VGGP+&' V8Q9RMH,(L!$@ MC[^MK+0CMI?-JUFQDC=LFV;6"URPT?Y%!PB\$B0Y.%R!H.A9@/? ;4B$L.E M;E22R97HR-2PD17][RS4'C#G7HF29&0BK>E5B\-S8_N2Z 7O$8Q9+9>UQ=++ MXBR -@7L$0P]0^!UNAQ*F_K>C NP.KR$3ZA4;0QCQ0XGW[D4AWF=FT1.*$(5 MH" \DC%/VD^@+L9@DE MK_[2Q&5<>^:3]!40+:.TC+)B^@]HTE!%9\LD+9-L1. 7-C-X0/TW>8-N,UAF M;8?+ZNVGFFZWJ951=^B+?5KHV*6E;.%6@RTF-V(R#52+T]UQ^N)?&$"H^[JO M:M5PR7OB"V+BBJI7M,O*R[%V][Q; ME&PGM>A!0Q:MJK)MS8G:]<;*Z[,*XEL!KO1?G].I$D>K8N*$IX8PWEZE;=L[ M[(YZT?V&+/HH5$R!NQ&J:FM>A39B>*5H86UT!!;U5E9T*0WX0J_H'L*J^*#L M?1>G1KVR"FWG^P2/'X$-H\C66\P1(/#(XG%U6]IK0$N*R=/'L+=9P:&IM'F6WC,:>&QH91IG<^*KP3U$&9 MW&UU#P& ]KGVN6J>R^'@Y-JO:E,MG7#_:=N4NTM)NW'=4[IF5TW=MJC=.:\@ MP4*O&0!T+U*C XU7T_X]@A^D$4J9OGBRI#TRGVE8;S>C^N\HD .]17UR=FO> M>U@D)\DK3#[9SWI*IID=6)KOE^W M*;FH& E[P](7.I:S/I:@7VV_5^1_%PA#TW)LT%5()#S;L-VBZ_EB!]_/ICYC MU#P "TLUK$\JZ6IO[:#J .Q/^YJL>SZ\6#W9OL(E.Q#KG4W%S9:VL)E3-M*_ M ]I RS9CLJ,0*;P#S,2-G%L=O-CHP<,B:<<.%WL3K=YPGX3;--T1B%=,.*5M MPCZ5X9,4M(*;]8X4=60. =@DF*X&&V#:H]]XD(K%]?J& M7$ORJ=#Y2K5*(JC2/B8YAVHI/;J-2I\4+$1=MH3KG'K= M8S[%@LI\*Y;2QB85Y]22M0>Y!RLXS2G^W,?\RB%L(<>\)?])U!L?AMG>)SOB M@9@MU]+=(@!5>]RP^HERY&#;29M1'M32II8D-T='J%TY'2,^H_E6:IW=_L_W3@/))#+KXZM)4K3:DH+_L) MHNYL#RBK2-7L6L.5:)4!A4\N"RZ]*%W*TN_)UR.5.S#84<;;A3>W)GO;_;Z1 MDMF4NMR],>C@J4IF?0MOW(YYV:8'K,=NW5%YM$R MY\73E,FZEMV0G3+;2.CJB&6R6U2AG QSZD]VJZQQY8W9*S^;H8>BV1T>_7;Y M]$2S_S3ELJYE-W.[/&['\NF%8B].J!-8R:SUCCYLM&3NL0O5.+K#6U*$".M% M,=+\A*\]I$[6UWLU&8M-(LNNQ].'3Y"IK!]2TYMTU#!D M+;E4IX*FZ\7L0'O>OZ*\-^W%4A?[^+)(77^C/==U(OS+ M<[K/<:EO"/8_(6!B$'+;GVCK6I^(SB?+BR9 LS7_ M'OYX31>8B:J"KX#:MPY\_N5__5_(DG^+@K,[PYB_OA6WDG^>WN+=BF^-@%F( M+.8&=.OIV/?QGF*\+/CM(GGDQEC@5^-'P[?$%'_0O<%CUY(UGU\]_$JI9OF* MC!E#@K>K(L6_L.G/SS[XW@Q7=];5X?^AQ_^^.NMWG_U"XM/6O[7U;Z?C-QQ' M 51;__:DR;]OLK?U;\GNLX8-3[L8J*U_.SW:[!Q@.&VTMO5O;?W;NC?;^K>V M_NV(4-?6O[5)%\>1>O!D4Q1//T.QK7\[9@9MZ]^:*IEM_=M3ELLGF]3_!'+Z MV_JW8V7.MOZMB1+9UK\]Y2*;MOZMN9+9UK\]:=%LZ]^:*)1M_=N3#L6V]6^- ME,*G&*E4#E4E_U[O;E/$)$+00_AL8)B]($U=8;ZY" M(R0G%W'[3 NB&4P"G&%M<>7U=DO87(E8JEJLFINLZ5)I,7K,RV06O-'$8C?6 MHY46\%4VP][@J#2!/Q?JM)TCI]Z!CRHM?*EF8JD6E'E+:]&#LT)3X*B\;F$_ M+"!JB/?->F-1LBP++_<]?U+G>31\O]:+VRI\EKN7%(5T>:E]7.BJ6OHUEAU2 ME)YY:SB&:[*.MEP&CY>H+M>DEPS4K:+93DNN3%,5L9J?"*1;N W2C.G;W!^%"[1T;3M!LG1U^XJ&0$<5=RBN M%*KM4E-1!7*&LCU]7ES5)AU&4JYO?80HT MV*/+OE(=U#ZS: SU3C:&6G*=ZW=1I66S?:WQAA'[W6UJD&/NKM?WJ&W5QS#B MCI3I@F7?>+)0!$:N=[C3>C]Y#]Q(N=R0*UQ2:#=F 32^:^[6B]WH;\Y_T9!S6D-.P21&IN++-1B#K-J5:2?X>\ MKP,N?+4RJ2AS)C]?9:E[<#0)V%\1N";O']C!$EO6GW9-N!46,DWOG6L)Q!J! M3.N>U!]?VQ@[J@\)RI)#;UV>#\&RJLVVZ*!]5"&V+0)G(%CKMCKI$_Q4PX&* M43@"DP;F:E0"FMU.AM]C#()9FNTB)SUZV@V(MAT$GK_04,0"[07R"B?C9:_7 M)<$+XL_ZFY?@5@';K>K)?N.SP,:((ITT7[__#'X.S#A9: :0)C0<#!H^UW6R M_[5'(] /$!LK7#C >FP;?:W ML MS"?%XQE\_?_O[(I2$(9AZ%7\\$<0U%_Q$%YAZS)6R-Q,&YFW]V75.E&'^#/H M5MJ\5_(2MK!079.+'D^UQUW;J?9L7WMFFC*3BG:E@RC>V MJU$\'OTB=@, MI;#?VQ7#&U!+ P04 " !:<6U+]X#O2=T+ 8=0 $0 '!K='@M,C Q M-S Y,S N>'-D[5W=8> _83NRU=XM@[%!Q#&?(9G=? MMN09 2H/(Z+1V+!__;4T'\RG&(ASGEO(@VN0NEO=O]9'MT:C7/R\G-OHB7"7 M,N>R9C2.:H@X)K.H,[VL?1[5.Z-NOU]#/__TC[\C^'?QSWH=75-B6^?HBIGU MOC-A/Z([/"?GZ(8XA&/!^(_H%VQ[LH1=4YMPU&7SA4T$@0J_I7-TW##.'E"] M7D+N+\2Q&/]\WX_DSH18G#>;S\_/#8<]X6?&']V&R&XD_&AY%/PKQ_Z)NF;$ M?/9Q]OOSV^4]_75*G'=>%[BVTU9_8!=$DF&6JJAIXXKL&,FZ"T1 M,<2)3YI^98*4YI*>^J0T)+5(BLXE9F/*GII0 ?3&-D-QSZU.,%Q'+ M!+L/2G10(5E.,RR/=!39)"8GAT,&.PV"$P0P2E,BRQ8+"$(*"OUW( MOG8NL1V#!4@^P+11+%_@)7/8?-64E$T8C)Y4N^-8/4=0L9(CD\]5@;CWT!U%++''[%C(5\6B@F[:*;%Q(1[+K$&SD_J><&) M"V(4TRT4!(P!20&3B6W3L[?C6:N2RQ(4A-#OX@SE@_?8EF-_-"-$N#[HR2(] MRBV 5D[!)(#Y?>>V<]?MH=&'7F\\0F\^.]BSJ"#6OP\(2SB'F(-M,Z C7/@ M3M;KL6^7QAZ]2CV!75Z'QRG?# :=\:]3[T[P']P MC0;#WGUGW!_<'49" OW!9"28^3ACM@7A:>^K![-QR@FY)'I?G!3Y0KIB-!YT M/WX8W%[U[D<_H-Y_/O?'OQVS.KFWVG#,BUE5Z)YQJ!T2W,_J KF\' M7PX#PE\:7 K8#F-FU6\89()=!BL"=S[+OP)3"%=(M#AOPZ+WU5L9%T$"9#/7 MXP1^& VDY",V0?$6H$JU@8)&4**5O77?R)O/,5_!5$6G#H3:)H9(U329![ X MTR&SJ1GYK22MWF'OT@YK-5 @6+HL)AJM9:-0^-[Z";KR E.KMUP0QR4N)!-7 M9,%<&@:\FGJ]/\[2_F@W4" ,A=)4PA'*VUL7],$69TH?;-)QW2C3R)1JX3:. MTG ?-]!:!/)E["W$74Y@.;W&)K6C<"I5IH?72,-[TD"^ !1*V%]PV7S.G-$, MTBBW[[H>L:X9'Q'^1,UPAM>3Z*%OI:$_;2!?'O(%(E\BFC".0IE[ZPR5&0P6 MB=PM5J*'NIV&^BVLH9(=!?Q["^L7S#F$#@&DT2\]G,=I.-\U4,BZMT@69[?; MI;3&21K=LZ"S!D(@DU5B]A;I>P)Z$6N(N5B-H=.YV%2#&&*X8%\MZ,YE"/6^ M.,UD2T<-%(A%2BZ*"U9Q7RAZ;_TC%S$JU!X"( WIH\Q(B&.NUFMF?K7>%]G, MU? 7S$"8 C\F;F_Q'WD/+OGJ@4F])_@3YJ+)0CW6F:334%EG* (I&7L,<)F\ M?I>]@')[ D8F!]UJ3P"]"9_V=Q>N./T?8\@K-VX2!%1:-[4RN>NFK0+TQI>[ MOWY)[P[$O5%0I_=!)L'-VS\XX*Y-9.-.*$.H]\A.>>_!0_%T-^Z0G'(]_AN3 MX0/683(;QSE5IL=8ER$?X"V1E\61+T^N=THFL=XBF3LXK5P >T4$IK9[)_NZ MH$]DF^ WPZMW9R8WWS((#II#47O[Z]OB.#< :5,X')+I/9;)X#?'PX'@_75- M.NA-.*2H4N^&3'*?'Q(?H,]'-S6W;:32.R.3RFN=<9BLTN\\\YVR@4;KDG8F M;<^^$STXI&SNF)BO2E'JG9/)Y\MECWL_F<73Q(1/\BKT+L@D\-D$\@!W%E6C M$&]C ^ E,O9P.C(.D,> ;15"WMH >2:!+X:\=8 \!FPZ\]-1Z%V02=>+77!8 MA*,MJ\3[=[/7>7]D!IFNS!J/7F1A M+&J.615LB90FU_LODX!O.(;UU_:9_"/O7;@G$Z3N:SB7G_5?UEPJ+^.H!64S M3B:7-?EA?SW\VOX/,*VQG-LAB12MN:]!>3R-1M!P* )S,R,EZU*=-3XIQW M/J/L*F>RJQBGWZC,;HKLK$6B\ZDS 7Q5VDMY?.&/'=R3D$F=)^(**;*]C2HQ MMN"YOA:QDR*N6' IS]A&C8A)/=77["D5@BN+5#PJ%Y$_KC'EZB*NP41>7T8@ M[!>,KX(-/O]-3DVI?%DK24MM6Y[4N:P)[LDE05Z$=0Y+!6766*UHEL>#VX;\ MN@<_N;BLF>H=7PWY"Y]?.6<0=6.^Z@LRE^R A_?@P@KC21$WG'F+D)0"B:)3"A'NM$>/PX0W\\+E*_DQ7N1IC$7Y%1MC;]/X0H..=]+C!1I^'L( M2:QHH(.(CE1OJDC?K]8D0[Q2MX4]8VX%2(<3TE0 M*XV.II1HG+U&RZ\]2O43ZXWL%&5GX37Q[M.P11Z^XRPL9TS93L>Q.G-8#^F? M2@MEC3R;("?:Q&?>OMG;LU46@.1YI2YSA0L9_Q-EGFNO^HYI>Y;JP9H+- ), M7D)299?KLM8%9TM=F VD(;*#F";88MU2_" /"U&R-6(E9586N]B@B([Y!+T@ M"%!@H4@/L6V9JCK BK;,UX) MZC1>W%U0%0 )%^[$2CWTN"P58P8A^A.,PZ$-";%_!>&$R"C6/TN87OUW%;)K M0.T?E'PU$"#2\=:YPK<*J>QJE;\:\L+JDTRFE,QZ_8& MJ1Y?5/OJ>LO]FW92V611)31L935L54O#XZR&Q]72T,@!T:@8BF=9%<^JI:%A MY*!H5$O'TZR*I]72, _$ZF@8O@%Q2%+-G/*JZ#I^9KFZQLM?7=>.-_575]=?]Y2P=DB< M9]JT3525,ROZ3J/0)!U%YU@Q#Y8PM2#?3)FXD MJYQA_S\C:=O*4%;.O/+?2:3-W86S:_SZMS__"<&_3W]I-M& $M 9 M.4=?B$7EL>6^(7Q9]&RF1F[,5MPFVQYS9_]56LU!=!7V(>_ MNQWKXU^[5Y85O$RLT_.3L_.CDW\;,O>QOQ!;YIU5)_RW)O_D4N_Y7+X\8$$0 MF,(3YRM!+QH[(KT$F]:1);-+84$DN2736V=E9 M._AT,S0V<^>R9>L2G*W"(6=O'*^:Q MV6M;CFR#M18SXOD]S^E[/O5?I>GX+$ .T@2LGSB97C2D5S2E*W3.CCKR^3^8 MT/JO)(QR"SB8C1Y MB<73P&4ON109(SJD+PH*3[CE1,"S FLUOS#(79<,'(U[]_+5QQ1F*#&8-WLP M.Z">%[,9YJ]@5/KHT2E,"X@NMLT6\#SO\9:YU#80(A^7PZ$'K:&<3T^]G!(_L"@O0R=T1?KIJ2,\9+9X$.3[ A[57\*+/BTD#B\[>QTVBU61S288DL$['SC1FBY-&E1GDSH+D9E1V]K@A4_ZZX MD0KUZ9(<)HJE<2TCFH7/WC^<11@4%\\,D6K("L=G[!NF]$5U&GGQFE&7E#$, MG2$/CV)RAB'0#))"<5E[ +-*0=;= UFW%&3FT=^ ]O U@:''I0PO#(_6T]+& M%]DC[V51(PZE5E>&)L_/J0HIC(WQ#I8EK!3D3J]Y&67)8&/77KC! O8U_*U0 MD)5//(M62"%1U%RI&^BJ7B[ '*[ M=0&_?^Y=]VXN^VC\M=^?C-&'>P\OH PBSD^;#<@-5I?9"CY7[H RKMH]A!=L M CV.A>B^8CQO W^<-HFKB\V[T@/.6UVK'#+\X?P[6_K@O%RP?G.2HZ+ M'X@;//9;."XRK%T=8+D!E(YS_6D4WH[M>]Q&C$/0O6ALTP+FMF+Q^.YQ.*(M M9!,6[.6 W68;^BEGLRQMA9IA"4AWE08/:: 70A^?_ !S2M=Z0,-S-# MMU(S9$I:.[NH&T=IT[0N$R!%Y@E/W.)7N1P)U1"\PQ?$R2-3+B95QX9T MP:)Q(K]J:N>9Z3NC<2LFC:VRT%HO>$E0P8G#C*(K-K)J'\O8D&8:Z#5UI)X# MK0+(C=U;*%>&WB6>4__MK%M"3$@CJ#H!&=M&(W+M3'0GNVN/.'W,/6BX!42K MQ6P1+"Q>LJJ@Z*I;!%KZ@[W MZ*Q7=GS94\Q]BXI/[:3EI=*6GI)//BOK4$?&ZU#H@\+NIX+7T#0'I!4ACB-" MC">]2?^W_@T(,!J@T6W_KC<9CF[JLJP6BN,];K:YTP-'PM JZXP9XS[]3V"* MT33MR&I"N:&AJSKXI1HD6G08R5^[O+7^?I0K>R1G!DV\\-5F,I*^=C8+CN1\QH(X\JN@ %790DQ89DD9;V:ED\JME"UO M[E=]L9?T>!Z]$==.CUP02D0E#A+"CKY_'HOY.;9-CCT M;*A"Z>ZW/!.#GS&/_X?R_#$BIX$B 20YR!PNS\8/<,EWOLE#QG*=1W8T2E.Z MLV>1\)W('7M(-KFYU""D[VFNO<2M:=4$#L<)U'A79/USZ*D'5=)GGYZRZJ[Q MW1/25#GUJ\/BR$TVN?,8VXQ?U1UI 2Z01Y'%!^\!ICS84 XBS[I+8_PU/,'_ M19Y.?ZN?(B';D+;J?O5]@3J7@FH7GJM=)3^MH4W_MY?/T\/)';$)7DHAWMFF)/*K<4<"O0:<]83W[^X)R8AZ?#$AK MVLYE&#*Z&6&JGOJ5CRFR#Z@'/<_[G#B11[7;8C8ACAB _3=-G=+%9>Z3Z4AK MZL09AHSOJ)FIIW:!6,HMOY4&/^1BYA*[$DZ9$\TPZ3;.QZ5J<^\CY25"3\.2IAMX5"?E+&'8[HC25ZXUFH M8 97+BK"G$6%.6JAD ?:, F^T_O&IE#\J>7?+FJK$T5]W$)OE"A:'1>"-.7" M1@6G%<5YTD)K.O1&6"Q*HYL;%=#=*.C3%EJS06L^:,T(31E'\:V*@G8L$VYY M5% ?15%_A%DIJ="6K%"$L1L@%73'470_M] ;1?&JTV]86R=1B&>A D/:'U'T MZ'PAE(L5>6;8LJ3*NNE2$T";=L@"G MW(2I@,W*P67AS'\1IB)"+$?GR'&E^<[[KL94Y(WE])S1.'P*VCZFNK 17Y6&[8NZE*5& 4)NZ?9C(L*K7+[,OR6%9T&NZ"AT<"L[I35DT M52^KYK&07O:Z+1+J+N)5(ENL+T@NUK;1K-PRTRP+Q7J"3!G*2S:&%_?NRG(4 MZP#B*U)52)+G.E]%GE@S8%9&E^1O6;?_*F+$NH%X(5T=9"L9LT'QOW$DJP+4 MW634L2X@'76W M2:Z1MK -+1ES9YTRX<5H#'*GFE^2K)MU-O(E:@QHKQ)*@E MN;39E<0*_%C&35G'KE?8XEJKWD;;<')[O MGF-%VE@BURQZITL85L3R1?[WHO#.?P%02P,$% @ 6G%M2_T*-1&<$0 M0Q@! !4 !P:W1X+3(P,3 M?(X,+';WM\ "NPOHEU^?YS9XA-BUD/-A3^OV]P!T#&1:SNS#WI=)9S@YO;C8 M ZZG.Z9N(P=^V'/0WJ___.M? /GOE[]U.N#<@K9Y LZ0T;EPINAG<*7/X0GX M!!V(=0_AG\%7W?;I)^C=C@#=K] Q$?YR M<[&B^^!YBY->[^GIJ>N@1_T)X>]NUT!BY";(QP9G^P?_D^0N*=[OKLBWG_N1_^%W7^Q+>?["?UQK[L0 M$"@<]^39M3[L)41ZVN\B/.L-^GVM]Y_/EQ/C <[UCN502 RX%_>B5/+Z:VS'8^SW8G96E,E?36_5(=GXL!?^,=G4*B"=8-JU3MQ DDMD MZ%Y@?%R. +,%_5 _I_8T&K4!48> M^FXYT+.>B>W,>Y[^C!PT7_9HRQX!UI]#QQLZYLCQ+&])4<;S@',B34#Z 1OMYR06:6:]&)L0=ZF[$<BZ/M=S& MDGBYUC%1P@-I8>AV*<9R>U;')9VDD +DCJ?C!5VS"#!#KQD/'] M =DF635'?_C$DH29+.HL1Y.GNOMP;J.G4HK,=*K2%EV+C'"-H4O&"M#J?$+$ MS9TB8FC8^4)_>KI%9B@4F#<;$*M0S_Y\KN,E =6:.=:43 NRNA@&\LEXSNP: MV98A($0Y*M5Q3[2VT"US]+R C@M=LBR>P05R+?YRQ>]9'9<7!%=G9MW;<.BZ M DLIJWUU')UB:%K>N6Y8ML#4SV]=(3=H/D?.Y(&LS>Z%Z_K0/$=X O&C9?!- M3ZASE>L26?O&"\%U/=NV.DZ^Z1B3:<;E8KU=Q;HHZ43D>XX;:!,O8!)/[RUO MB>2N;@0(D"D>;06X*BM!HMI98'F!]R+CD-6?+IWD ,6?GKR.57J+>Q?^X9.A M1H_D!]\MY#:OVWM5Z\6:\&:W.G$&K_!IZ?[R/)L8G\6]:O(K8JR6("''QXBQ MR>Y1O;\1XRB_=:VKO!BCI0G5O7J=0;+[M]TKJE#/>H35K&(LJG6L9M'8FR]G M:P3DK6>"G'*Z2>=/V#9$^\LZ:93E5ZQW31Y#T!C*T)#C,P09+>@BE2]M \:T M6C@;;,#9H!;.Q%=_@;[5[PD$+8[17!H_7$MCM9=Y1MX(42$*M>ZN!"$O3ZD) M*83!> 7)&B(%I=UK64)%,NC8B,7(:YSDA)%\BW. -.MV&##X0$A@P[^''=,B M;+I!FBL:**FG%17+\7JD:2]JT\LE()_OU6 =$\UUJR33V=XUL"QK<9]:;1).==_V-C;*N'N:9_*QY5AT-;PD M_TSQ#9\]Z)C0C#FG!*M,EY./*<&H($(#'1#W2OZJ.R8(28 4#4EB1*G"O*QX MBMT!X7&5N"2_?QQ>#J].1V#RVVAT.P%OOSBZ3PY!T/Q'C:SFY\E3?.\+\PW> MILA)EH.334_)<+ FP^1V>#OZ/+HB_(_/P?AZ=#.\O1A?U8B"6)H])<0A2P@J MP^1V?/JOW\:79Z.;R1LP^O>7B]O_IJ2)9(FEL9&1$L&F-34(YZXYP5HQU=W[ M8,'PWM#VW/@3NN*8^6C!%?1JX2I_8I"]&[&VD1V,1CP% MG,T3&9!4CA[ M:*T@C[YV+7PM@H&0+!#WFP4QBDK3+<7G MZ*#& C#3]*YR[-(G1@8NQ;,$\7E6<[$;FF:@-]V^UBWSPCG5%Y:GVSQ4"KM) MF%Z50\07@(E7LX#=T&"8 \V1CAW+F;D\I/+;W^6MXHI!5, YTSKVM^BCDL\RDX>B G7AK?^UC^JEW MBZZQ]4C$NK9U(XJ63B&UGW#.,U!Z%4VUX7N]:"Q[@MZ%8Z YO$1N02@VU4Q=I)C^"B :(B01Y_1>C+@C)@) ." F!*<+@A93PSMS[+GCI(5UQ_/(&[7"=P^-(?5'?-R#N+9/;,E="4^P? M9?Q-OPLB:B @!Y+T@M7LA:+L^5=\;S0E2-9Q:N'DBV@$G*>HR/60^5=+4RQG M7*$6^,*X)XBZ-N_)"SVZEO&"I3PZ>!O_)GES)GS]-"G<(.,M>2X>O W)29:& M9Y_)KX+G-C-27$1KZU)J$*[K>F9."ZVIKX9=Q^3?%:Y'EK8K/\ MW=>4!!G/7,*UU64XK[L,FQ(WX\E++L/1*& U3%M\V19?[FSQY?!)Q^8M&:6X MV'*MF=K%E;DR*9>8I\[ZHTZL8)7("=1'5N)9&/C[N'QI7,AS>G.D.2=I6K_-Q^4U*Y[K0I>5V66: M-E2F*G5%R"F76!=932\T)+M?T[)]NL^=0,/'%LV:C)X-VR<[^'.B1*HM/TRU MC*=QQ>$UQ*&NEOD$.)L)F8,JOC61KV_5JM[R.1;Q-/R>#6U :@!1Q&RV8&LB M#WREMPS*&8C*FXDHFL;;2*2:-56F+SP1$8=WYGS=ZOT L_ZKFHFA>BE8Y5*R MK"2A@+H+D\2?^TM%93-I27[^**)7GT,?E9_UWA$]MW>6 MUV1D42V^'##(?>PAV:B9W496D3F*3LNAW#ZAK*Y5]N\E\%#:,V-$9KRWI)G) MX/7-/WQK$>0N[UT/ZT9!-([;]4Y3/=0F*() '$VM7?S,>#*X2&\ M74X(I>;1.:H7<&_1T" BX_!9!*(-TS=H&#A]$2UOXRS2?RMA+2-:U3L,QB9[ M:!C^W \*H(=SA#WKS[ 8A+UBTFZ<7@HOEL+TM=)AE0;K9P,6O7C M6A8NX66T4$(6]IN^&%+5,WR_^VYP<^T<83&(F5VV#4F.("S -GT*1/IDO8(% MF]'B?@HOKB7X9R'6X#L3PE\UELJ#9JXZ%N9!DU=I:KQ/+R3*?N9B8_9^?0." ME/ERLI0XF3N.8M<#Z\FU%WV564J*S"7'[ 7!-L?>YMAW/7LYJ:GIL_8V: M]G*6(B'S[36L]G+6SE[.XFJ%I91HDSSV/9>JB[ M=XJ?U^5(K&:BZ;6R?@I>.[EPPF>?Y5E1>IR=-Z$<<7=S(1H]+ZSH"_[D&U'. M8#MO22R9J\ZGJ6%.B:7W&Z0E8= 8\LHBFK4P\#.FUT9 M/:B96MQ\XYF[ADLRQ^J8V'Z3K%@7:F8]7ZV%'(?0D&V6Y&3W#703A:B9Z@W$ MO.>[CWN&)JZ0\PA=(O>:_,$4/B-XK+[MA&.?M?"P'999GRH$DMDJKIRO<1^E M#;,^1K;#.FO6!\M$CZLM)ZSD]$;+1AC>(/@KS^PH)_4SHJ[9-:B/HA1STTOC M*_P#^[1W REFX?>[!$5MOF[?0CP?R//;&S"CKJTVK!.FO2;"1/5__U&F5$C+ MKQ42>$P\+M_2VFJAMEJHK19JJX54B=:H4N+15@NUU4)MM5!;+=16"_V U4*K MP^O0=?UYN&>^L=SOYQC""S+!,'2]&^*K)<2Z1(>^RYLDRAW=I&M@QZJ+\F2G M;T$:Y.!Z9CU:)CDTUFAX>4/_6(;'U, /L.+%LG]%-B%#KWTU8'KIP7],X\O1 M0=5E3(PX?LS!.<)3:'D^A@P3H*WS&ZL+&8=GYNZT^1F^242TR,!HX%/C3&PI M8ZIK'/6(+E "ID"8>96T2(>9,]\#R0XS#]HP0EL2>]\>:U0Y\K[5%BLG?,\XA-)RHOW"YYX3+90*P%>S*B"FH%7[ ML ( !EP !LV^KETC DE)F1!(P."(B\%1L]\%5B,&24F9WE,"!@=<#*(6C84V MZL,@*2G3&4C 0.-B$+6X.]AY#)*2,J-)$C XYF(0M6CLN^GJPR I*0N#0QGS M0& BQ/9QM/,HI$1EP7 D P;^WBANTEC!=8TP)$5EP?"N8AB&_LQWO7UMT!\4 MSXELP[OW.PT)0V 6,.]5#'_MX#L(6E.G)-4>0M"*#E$J1K^VY+&I'\G DB)O M4UB_S+6[8,[0'(EL4\H,M?NFQ!"9&590*CG/>+1WPMH[8>V=L&TR)94ST^V=L(KOA"F5A:CI4IB4?$3%^S3ZG7W> MDBH'.50=G,*[XFYJ[Q"$9%;M5=0U7GGK-*-Y0P5I0@I'(@(HZH2K0$=E-U@9 M@BK[M>AKM>CRS?-KF:9-97:+IPD28+KR)&W#4<(P:C6>1MFC1]VRJ2\X1SAX M!DY"L) SXG8\+"5+\-U,9WP-7L*D7W4<7V-"]*-$''XXFV$X(PA<.!ZVR"IL M2'X1:/W%67QB;GX\Y6L_'O.^" MN&-=7SJZQBCC%<%W(IRV#PBVR:(V6=0FB]H(?YLL4C1.M?VFI'*4;+>218SR MXFC;,W9@87'Q>C.E[B)6F_=AB5NU-RD&Y/8)B0"R:J;6W41IB*3E94+2K(<_ MM777'4]C(\(W]-27B$\4!*(Y/1N[ZR*Z(Q82H.H@(F,FY?+B\JKE:5>!GNHB M44: FM:TX,LSEC32L>*)H?F5&NVY@391//$JV%O>$M6[NA%$W8A'^:@3EV+ XHC5\;ID M6K\+(J(@H J29 %9PT!,.!'14B#4TD:)VBB1#)18,^SC,OF7XA!2&1IJQY?* M:T.UX%.23]YY/Z]M,X&?#?3.!D[QF,[K$%(YGB(!Q5I#)613C2%Q_9.YY3V< MCL:%Y_/\Q@V%30K,'XFPK.9:-C0,Y#N>>ZTOZ9I--GWD$^(PS4M+OZ=O2EO0 M/?4QAD5E0B6(-/;/Z/#00.Y/./2B^,O]52'W.4V7']^]^_KUZ]LP6CM?H_BW MY*T;F8E[B%:QBPM9R]_2E[Y.H5D\M57T)9DA_2GP\GQXV5;V#L=^Y%V$W;2N)Z M#>B/U^1O%17Q2TK&1NSE2E(1"@_,2F #0R:[D!ZY%;D!]>91++2=B9P[R2.3 MNTH.GQQG2>1//KS#09KDOQS27PZ/)IG[_M?LYU_O<.C/]AS==!+RKVTE%3>/<6"=V-3664;QS(S+>+=/#@+<-9Y_' MT:*;7EE=1UVX?PT>"PUX:Q$E):96R&*W<$)G*BX"(H+-,'!Y^ M>7CSQXP,,3KT"Z7\WS^\VQ;5!:1T-D>A]_W1ZSP(G)+!<_+/ST M^>SB]D>\>,1QS3 EI0TH&:A*,:,@&QT<>MWJ*,B)$:-&WQ#Z;W=%03^NBL[E M\0*'Z<7?5WZZH8L8LAP*TT3AG30\-AV2D?IE'Z1D&!U9;;2L8ZS@.4"<"VW9 M>G(\_4".J+6(PH# M@;1[G#I^B+T+)P[]\"E10DQ&;'?^K5*X.M<648)!DU*]!HQ<=[58\7GT.9[[ MKI_"P,\T3'W/#U:IO\8/V%W%!.TXN7AQ@Q59L%Z2IJ-#\"IENX:W\]S8.QP_ M/),)X:>-6(!BZC5HB5:]Y/!55_&QPQ4'ID\-;V.C8Y88T)8#U&SS9R#0Z)F=5.C1@0&(#+-FIL7A Y% MC# ! A V*#H)]NBPB<.$C9OLUV2Z2I^CV/\']KZ$'AD_MU;>$;.23YN+%QR[ M?H+O8M_%]\12E=\9I"2K(!VNJBHP[[\8.!UE,-OJ72TG1HP:,?)A#R9HS,F) M_#2B\MG:$81 J>+C MM.6QHBV/H;7EL6%;OJ=M.?F/ =ORO;HMWX_2EN\5;?D>6EN^-VS+_QB\7TXT M'7,R3L^LJU5IS@FXOCE1=\YS[++/Z&0R>(.>JMOS=)3F/%6TYBFTQCQMTY:3 MTR$[YT33.2?C=,Z)JG-.H+5G3:-Z@]ZZ:43;\^B[P0?.#^KF_#!*:WY0-.8' M:&WYH=V$%MV&>,C^J>F>X_1.5>>$UI[JKOF?JQ"CDZ-!^V6VXTR (F_,)HVU M%I6I5S1KG0!&VTJTDFSW#]A-LQ)F7R-M\Y9H;#=O0[UZ\Q8$H)JWKI6L>0G= M0,T[73VMDO1D0IR]PAF+J*PUL5S%HI&;)#":6:I7X[R&$>;+FPF,S?A+/_13 M?.VOL7<5ID1=_S' TR3!:?)I\Z/SMR@^"YQ$%3G12H+-S?,.II4WQ5NPCP[$ M[CHW9H=,PB$3@;8R$!>"'C>(B4%,#JASQSLR4PI3=:A9C<8F&H7JE?%6(0"# M*)%6=MXP528/B9I[+BIK!+MOGZ+U.P_[=*1Z3_]" MT?>^-$"1GW[E"MWC)Y\J$:;TOG^M N1D-M"E4Y*"248S.G8TBC4.ZCDZMK0L M_<)XL#@CL(V=X"KT\,M?\$9J7(/.+C D:E:142,"! VQ9A)L9,2(42-"/@8Z MH)!TW* T8[3RE)3N40TN ^=)8$/MNZUV M%JJ5-W3E(XB6%FG4V(#):1 E&K-'%SE3Z/:^ KN$_P5.['<&26D!00EI8*RK:QL(E,P96EF1\31-H,.OX=U MNTI9QF"BG-QT)9-E3!D84$.6@@,2OO1JRE!6RG9T@#@S*G&/N=O"I_!\@7]) M?A.Y+ 6M[5T7J;KUG9<&(0@DZ;23[L!D*ZUL(X:QC(\:NNXSPTR)>](Z2'IX^W\T@^=T/5)#X@27Q%ET(YUE!20!L8(,T$J M^$;'7@=EI7DA431'!3/*N0>*.-@A4PL+X=/ L$YD-5>+4,%*LI8*!1@0"=5J MG#X]/%S,'B!!(5L9&"&B06L?&!)UF_BH$0*#B5@[V?8SYX&!FC,G>9:8QC]9 MS2);4J:2.);\#J;%2\HT&IA\@M&L=S&F240O7FAV%)P!3V*0A-9J(+5*W4I MM8@0##14VC6B9CDMPIPX83&.'E[2F4:"OKF)4O+;"?MU,@&2_[SB[$P4/6D,SR-W.1!]C=+)0'(NU[[SZ <\O6[HL=WH MYRCP<)SPIQLT:QUS=IN(:6M4&5.FO&"<4$N%ZY"\OII^NKJ^FEU=/*#IS3EZ MF-V>_>7/M]?G%_M,K8:LX.!I?M=18\\, D MH"47P9:(#A>"@JV4;,XV.0(R:3.&Z]BH- /?R!C33O*,\51=50;0W%_K^1Z4 M&5Z[.=T>S.):S]O*#+_+WEF# :I23 Q[EUNVU=L@&^E-M8J2DB?5& T8L$@4 MDSRHEO 0HW\[>LN>1O_NA QN,5I3QM^C]T='!T?\_\C-Z'DLDE/D^OX].O[N MZ.#DN^.#]R=\T_3XY/N#T^S?&;E/8RT]]C7:1C&1M2YR4O1 6B/+;\GSKGW/ M".M9+S\@(FF)7?J*2[#)QMA3($.LY-DQV51$1@W@ 3CA=$],:A7R:QP_1L63 MT6VJ]96\^E9Z7BQ[74Q2#2:,8[X&)S=$]3):.# MSM/@HK$T$[YSXMN8A1AZ;%*A,D2Q29&Q@1E%S755O0Q\@ MPHP8%XU]YWA&RUP<0U$<]8@I;:),(W*97!)2,'@2JU?,TR-4J/MG1UHMW-N MESAVZ/7L+")8=U%'06\34%JURY"2$H,!E4[#QNWG_[Z[N'FX@'*M9T%O^/\C M>X>^'L,IVX/6,%G=X345I2X;F&%Y(V3U.,*G"9](!SO$: M!]&23@/5ODG#8_=(TD#]ZFFD@@$,NDRTK$,MY\ENP15<,' F?F]>=HPF(;9Z M(*E4N'(H*:0$@R6E>HUX,TI\^$BI::!000[-;346)*8+EY&7@4;+/SO0.>70 M"?$3/9Z9Z8X:95H*SQ:!@"1]QC'?X: OIQAN(&B8K,+'R( *EI0<8'R2D9J- MQY9G?[ZX1U>SBQ\!P>LF"J.\9W"#U',G'9-U>&D-:,!+R@$+7CHU&T_\13'V MGT*$7]QG\CM&090 ">"_P2FWX)JH)+&Y1F,31T+URK"I$,"*H!&I5D<&H6%@ M0/,H1@1::,ER\<' 1AZKF(=6D)F>[])U@Q^L4NEYL9;+)GX,32@C2L,"QA.9 MZ2D%' %:)5X???-(!? E'A]&T]Z9U*0P\6@D,FA>0*KEU+*5TO (KXX,YW1*Z2R MQ7>-:)1$E14%A2DI&048M G5DJ>9_(61 3FO+M2Z]D-\1?XJFZ^)"$=!1T-1 M(4(**G@HJ:NF0 HE18Q6"1<;UJ6F;J-> %& MC+;4H)Y0-XB_'"_H4A=I.5IX)5\D$3S$J1(P^O#*3_C)#^DT&GURR <7Y\%O MH_7ACG>5[/96TP:0ZVG0$-,%S:0!I)]22SB2SEMHKGNNTX+,!O]9F4/@9,XT.O[::-HXS M""M/_Y$!L.!&$6?/DGD,!+ <_DSSXCY@!OU9=,>!?Y?C_C:#/1\"1'6QHT!K MD.S%\ *K.TF#LCCLS1*@TX%^NP"?4O=8A;E Z%V@:OBN78!+>PU=H&+)"-,, M.$?'=A?0JEFA6*\>3HZA;!6-L5=Q$7K&6T72K41^;+3G.T4G &M?KJ6N#6!M M$A4OF]&W9BZ#Z*LN)%#-,M+;C!N%(#)95OS%$FQ+C W5XE_I]J M=Q=':]_#WJ?-EX0^(E'$TDYI$D2>OD<-P2Z"+(> =32T-MBWE (&Q)U5;USR MGS[\&5U>W_[\@+X\7)RCJQMT>W=Q/YU=W7Q&T[/9U4\LBS\,?$^]OZV2E';$ MY(: A%0 .UR=1?>8@L8/<&6>-(OZZ0W#%VLW?Z>=2JPF AVV3##]TI*AS9RD M1;%T_17GA:$P7Q&07ZDV:$6OVO@A*F*5D5,4\G&D:6OO]\W!A2D8ZMOVZOG M&TGTEG)%\=(VPF44/^!X[;OJW5-C$=8WBUH:U]@>,N0?W3/MH+1T[X?=0R]C ML[X91/+R.P5^VM%X+D9Z[B E1NCAFJ3#S!(IO,MY9WWI*$>%NQV2 #NIGD[O47!!-HM0]#0O0K7 M..GCW$LI" "4#0PU@+1""AC_W%EU@W.OJYN?+AY GGN1L8?M[<^BJ?OWE1]C MPZ2R!GQ6,S":FE%)R:AC@C8M-E6X,2\FNCR3*0?=Z+KJ>Z??MI_=N?M"]:N[ M^=.]F"+(]=9.$?R<=5^F")=^Z(1N#U,$I2 4#8PU #2"BG0IPAZU153A,O[ MVQ_1Y=7-].8,Y/P@CER,O>22($$8]"T;JO1\EC,TFYE12]FL9@(#3%--C4/N MZ2DK=;\P0&C>[W;NN% ]ZFZ>="\F!W*]I9,#6IMHGO.!FQE0*Z>A1_^@<>9K M)Z"S=W[KMKX=**FK=B*LOF75P;C*VU8M^&'AMX/F0@3SY)SLD6^UIQVX%66M M S/+1T6SQL2*?#Q CT5V#S*NC7I125F] *_&5/025RX./;-JM7FHEF)2)>F= MX\O2&E5)[!Z -96K'FMMOX.94 J4$J$!L>-6.EGT,P8H@*!AT#/G!2=*3-2H M[#_4UU"Q^4!?00(('"*]=/A@S_.EE D&1AY6RV7 KEXY07Y;ZRHDNBY8X*GN M)ITIM]5+=>U,JMRO,V,%@\%V^C9NW6VYXPW!9L&'#E$8A8=L<4$$A E=4D3A M[F%TDE#CTA*=WP:^C.(LBN6,%+L*Z(ZG*AJ^I0!KH<>=#"M"D%MQCX[)SBI+ MGL7E6S \IPW?B2D$#!WZ7CM0.HL2LK")\=J/5DFP(8X_6'ETK=XA:&D ^?9N M=@Q0+=MK'ST*A]$7!K"H^=QO]1B3])&$AD,5I= 9!RN&+K =2^%2._:J:I!C MPMY,X\&+N]2R2BJX'J2O@M;]1BYROWJ+UH[=^LARR.#9%AUCF$%FKX:6 0:4 MUS*,##EXC#%B]/2 5_SDA-F-23K;C +?X^N@T"-N(Z$+'7XK,SMD<8(B\8CV M&;E^9%M]#JS/ZJB\&M:'X-$[UQ#6-)ZX*\D^0!7IK"N5Y=/MY*($M"T"7!*< MG2KLW$_<($I6,9[AE_13((^=Z+^8O>E\BDKJK1\*RG@=75)N6"/]O9/X">UV ME6YXB#Y'=(_AC#9R'*(O](_4\4,X UTVZ-/U=:RY"<4Z5<\R.KS:Z2F[CYQS M(L**SD'=1S['HGY%'9WL3:]9%^54/:? MN\H<'?H]&Z+M&PZXOO$YBKRO?A 0$^L7K;9V:N:?+6781'TG\\H0;R4 #)Z[ M:%T';RZ#@;:TF\C%H*T<<#-'02,L'-;MOKO-2.0JUZLUXJH.+U=I((!MJ]F-'PHEL'2A]W*(E%F5S$!&=/ MNQPRV2@7#L[I&M?1IW(=:7<*=I4*LO^HJZ!3!Q*+W+\>I+1#$A'+GSY"5]N0 MV(=AXV!9'&^61E@[7S7BL+81:Z9ZL0FK)A\=7N8Z-E_6H5'4&9<%F,@$7M/K5(9$S#(P& MI2L0$%EO>[D+:%" ZOXR[89JY[X>ZJN_-W@3I;K-+QV3W[124SBN9$R_0YP-43YP*S:Q>>9;_BWXQX>CX?:_,3,4Q]=5<1/8PH!IMD2\ M<^)T,RM=NM5X2#V;35":&E'&HHX'C)\T5+0.N7R7B_&A,B,X5RFST-Q9MI( M 9F&#K,%.WB\FGM+!73IF7_V(#20"2;=)?/Y&XTT+U7$8A9Q2 ,6C0];6\JP MFFFLBWF5;$MM!( !<1>M1?NGF0R&VXH4R">\)<7-7;".:230&CI:-0=$6)J[ M4SD.@"# 8H))F1C;R4(2^ %-=Z'V7$"&V#N8W2HF2?,"!8>A*\N")_%9*) MX6JQ-4=2 X:\-B'8RIPR!(T8P?B\-MH*'W+_*7_(?9M(I,0/ YI%WEPSAR@G M'R5/L8';D]&"@9E&P>8E&I:T> 8G:7']0A!!NY_B:W^-/:5G,^ ;\^J6U S5 MQ:T&$R"8F6FJO;2%#M$=F=V1M2C+F<3_.ETNB0P>1\[":F% \YZL4$A]/[/K M\6L<1$OJ>K/KO4IP&G':/3$S-J5Z4J9E P-1=^L$J)AT4/V%W%@'(S;B\]E*]%\+!D=@?=I3:L\1VQ5KT\Z23)ZM9Q=U,K MF\KMQ8#!=G?=&QO1[$X8$U6Y.P8$U8UH-#,?:\ W;BBA@9_5,L%!HZ&FJH<( M!HJ5EX7H"#V@$8>U*'HSU8N0>C7YZ%@QU]$\1@J&C[K!7TO'+G$4DK^ZN+2A M9.:RVHNQ^X1H-R.K#XFVDS$Z9G=4O ED%]?R_55D6<_Z-Z,IQSOF_JOS L@ M*#;'( ]@E7%TV'71ME5.0,1%#'5;U7W&WBK MW.%# MB/-$$M-5^AS%-(GEEY LC4J7RMFR_-/FX@7'KI_@N]AW\3U]IEF[KK50L-6% ML;6*K*RL!R]U]-YGW=3&OE)6,,MVS5(D%)M2B H]8&E6 -UNT=94*2?$E#BC MM4_6L*J1I4_!H/JD<46TZG-:J?O3ITQ-4?:94JZNLO #5$DX()%EFVE:X]:I="QNY=NU>0KJ=U+P%TK]O9+%4/7.=" MZ#0TE\*R@D7])/NQ,VY-:8Z2)[;#]&DCKKJ\UG"28IIIG2[S7/+7641_NEVE M"9F1>W[XU,MX-Z1"8_=DNQ7?9GP=3AO0'L)J%:B\2>8ST.,&X6PRC99T-CWX M+IPXHT>>N^@VOO>?GM/M1,5L9ZZST!%VZW:L ,$.7D>)H_>47LU0H3V3 7=R M:F1YBY&NK;R1!JIN9DO&F7;"1@=_7Q9H=SI$2;L.\BZ1(#*!Y(*A=0K9Z7S+ M69^IF'&Z0#LCQ<@WDP$0\*T45^$\SF(REBPF ]X&_31,?2\+U=Q&:EZ\\)>W M+PDVZ,1PE;]R6@\5G2[H";VD.GN2;?59T#ZKH_*":!^"P724/JUIO$M:DET* M'D:Y=$1;#)7DLWNW60GH+@](MAXC$V,)CJ\V01JD37"O:0JVDU<"MGNZ"TNWZZRK5;F]F7\$TT7K&C7"ENEW] NE )+R["Z.EI@L/&D<24IWZ?^^ M\MGE4$TZ/0,^FS@Q-J/J:31,8'!EJFGS5E ")!U:Z4)]_:[]YSA*9&Y'SV8U MM8NA$96L+AH>JQ@C(/(C[R%UXE0UNAGJW,A]AI_\D"ZRT2-/M@P#>L7+9='4 M)?TFQME$*O)6]$@%*Q=!ILQ6G5TK@RH>SX@3CMMKHVYCE\CS?.TVZKXY"[O3 M8.XN+D)O)VC]NH62C=Z\Y4).B0W&$*/H Q)SVW2PXVL@6[O7?DA? M^(XQ60]);*Z2V/36(N7*Z"E_!^.3!4HUQV= M[C.[VG(5E M'S.>H3N6L*1]ZEV*JNJSBPF*L=//3GD_"_$3W7@=G[Y-E;5NE MO595]"M?TAB87N_?.0O*>%#.A!C7WJU]DE93U"%Z?I\:@.K]_5=M*P_07_'[ ML][JW>:6W?]@SU9INOH2S)C'< &MU=@K/]"QDGMU!BUU>#T>H9OAK=W"JUE( M0IVHONY%IY'I;:>JX%:GC_JZ>I34U4T4KEE>PUI-L0'_W$EQ\3JVJK$L*6!] M=+):L8W>;Z5TL"M5F]9K/<#VG?=7?DJWDQNPJ06HF>HP53S<02 LKV#OI' 0 M?]#3RE469-C'V0T- )?,T=E750\?30M[ 8ZC5?$V/-*Z"J/W\''M;M7# 2Q" M_S_,1*$N1>U:WPZ9KV@I*E^VW^.%X],9]UD4LJO5*R>8X7AQ/%"K==)DGQ:G M.U1UG[ZA@QJC#UOCVZYU$(4 =.W/,?KFK]B)$R!)&#L/^(6C++W><^\GOUW& M&%^1^3=IW_2>.-2^UQ'FY>[%BK1M-?:R!C4M%%;GMF!I(ZL>(3V<$UKD9\0H M)M2OL.OF;^B<^VO?([,86UU77.[>=EU5-0[6=46%OLZNJ["TD0TY(T$;'P?[ M$L;0I2Y^B@(B)O#3C>T^6R]Y[WNMN"H'[[?58E]WSQ7:VLA'DA&CA+VBREY@ M0^N"8S]=Q5C0H924UG9(U:H6NYABLM$!IM=-"HAY00UM(M9E MZ:GJ*'2%.>E[K6M0X%YLFQA77"^[(]K21N]1UDR4=LS GX^5..K_05#8"2R$ M6;2X";ARZ-?^(\[F?;97B:*:;?+40_E5R!(OH.G#3F>NK$O0UP$'S:4A*&8?CMF4OER?3M>,'U"JRA&'GQWW7 MO+:XO>A^AI762R_4E+7_G=',P.9C+8M%%&:[*?MUL4OCE7YBP1STW9I\L1+1 MGTIC_/3I*689&:["-/;#Q'>'#)O=09^]Z,Q]57N?8VYG9?;?'?14 XU,WSDU M/?;DY&A-Z?=TO;6'\=[@DE>/50'2Z!HGBZZ9T_ [ADXZZ>1C7#[US,8ZEN(S MH=H-='1 WU9-9M&E'SJAZSO!0TILH36@?)+9A,O:D8*Y"<7Q@IYE= _;3L_& M6H8RHC1"!2O:\J)?^D]/&_=',5$K-6S,;!TW2V*GHO9D@= M*K.?I8]YN:/WRA&,;0PC#BTE15&[-%<0$;<_QQCO7]NDIJWA,A1^K4]J<'[, ML=0=<]@;7\X")TENYYG.M_$]U;E4 Y(ZUK/9].NF1I2[AXX'C#\U5%2^99MQ M#O5 @U"_1)5YQYS-VD2YA1'%3-F 9W00M514YLK,#VAW"]7RXPU=,!:Z2F*, MFF0V@[1D2I8CM.HT,( @5TP0 D(HT3F8<*P\\C>YQR[VUW1_7.(OA90V1R.% MJN4!2$ V.DKTNLDBLA/D83=PQKO .W5=]H@:F=!1=:>A1WZ)5]B[]IU'&F'J MX^1L%<=8?#K5@AW>-EX7Y04OYC(9:,F%(#*[0 X7@X*M'!CN8!HPX=@33_;I MEGF8R#R$*;/59TA;&51!KA$G&-?22MTZ2!D/8H&.J,P% Y3WF+W.>>?$Z69& M!M?$<=G*D[_N>#LO_2:IG%82;,*S@VEEC+9@!P/4]CK7T9KM+="]YK/+VZ&6 M7]%BX:=\XSOTZ&UFLB;$H;LYQZGC!\D-G>>E_AJK#BTZ"+&W-.MJX':AUE;" MZ!C<26U1H$@F!Q%!J"0)9:)0(0N&)[V+\=+QO6PPR*8N1/<;@I7J'*[6:4T8 M;?I-D M_M6+7&M@(66Q0QM',,TQ5K7APE9)&BW01<#V[]]:7F+FFV@$S2Y^(+[T^>SB M5M(08C)8+:#4$6;5#[(Y"ZU1#!7>?9-VR*E:%)9>1;V,XLS/9^_VDGF'Z!G8 M]MS &J^#ZLIX7I])H3=CD5L(0$DF8;"E1)+*!\;R5XN3_[I*);CDGZ!AH:87 M0(]*]_4G$TG%EC_"JEJ!9E K]UA5N<=@*_=X+RI75;=@JW8?:E:%6K"@W0O, MGBAJ]@1JS9[L0\V^5]3L>Z@U^WX?:O:#HF8_0*W9#_M0LZ>*FCV%6K.GRIJE M%.@4_<*)E-'S@]5L9@6],Q6F+(28+* 6//Q3=CA@P@2L+.U'JR0@8Z<;K#SZN(E)$%VC,?L4#JO1![!LC\%1/>:F\1CG M>!DE?MH=$G*1^PD$K3WPFW]&$3S#+^FG(')_T[5LE1ITHPE5A=@>9"QQ" GU M(J78 #;NY =L9$HM/4)LR0^LS3HI7V_%7 J/WR[)R690VS-&>K@X\(GBCZ0^ MG^5'BI7/ULX4!4H5 "I]@P6.IF+UAF<4Q?Z+LOONDA2#C !D:;6AZ6=8)*R\ M=:6D]M)?J)7=YKP0T\%"@%I)@,Y\F.0CL-K$5-\ADI ,U6YW1(\PG2Z7@>\R MRWDHDJ3O**EAM9:)J@#[D>0B0G(7$3LVC091D\-J$2-= 3;)@_N,O56 ;^?R M58]\'=&*&U:#=5$==/NQ6?5S%'@X3GC>&>J:\Y0)>1CFE,!R3;Z9M&E'B5#; M>3=S&A?X,KFEO!0HYT6_L&4JHC(0$S+*\+=[3N5]?*@:%OK&LE]UW]0MJ8*< MK2[H<B!.XM&3]&T"Q'$.@&L.I9H![>B%9ZK00&RJK4>*ZN^"J55.?(U6C64:MT1-G MJ:JW16*L$NGH^/4\GWH[)[AS?+*\/7.6/IDB"0$M)@74!#H-&Y OZ!%EH"OI MC&6LW,Z-G3%10S2I+&=,5K6!0CGA.BHC_1WBQ&B:IK'_N$K9OET:D889L7>4 M.NHT],Q:1\<#J+\8JZIP8#SNGY&/U$BW2TP3#85/^<&!J%4:1(":0:Y;O=X+ M2G1AD.-F2$?%WA5KAB.+OD-[3[2NEG"'E@S,G&S,F+5*G-;=*J:_IK/H+O;7 M3HKO L=E"XS;^1S'-!L$4[RQI-I)&H!NTJ,1LLBV3E+W"!D\NJXZ, MFA$](8-+'+ MR]A':C06@Y<\W\41S7KM?=I\2>@Q8S'29T?9OGA:8\X-J"$[*-T(=L,IHC)0 M+H0>F7Y#Y9"6_19MYTE;62.U;W:6G,RBJ4MFR3&NQ=$+FU7+!*@US765)+-E M08L9+]HRHU$WI"08O0K7..G<+07<@!JR@](MNV4A:OQN*3$VBYWMV+X";OCM MJU*Z9?L6HL9O7ZHE37%,_J";$VLGH)Z&!^_4)Q*B%F[##ZB-.ZG=.+ZB+4RW M==A?2G(.$)>$!#.J?8L^&7]3PD"Y?B)/(!V? ZEVN6(0C\[E>^LT _6ZO:R,#"& \99W.]=X 8-[PV MDR29;]F*$BG[T:XZY=NV=$D>*@O5V2T AV>PR>X)2,_&^BT&D'\?TCKA M2=UA\^TN-*W>I2C3Y2\HL3(/\KGT 2J5RS:'6/DCJ\B=A&"ZY? M4V&9L:3WA.R7#LCKC6#TD&@NU#E N4(HTP@QE=@[K(@E0V-:"9!>_NF:_(W\ MG/]$_D/+)[_\'U!+ P04 " !:<6U+HN2*$+T? !I%@( %0 '!K='@M M,C Q-S Y,S!?<')E+GAM;.U=W7/;.))_OZK['WC9NIJY!W_(3C+C[,QMR5\9 MUWHLG^U,;N\E19.0C!F*T("D8\U??P!)R11) V*)"!%^Y#-*&BPNW_=^&AT M S_]XV4:.,^(1IB$/[\9[!^^<5#H$1^'DY_??+K?&]Z?75V]<:+8#7TW("'Z M^4U(WOSCO__]WQSVOY_^8V_/N<0H\#\XY\3;NPK'Y._.C3M%'YR/*$34C0G] MN_.;&R3\%W*) T2=,S*=!2A&[!^R#W]PWNX/3AZ=O3U O[^AT"?TT]W5LM^G M.)Y].#CX^O7K?DB>W:^$_A'M>P36W3U)J(>6?#](^'P?L/[TX^'+_[/V#GL1LGT;+SPY?#_'\9^4\!#O_XP/]X="/D M,"C"Z,-+A']^4Q#IZ_$^H9.#H\/#P<'__GI][SVAJ;N'0PZ)A]XLJ'@O=72# MDY.3@_1?%TTK+5\>:;#XQO'!@IUES^Q?L:1]@9,(?XA2]JZ)Y\:I12D_XPA; M\/_:6S3;XS_M#8[VC@?[+Y'_9J'\5(.4!.@.C1W^_\PPEE^=41*3/W"(8OS" M#&)Z$+LO)"33^0%O><#02J8HC(>A?Q'&.)YSZ.@TY9Q)DW;]1-'XYS?<*O:X M*1R>'!_R[_\-0AO/9\Q=(LRM_8UST(SEE--3-^ JOG]"*(Y4K-4V[HB76YE]SS$ N,,$.C MX2?^9^QBYJ$(X#<-.FM1S\ETZM(Y Q5/0CQF;L%&%\\C"?M>.+DE ?8 0NCU MTA[W3&LS%_L7+S,41BABP^(YFI$(JXF!B-LQ2RMQ,R46Y7B@!S M\7PIH%291A?M>@&.T]F+?8>-_GSH9+LBM7NJ"-N<+1XC]&?"/G7QS/Y03PNU MS?N>O=J=Q4S,9@\NFPS6F--6Z;N;V6!\RJEZFE=@K&ITTOV#2A]5SL-77YAU#W-&$!CT.FCFSD#R*B$I%.^!@T8&_3"V5$#SHYZ MX0P^^@-HVU\3 "U.T+PS?I26)FK?Y1ZY$:*@'GI=70$AU^_)A!1@,-;HLH=( M@?;TJMN13(99(8)]S7Y8(4$O,0I]Y"\ZXG*T>6#&?N8=YN>< V?/65 5_^J& MOI-UX13[R,58"!(0;X7W@!\K$JI2)O_EBXS7X6,44V8OBXX"]Q$%:?=?."V, M]* )L[F>TX/."'G[$_)\X"-\P/A_R__"!7F[=SC(CSG_QG[ZDO%PAR:8?SJ, M^=%R#>>L:7W+,J-%\QA2SR&4#6@,L46?+O56C*)Z,INW.)BE9WA[WA,.EO8T MIF2JJ\I<;40A2%&[C(7>(3AC@E WN&+N\_)/-)=A4&D*!&%@'PH"J4W L)#C M@75;K_W5%D"E']FD]#H93>AZR)CP.2.7@3NI5W:I"5#;QS9INU9*DZ9]BR@F M3 2?IQ_);;S4%*C^MS:I7RJU"1C82I*GOMW/IX\DJ%=_J0E0[>]L4GNME";4 M?990+N(ECCPW^!=RJ=3PQ:V!(+RW"025[.;6.6F6YAEC94*H=)53:@A$X0>; M4)!(; Z WTB0,+W1C*](!D&E*1"$'^T#02"U.1@^HR#X9TB^AO?(C4B(_#2( M3&5P"$F L)S8!XM""P:W8]D >H=FA/)P299L+=V5"2C FS/[T)$KP2 XV=D+ MCYAF!S"C)$Z+"!B/4HBD=%"@;-Q& Q1B/"5\;@A$I-(;B8=6&7"%Z#1H_'52DNV8_=!413\6O+[%8B7P?.7O.,@N> M_?UT>#V\.;MP[G^YN'BX=[[_%+J)CV/D_U>CJ'?1K,9N])A"E$1[$]>=<=MZ M?X"".%K\PHWL?<'(\I^_%$H)+G'(1,+,!WABASQ(GI/#J-?VFN;B9:D5:D'* M[4Q%S+7TNNHZ DG:'\/612-?L$!!J30W%DB7:[@.!H&H=J#!JW+$RL_^U5C\ M'*1&4L.Q31I>S9K+I1"K7-#<6%2] 092B>T 944 (1:"0O*9[R/ M$?M'_SJ36LAAREY,8C=(6QJ%C:L(&E(H!D:-7IQ-BQ!!P9TEPZ MF[#5@7 -I#HXHV@*%0B1C9P[F\R6+R-A\=G M1!])A,P/D'>\:B%$_H5+0QQ.(C9')],D+=@X1V/L8+N%M$TK0BTI!43;^[)MX9N[)AA M*PEAPR1^(A3_]>K64A"K1*:/QMM!3Z0,2U'++I;00&Q!8/IPO4VT5I5@*5+R M#%21:$WR3SO<:;:'&2S_U,1217$+[\HRY6UIF7+_,'RX^/7BABU11I?.Z/;B M;OAP-;JQ)>'N*F12HB7#ZC6)D,"@9^68A)/EA5!*,20DAI<<"D1*7J04W8ZQ M;SCEU0!_I3H MTNL)GU% 9GQ 5[J/@LQTZI\N1B MV %8N@X]=2/D\Q=A&'\K%PG5Q&<$[4TG M\>E"))?;#FPJ,FFL[DB(I16/^Q[DNUA0C3A\:<'.TX 1O$3HME*E]=C MP9?M"CK3B7V:BW>0%BSQ/\[K#0G)PC(SOI6SF8K.="8?$(,:X)3*L .X&Q1G MW%V32#)HEIJ9SL-K!$NMJ)M^6+HXH%\<&O!7@3R^F,)!$LL"O4I"XQE\C4 & MZL,.Y_N,\.2)<35\9@/%!-TDTT=$1^.<5XTPL'9'QE/X&H';4%^VQ8FE#Z&M MA(O?B<+%/%I\_S Z^^$+A@!23[:)V-1+4CAP,+EF7.7MG$Q=+(EC"9I;AHK, MXLIKQ'J!"J%1._( ?D5\?0,Z_%\T-7WBU00.H<1V+-(%V>\JG&F67K' M&_LVC\V)#-+QY. M'5P T9I]FDXG@&'7BN),UOZV:Q##*;^HHUV#6/1I.N^@4X-85=SF%X-W>B+> M6:(">.94G8)OU*;PRY'Y7(1&V$O1VL[S&SQ")%YEUEO6Z@!8G?)!FOL##O$ MTG0Y$[^E]C(@7P753.^EU4QGP_M?G,OKT6=;JID*QYY+P;0.HVNHS$Y4G*%; M2IXQ@_AT_BGB5VTNDT.'7HR?LZL"E$(VZXFLAFM6YKZ'&[)@@.UV:=!8W M74/K&[-T&?J_)U'V(/(-"3TF;CJ'/) [Y+'_Q@%:8?Z!M.:YW7_9=-"V-?OI M"R1+3-)L465W-[SWA>*:M9FVQ4-X?>**#(5=_B6A]X@^8T\9$@/W8CJ4W+>9 M-%*2P1CU1_Y0><,@]9+6=)3:!,A::K5C*F :H,B-T#G*_K\@Z-J)_%D3JUT9= M7V.;7B0JD/@J?$912Y%B:5_&JPW;BQ4#=&;'N,!&L'1?]$"&WI$I@@> 0*0 M&G]>8 UXB*ZPV[)N@.NL#?>WX*6#UHQ$7W-;.F7DUWBV,F5(^[+@R82VI@R MSBR9,BCQ$/*C2Z:+VF0PR92A)C7^Q,(:\%3NE8/IR0Y8X7*WX<(6O+'0&M#Z MFMOT89^+RS:]_/]XHO?3QWB9TJ&^BIVVP#3GF M<"R[SX/5P[*E##Y+JKO42.GD7':?.:N'U7;ESK+M)F**CWE)M2Q$6VP%SLBQ M"+DZ.>U8'V7GPP_N"XI4()0:0G&P*:XED-8.*.Z3V2Q(!7*#A4!7X9C0J0M\ M$PG: 12Z/MXS@4*GJ9V.TDH*^YRLEN&2T/RD[8R$41+P@(@BFTBS#RA8W943 M:VJ>-!:U4^A*HD>]L'.C*^[LKI&X7 M^=9\WLR#G!&.1N/;0K=['PD_=">AAVCXB?_)+QY:X7VE7.P'9\\YQY$7D"BA MB/W'8-])NW7(V"EVS/XI[=K)^W96.S=XS3F=N&&>U!+B,?;<,,Z'6'XU#)/6$PY*/Y8'I:-])^^/#TN%'IW7+IUEGP;K M>RH" HK%)#0FM_TRV !C 93>L(>K$2MO^+7T8HDS M:R*PYX4G; XWTG[\-9 M=.*XH>\LNVEQ_2MF5N),G!)":-"CSO-H>+KNS-,B^>O$.=N,W?26K"S#26O> M7;]G4UX(A:W6%=M2J"5.*DQR*[KFX+#LFF_WG5=*)RP#/!1$;GB(;(5H]:8(JR1)O/&,#"XXO78]O_>N? AD, MRK[X;M_)Z)PEHX.^=4W"R0.B4\X:P)L$S0W[CQR'DJ-();;% M-;+CD\+5674%U"N>>/IBB-E_)&_P;G(5P?XV)K]FER^0ED_+;(.6;VNV[%I_V[%5LIKVW:T;1M"FO2^^H[+U MFG8F[5RMSZ*-"X7< OL&/IXX>%>V])-\F,]IOW-R:ILN3KTA,6#[I**SZBY8 MSII6H$*C"^-W4$+P4]X@J]#0%OALOI2\=6D\?V C4\34P^??8>B?N@$OH!), M5^\K.0.'^T[>FY-VYQ3[2P\*ECV:?']*(*_2M=641I_5JF=.R[VU.C'LX% < M*T]P:>O)DMT3#Y3@[$8U7M]$TB-'%'J".;::TC/(@BUY'ZD_%GLQ6!0CD PC MK<,"S6X,OR29:)R?5JK'$)>^3QPC]F; N+YY1X:6-%4>L MI+$,TCR6!:63D9JL[%@1 G+ONI#":('**E.0U:R8Q/3J58%)I?Q$(;LU_@+) M!I-FA0TJ22E:66'.]XN_F7SN8(L2Q/+DXQ)W\^Q/@ ]"Z3*F$MP6B MU;0T9EHX1M?X&?DJ1P.0&K^)7Q\TH#KL0.^.J9/Q\)1F##^C@,SX6)#G$:OP M Q&;OC1?&T$-E=B!X85+0R8>OZ8I36.20%>RN U/3-]?IX0M71 MT3T!H@,MH;=Q*A61\:ODX3! Q+')?6[0UX)PE(3LK]FSW9%FZ$R_)^.WO6M[ M5U-M61+P%A>U/?#;)>I#W$>5XBY5W:7S?=9=LYBV=@%F]K'&99AE\E939KTG MY"=19/U&*TDVS91E25^5=ZBRKRI4IY55RJYG@=]OI_.(%40]'Z)8RK.^8"X#2BWOX]C:6B?6'F24CU4JA MD&1@4M:3=;)RMJ>PK*?*A:_C5 MI7Y1'GY\FR'#E@33@@LW-)9UOF,L<:55RUE?T_9:4=$KAKQP;I(&?T[G]>(O M)$<1FTO9FIUO:3WVUP?"?QHE<<16XSX.)VT-3UWR9"Q'I[-QK7L$+5F?+(L\ M)6L36;EO)\L2:^M^"V936X"WX&-$[_#D*7Z=$L&!O,;];DY=<6M*M&XR (FC M-Y;K=FETH0"W@_4%M6H4!92FR@;82I6Y1H&J#<&I+:U4?;5.$9OZBS-H3YM9 ML]I48Y:X,:SJYQS%+@ZB&SXV\?R7>I^N%)UK5O_D7W&6G]F5 ;64%)3?29Y: MHBP#:+6=RB$KAFQ'6D)9C&(^C TH,+=%5^RODB*>NK9VH%%O2R($"NP7']??(2VCZ=M/%2_;2$W\AGFLH63RO4LZ[/YW7=Z 8U+O\ MJ!W# VR*Z%(/A<"W=?8%F3S4E'8@W8,'@,<%/8[IB]JDU+8D_BU.8\$E0?9JIG*V+DUH9=H"FB==Z4'63;[(N5%"4].Z#B4GL!A9!6ZD M",%I=;)!N&G)9<>9C(3E5X8A$3/MCNS M8$]PT&O%]R*^-@M,^>0<:B(CY6: MF3XZ:6BMY85HG>P=W?V1?6LXFP78RZK(TGP^H=[3A;:P8U$"358%K.TYK4H94 ])*(SNT7;&0.D4O6+9C\*=DAF@\YV?( M,:_@^#/!Z?USZHT<@'13@NE@+=@Q$$F&W8^41,V6VSFEZ7D=#@5X[;6BD\;1 M)<85)CXS*1J;OW%X^7@H&7I,013EP4_B)[Q2!*G"\U!ZTPN,IM:@IY]M]^HO M1^;/L[OR:RY;*YY]$?KK^+5@T3_TO&2:I'4 PRFA,?XKT[C\*%!)9?IN:?7, M"A)C0]Q/($SF:1VDP+ZI4-EVS,)#__SMJ&+^Y(_SB\#0:EYF53-,*NDV^Z!(HXM:X]QEC&<>7KH<#',]! MSGU,L.K+,M<_18ZSCPZ+V!IV53TBC<:9F,>.KK4Q?$"G5>LGC MZN2S)/-:>IFL+'_MN')A,^PV60ORV7;7R=974V9XG2>45]AGV^UZNY E7>GU M8]J+.[GFM9$N.\H]*#"3OLBW* /)?KHA(9K. C)'Z(R$41+$_,(A06RR65>F MCY7:A;BY'FP*BP@L-)5F?6<7=6/Z2*E/9Y>KTI*Y?^7R2-E47[DXOGH_CZF]R1?A=G>JSL++'_'^##6E_W5*W@[1K"+ MEQFF*4T/%E3[,=.!D=[,2*)J_8'L)!O(0C3AT9O-'\1,SJ0VY F;FTRW*WVI M1?5\1KPD#_G#9T3="5IY>*X7ZY0S8'\N=-\:^:86A<(]6NVBI2-;;I,)8XG@ MK=MS^]!LR%I3)7C-"LB086IS8BQ+O7?K; C2AICHEDS_1I/K+5T ;.%"]E&M MM$>!TFY(^)R^3UA263KYG#/D+EU,TX-ZA3'WQ,/&U ?T#\PWLJ)=9]6D;=5] M,@(T[1,[3+M_B+I*_FLC7L>+@ 2+H/1?53:7IH\88 0B/2XK051@CAFA\QX;)#N*1\$]O?::P+@I;:'3\52&/ M[;_.\3/VV2ZH1Z.K_[3QP)S,H'K8;*%RZHV]N5I)KIXJW M-U[Z&M)=B9>^A<=+CW;QTEV\=!\)]JC_H][T M_UZI__>:^N]N_]^?_M_WIO^W2OV_U=1_=[OL_O3_MC?]#Y3Z'VCJO[O2Q_[T M/^A-_R=*_9]HZK^[XK[^]'_2G_T#'$#7 [JK9>O1 _IS@8%Z#330701U5X#5 M(P3]K(*&R22)XN/!T>&1W!?J&AHO&NH'#K&.+#I0^08*BK^!')&UKQ/9#C.T M]Z+"#E M=D?"NR/AW9'PMW4DO"NAL7(QL2NAV9706%-"TW/L_)LLH5D,91=_)CB>%.-NX+FEJ$BL[@22 *!K!@)\^=(N9NK M1L*:IJ9/L:2654)!**DE0UG3'7RV7Q^-\SCY,]O2\@'CDM#TUI<.XB7*+VY] M7!>H\PVWK'S'_%MZHQ!;,2QK! C_J1!X'$XF-'T5X"J,*0XC['5\']X:+'TS M@>&U8=L.Z]WZ.QPW/_B\_AV.>A>7L8X?281*UY:9"&M_YI%G)KOT,=CWY4CV MC_O.@K";=V!O2(RB!W*)0S?TL!LL+4'V)CNGA!!NXEAR0\+,5K,%YU7(A$E2 MN?HXY=3ZNJFU%Q3^EA=B^L!LQ[2V=4D>[2^XS%ADSR_(6#N7"6XT_ $RF;5\ MF>'63F>;>R+;W"]WI[*VA)RO=Z>RNU/9W:GL[E16./'F$_LH1-)<]&HSXT&Z M'DY8ZR5O9X\BQ^/A*X'@46AF/!35+QX5!=FQ9SP+W"@:C1=&0^_XOJ*PT9 < MW2DI-^7(!JJ#CCRH]O.1:LO-24&4QL<]T*UD&DKH[@HX3.<\*KQD0Z#VVI;& MAS/HY6\B(6W*RGXB =-6E 7@8+G9/Y:# "=Y;G;>UW=.UEMK*=HM9HVMB,NW ML9(80C&)2D)G1_K'K4M'-+5,/SUFN44TG5)!"2%B8N,3"P0S<:J(2BN6K Q> M&2Z72X+@JQ*9GXG6PTVD!COP6MS4&]TA#^%G>?BNMK'Y*:P!/A*Q+9G1[E# M79UY?3Q_8#-NQ(3AX7RV>SAUV?;!0_*SVI/RS#8XW'?R3IVT5Z?8K<,6K<'QYI#M@N66!6PM#I:+K.QT7OP7>21=IX\-0DU' M+#MB\$6^5!'TNK9V@*-ODA+@N@UMGP5<( _=3W'\='8QD@9418U-+[+%5E,* M]TA$M6-!/?0\DH1Q=.O.N5^SF9+]0A/D7V/WD3],@%%TEE"N$\FYH$XGQO>U MP(!I \UL03(*? DE#U6]/6QC06]'^$JH$V4 2TUITO6#M'/DUQ\2\>SW,))L M *#TAAT>BE[9_;6T8\=@+A!U.$T'LM&X\)NVS=9W8M-$K %N T59$F?AD3H< M9PE?H<_?:\;AA"TR8 <(;P>547FP[Q3Z3(?A0J]=W_4"%D<18VG0CT$_O:5H MYF(_'T/R103C^X:$GFJM!:$UF&-&2B\)UI.69^;_P/_CS/NR7_P=02P$" M% ,4 " !:<6U+'Y=XT5AP !G%P4 $0 @ $ <&MT M>"TR,#$W,#DS,"YX;6Q02P$"% ,4 " !:<6U+]X#O2=T+ 8=0 $0 M @ &'< <&MT>"TR,#$W,#DS,"YX"TR,#$W,#DS M,%]C86PN>&UL4$L! A0#% @ 6G%M2_T*-1&<$0 0Q@! !4 M ( !GH< '!K='@M,C Q-S Y,S!?9&5F+GAM;%!+ 0(4 Q0 ( %IQ M;4N 1$"TR,#$W,#DS,%]P&UL4$L%!@ & 8 B@$ ' .CE $! end